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“Never put off till tomorrow what you can do the day after tomorrow.”
Mark Twain
UNIVERSITY COLLEGE LONDON
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Doctor of Philosophy
by Zubin Saihan
Usher syndrome (USH) is the name given to a group of recessively inherited disorders
characterised by hearing loss, progressive visual loss due to a retinal degeneration termed
retinitis pigmentosa (RP) and in some cases vestibular dysfunction. It is the most
common form of syndromic RP and is clinically and genetically heterogeneous. There
are three clinical subtypes termed USH1, USH2 and USH3, which are defined by the
severity of hearing loss and vestibular dysfunction with visual loss due to RP being
common to each subtype. To date, mutations in nine genes have been associated with
the three clinical subtypes of Usher syndrome as well as non-syndromic hearing loss
and RP. This wide spectrum of clinical and genetic variability provides challenges to
clinicians in making a diagnosis of Usher syndrome and delivering prognostic information
to affected individuals, whilst the genetic heterogeneity presents problems to geneticists
attempting to achieve a molecular diagnosis.
This study aims to address these issues by determining the distribution of clinical and
molecular subtypes of USH in the United Kingdom (UK). This study represents an
original contribution to the knowledge of Usher syndrome, as it is the first prospective
clinical study to sequence the coding regions of each of the nine genes associated with this
disorder in 187 affected families regardless of their clinical subtype. Detailed ophthalmic
phenotyping was performed in 219 individuals.
This comprehensive strategy of molecular analysis afforded the opportunity to interro-
gate for the possibility of digenic effects for which no evidence was found. This strategy
enabled the discovery of an atypical and novel phenotype associated with the USH1C
gene. A molecular diagnosis was achieved in 80% of families with Usher syndrome and
the ophthalmic phenotype of a large cohort of affected individuals with Usher syndrome
has been further delineated.
This study has resulted in a large cohort of UK patients with a confirmed molecular
diagnosis and detailed ophthalmic phenotyping, which will provide a framework for
subsequent longitudinal studies enabling the characterisation of how visual function
progresses over time. Understanding the natural history of this disorder in genotyped
individuals will help pave the way for subsequent gene-directed therapy studies in the
future.
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Chapter 1
Introduction
1.1 Usher syndrome
1.1.1 Definition
Usher syndrome (USH) is the name given to a group of recessively inherited disorders in
which there is dual sensory impairment of the audiovestibular (hearing and balance) and
visual systems. There are over 50 known human syndromes which include symptoms of
combined visual and hearing loss (sometimes termed “deafblindness”) of which Usher
syndrome is the most common [1], representing over 50 percent of deafblind adults [2–4]
[5–7].
A “syndrome” can be defined as a group of symptoms (or signs) that collectively indicate
or characterize a disease. Thus Usher syndrome is often referred to as a syndromic form
of hearing impairment or a syndromic form or retinitis pigmentosa (RP), as both hearing
loss and RP can also occur in isolation.
1.1.2 History of Usher syndrome
Following the invention of the ophthalmoscope by German optical physiologists during
the mid-nineteenth century, the occurrence of a pigmentary retinopathy with deafness
was observed in three out of five siblings by the German ophthalmologist Alfred von
Graefe and reported by his cousin Albrecht von Graefe in 1858 [8].
Three years later in 1861, his student Richard Liebreich reported a survey of deaf inhab-
itants from Berlin, in whom he noted the frequent presence of retinal pigmentation in
individuals with congenital deafness [9]. Significantly he emphasised the genetic nature
1
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of the disease by commenting on the presence of these findings in Jewish consanguineous
families or in families with several members affected in different generations.
Following these reports of heritable pigmentary retinopathy and deafness the disease
finally received its eponymous name from the Scottish ophthalmologist Charles Usher,
who examined a cohort of 69 cases of retinitis pigmentosa reporting 19 cases with addi-
tional hearing loss. He also emphasised the heritable nature of their disease [10].
Although the name “Usher syndrome” is still used to this day, it has also been re-
ferred to as Hallgren syndrome, Usher-Hallgren syndrome, RP-dysacusis syndrome, and
dystrophia retinae dysacusis syndrome by others [11][1].
The variability in the severity of hearing and visual loss has been noted since the early
literature at the start of the last century [12][13] and following the confirmation of ge-
netic heterogeneity of Usher syndrome in the early 1990s, Smith et al. [14] proposed
clinical criteria that could be used to divide the syndrome in to two distinct phenotypic
forms based on the severity of hearing loss. USH1 (Usher syndrome type 1) is associated
with profound hearing loss preventing the attainment of language and vestibular abnor-
malities, whilstUSH2 (Usher syndrome type 2) is associated with moderate to severe
congenital hearing loss.
USH3 (Usher syndrome type 3) is distinguished from USH1 and USH2 by onset of
deafness later in life (sometimes referred to as “postlingual”) progressive hearing loss,
variable vestibular dysfunction and onset of RP usually in the second decade of life.
1.1.3 Clinical characterisation of Usher syndrome
Historically Usher syndrome has been divided into three clinical subtypes, USH1, USH2
and USH3, all manifesting combined sensorineural hearing loss and visual loss due to a
progressive retinal degeneration termed retinitis pigmentosa (RP). Vestibular dysfunc-
tion may also be a feature for USH1 and USH3 [15]. The three subtypes are distinguished
purely on the severity and progression of hearing loss and the presence or absence of
vestibular dysfunction, with visual loss due to RP being common to all. It is important
to appreciate that visual symptoms do not define the subtypes.
USH1 is the most severe audiovestibular phenotype, with congenital profound hearing
loss and absent vestibular function (vestibular arreflexia). USH2 accounts for over a
half of all Usher syndrome cases in the western world [16, 17] and is characterised by
congenital moderate to severe hearing impairment, generally more severe in the higher
frequencies, with normal vestibular function. In USH3 the hearing loss is progressive
and the vestibular function variable. USH3 is rare in most populations apart from in
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Finland [18–20] and among Ashkenazi Jews where it may be responsible for over 40
percent of USH cases in these population groups [21–23].
The onset of night-blindness, termed “nyctalopia”, is generally the first visual symptom
of the RP. This has been reported as occurring at an earlier age in USH1 than in USH2,
however due to the overlap between the age of onset of visual symptoms in the USH
subtypes, it cannot be regarded as a reliable diagnostic discriminator [24–29]
The numbers of patients affected by the three distinct USH types is unequal
During the 1990s, each of three clinical forms of USH were shown to be genetically het-
erogeneous. Initially USH1 was reported as being the most prevalent subtype; however
this probably represented sample bias, as the groups studied were all profoundly deaf
(thus reducing likelihood of picking up USH2 cases) [3, 13, 30].
Studies in Europe generally demonstrate that USH2 is more common than USH1, with
reported percentages in the region of 56 - 75% (USH2) and 25 - 44% (USH1) [4, 6, 7, 24].
The USH3 subtype occurs in a much smaller proportion of Usher syndrome, apart from
in Finnish and Ashkenazi Jewish populations, where it accounts for up to 40% of cases,
due to intermarriage and “founder effects”. [23, 31].
1.1.4 Reported prevalence of Usher syndrome
The “prevalence” of Usher Syndrome can be defined as the number of people affected
with Usher Syndrome in a given population at any given time and reports range from
1 in 23,000 in the U.S. [3], 1 in 29,000 in Scandinavia and 1 in 12,500 in Germany [32].
The prevalence of retintis pigmentosa in the general population is estimated at about
1 in 3700 - 4450 [33]; suggesting that Usher syndrome may make up approximately 17
percent of retinitis pigmentosa cases [34].
Accurate estimates of prevalence require a high rate of diagnostic accuracy, which may
prove difficult in the case of Usher syndrome. Hearing loss is extremely common and
can present at any time from infancy to old age. About 1 per 1000 children in the UK
is born with a permanent hearing impairment and a similar number develop this during
early childhood [35]. Approximately half of all congenital hearing loss is thought to be
of genetic origin[36].
Thus, Usher syndrome is found more frequently amongst those with retinitis pigmentosa
than those that are deaf.
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1.1.5 Importance of screening deaf children for syndromic causes of
deafness
In the absence of an affected family member, a child with Usher syndrome is likely
to initially receive a (mis)diagnosis of nonsyndromic congenital hearing loss, with the
correct diagnosis not being considered until the onset of visual symptoms later in life.
Thus, effective ophthalmological and/or genetic tests are important for children with
congenital sensorineural hearing loss in order to exclude Usher syndrome.
The prevalence of hearing impairment increases with age such that by the fifth decade
of life 2.3% of the population experiences hearing loss exceeding 40dB and this figure
rises to 30% by the eighth decade [37, 38].
Syndromic hearing loss accounts for about a third of all cases of hearing loss with a
genetic aetiology [38]. Screening hearing impaired children for syndromic causes of
hearing loss important for a number of reasons.
1. Inheritance patterns may be known for specific syndromic causes of deafness, al-
lowing for genetic counselling of the family in the absence of a molecular diagnosis.
2. Molecular diagnosis for many of the commoner forms of syndromic deafness may
be available, which has implications for genetic counselling [38].
3. Diagnosis will allow monitoring of known complications of the syndrome, such as
renal, ocular or endocrine disease [38].
4. Early diagnosis may allow preparation for the physical and emotional impact of
the approaching additional sensory loss [11]. e.g. a deaf person with USH learning
hands-on signing prior to the onset of severe visual impairment.
Even if no ’cure’ for a genetic disease exists, it is still important for a clinican to ar-
rive at an accurate clinical and molecular diagnosis as this may enable them to deliver
important prognostic information regarding disease progression which may have a sig-
nificant influence upon important career and lifestyle choices to allow for appropriate
genetic counselling. This is particularly relevant in the case of Usher syndrome, where a
number of other rare syndromic syndromes resulting in dual sensory loss may manifest
similar symptoms.
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1.2 Molecular genetics of Usher syndrome
Since the first gene for USH was discovered in 1995, a total of eleven loci including nine
genes have been identified as causing the various clinical subtypes of USH [17, 21, 39–50]
[51, 52]. see Table1.1
The genes that are associated with the USH phenotype code for proteins of different
classes which are predicted to have different functions. Moreover there is a wide spectrum
of clinical variability associated with mutations in these nine genes. Mutations in five of
these genes can also give rise to isolated (non-syndromic) sensorineural hearing loss [41,
48, 53–57], and mutations in USH2A can produce isolated (non-syndromic) autosomal
recessive RP without hearing loss [58, 59].
For three of the USH1 genes, USH1C, CDH23 and PCDH15, a genotype-phenotype
correlation exists with truncating mutations causing USH, while missense/in-frame al-
terations result in non-syndromic deafness [43, 45–48, 54, 60, 61] [62–65]
Although such genotype-phenotype relationships exist, monozygotic twins with disease
due to the same mutations in the gene USH2A have also been reported to manifest
different phenotypes, suggesting that the severity of disease due to some of these genes
may be influenced by environmental or genetic modifiers, or stochastic factors [66, 67].
1.2.1 The Usher genes
How do mutations in the nine known Usher genes that code for proteins with such
different functions, give rise to similar pathology in the inner ear and retina? Both the
inner ear and retina share structural and functional similarities, in that both are highly
specialised neurosensory cells and both contain non-motile cilia and ribbon synapses (see
Figure 1.1).
These synapses allow continuous release of neurotransmitter from the presynaptic ter-
minals, a property thought to be necessary for high frequency transmission needed in
sensory cells [68]. The ciliary structures in both the hair cell and photoreceptor are the
kinocilium and connecting cilium respectively.
The localization of the USH proteins to the common synaptic and periciliary areas of the
ear and eye and the identification of a network of USH protein interactions, led to the
proposal of an USH protein interactome model functioning at these locations, explaining
the pleiotropic effects of mutant USH genes [49, 69–77].
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Figure 1.1: Schematic of (left) retinal photoreceptor cell and (right) cochlear hair cell
1.2.2 The retinal clilopathies
Usher syndrome is one of a number of inherited syndromic conditions that result in reti-
nal degeneration secondary to dysfunction at the level of the photoreceptor connecting
cilium.
A cilium is an organelle found in eukaryotic cells and are present in most human cells.
There are two types of cilia,motile cilia (“ 9+2” central configuration) and non-motile, or
primary, cilia (“9+0” central configuration), which typically serve as sensory organelles.
Although USH lacks many of the systemic features associated with the more recognised
ciliopathies such as primary ciliary dyskinesia, hydrocephalus and polycystic liver/kid-
ney disease, it has nevertheless been classed as an example of a “retinal ciliopathy”,
a term used to describe a retinal disorder in which the retinal connecting cilium has
been shown to be involved [78]. Dysfunction of components of the photoreceptor con-
necting cilium are known to give rise to both syndromic and non-syndromic forms of
retinal degeneration such as Retinitis Pigmentosa GTPase Regulator Interacting Pro-
tein (RPGR-IP) causing Lebers Congenital Amaurosis (LCA6) OMIM 605446 [79], and
Retinitis Pigmentosa GTPase Regulator (RPGR) causing X-Linked RP (RP3) OMIM
312610 [80], which is important in photoreceptor disc morphogenesis; the Bardet-Biedl
syndrome (BBS) proteins OMIM 209900, appear to play a role in intracellular transport
Chapter 1. Introdution 7
!"#$ %&'()(*+,$-(*./+/'$!"$
!"0!$ 123./456$!"$
123./456$7+8&,(9+':;$
123./456$<(/5$-;)'=(9:;$
!"0!2>"$ 35?5=@)$<(/A5/.'+,$%*+&=().)$
<(/52!(6$-;)'=(9:;$
B"C"#2D$ E5/.(=$3(45/$);/6=(*5$
F(&?5='$);/6=(*5$
GGE#2H$ G+=65'2G.56,$E;/6=(*5$
%37E#$ %,)'=(*$E;/6=(*5$
IEC$A5/5)$
J#2KL$
I):5=$E;/6=(*5$
Figure 1.2: Schematic of photoreceptor and table of the retinal ciliopathies
between the inner and outer segments of the retinal photoreceptor reviewed elsewhere
[81]. Similarly to USH, the BBS proteins have recently shown to also interact forming a
molecular complex, the “BBSome” that has been shown to be required for ciliogenesis
[82].
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1.2.3 Protein structure of the Usher genes
MYO7A, molecular subtype USH1B
Figure 1.3: The Usher 1B protein, myosin 7a, consists of a motor head domain, five
calmodulin binding IQ motifs, two FERM domains, two MyTH4 domains and an Src
homology 3 (SRC3) domain
MYO7A (USH1B) encodes myosin 7A, an unconventional myosin, with a predicted do-
main structure consisting of a motor head domain, ve calmodulin-binding IQ motifs,
two FERM domains, two MyTH4 domains and an Src homology 3 (SH3) domain. [83]
Mutations in MYO7A are responsible for Usher syndrome type 1B,[84, 85], recessively
inherited atypical Usher syndrome [86, 87], autosomal recessive (DFNB2) and dominant
(DFNA11) non-syndromic sensorineural deafness [88, 89]. Shaker-1 (sh1) mice have loss-
of-function mutations in the orthologous gene, Myo7a, and thus serve as model of Usher
1B. Shaker-1 homozygous mice exhibit an audiovestibular but not a retinal phenotype
as is found in humans with mutations in MYO7A [90]. Myo7a has also been shown to
be important for melanosome localisation in the RPE [91].
USH1C (molecular subtype USH1C)
The USH1C gene (OMIM 605242) encodes a PDZ-containing protein called Harmonin
or USH1C, which is expressed in alternatively spliced isoforms that make up three dif-
ferent sized subclasses [43, 44]. Mutations in this gene have been associated with Usher
syndrome (the combination of generalized RP and hearing loss) [44, 92–97], as well as
with non-syndromic autosomal recessive hearing loss (DFNB18) [54, 62]. USH1C en-
codes a scaffold protein that functions in the assembly of Usher protein complexes. The
protein contains PDZ binding domains, which facilitates interaction with other Usher
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Figure 1.4: The USH1C protein, harmonin, of which three different classes of isoforms
are identified. All three isoforms consist of two PDZ (PSD95, discs large, ZO-1) domains
(PDZ1 and 2) and one coiled-coil domain. In addition, class A isoforms contain an
additional PDZ domain (PDZ3). The class B isoforms contain also this third PDZ
domain, a second coiled-coil domain and a proline, serine, threonine-rich region (PST).
Isoforms A1 and B4 contain a C-terminal class I PDZ binding motif (PBM)
proteins, a coiled-coil region with a bipartite nuclear localization signal and a PEST
degradation sequence.
There appears to be some genotype-phenotype correlation with hypomorphic alleles
causing hearing loss without RP, whilst more severe truncating mutations result in
hearing loss and RP [54, 62]. The audiovestibular phenotype associated with mutations
in USH1C is one of prelingual profound hearing loss with absent peripheral vestibular
function when associated with RP [43, 44, 97], and with normal vestibular function when
associated with non-syndromic hearing loss [54, 62].
CDH23 (molecular subtype USH1D)
CDH23 is one of the two USH genes from the cadhedrin family of genes encoding calcium
dependent cell-cell adhesion glycoproteins. The protein encoded by this gene is a large
transmembrane protein composed of an extracellular domain and expressed in the neu-
rosensory epithelium. Cadhedrins preferentially interact with themselves in connecting
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Figure 1.5: Cadherin 23 (USH1D) is represented by three different isoforms. Isoform
A is composed of 27 Ca2+-binding extracellular cadherin domains (EC1-27), a trans-
membrane domain (grey disks) and a short intracellular domain with a C-terminal class
I PBM. Isoform B is similar to isoform A, but only contains the last six EC domains.
Isoform C only consists of the intracellular domain and C-terminal PBM.
cells and are required for establishing and/or maintaining organization of the stere-
ocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early
postnatal development. Null mutations in CDH23 result in retinal and audiovestibular
dysfunction (USH1D) whereas hypomorphic alleles may affect hearing alone (DFNB12).
Two PDZ domains in the USH1C encoded protein harmonin, interact with two comple-
mentary binding surfaces in the cadhedrin-23 cytoplasmic domain. As murine models
of the CDH23 ortholog Cdh-23 have splayed stereocilia, it was postulated that via their
interaction with harmonin, form a transmembrane complex that connects stereocilia into
a bundle, and that defects in the formation of this complex result hearing loss associated
with defects in the gene [98] in mice and humans.
Kazmierczak et al. (2007) demonstrated that CDH23 and PCDH15 (605514), 2 cad-
herins that are linked to inherited forms of deafness in humans, interact to form tip links,
extracellular filaments that connect the stereocilia and are thought to gate the mecha-
noelectrical transduction channel. Immunohistochemical studies using rodent hair cells
demonstrated that two cadhedrin-related USH genes cadhedrin-23 and protocadherin-15
are localised to the upper and lower part of tip links, respectively.
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PCDH15 (molecular subtype USH1F)
Figure 1.6: Like cadherin 23, the non-classical cadherin protocadherin 15 (USH1F)
consists of either 11 (isoform A) or one (isoform B) EC domain, a transmembrane
domain and a C-terminal class I PBM
Along with CDH23, PCDH15 is the other Usher gene that is a member of the cadherin
superfamily and both genes are components of kinociliary links, transient lateral links
and tip links between adjacent cochlear sterocilia [73, 99–103].
RT-PCR and immunohistochemistry has demonstrated PCDH15 expression in both
retina and cochlea [46], and was further localised to inner ear hair cell stereocilia and to
retinal photoreceptors by immunocytochemistry [63].
Similarly to USH1C and CDH23, missense mutations in PCDH15 have been found to
cause DFNB23 [104, 105], while more severe mutations (splicing, frameshift, nonsense,
large deletions) cause USH1F.
PCDH15 is expressed in several isoforms differing in their cytoplasmic domains. Recent
knock-out mouse model studies have shown that mice lacking PCDH15-CD2 develop tip
links, but are deaf, whereas surprisingly, mice lacking PCDH15-CD1 and PCDH15-CD3
isoforms form normal hair bundles and tip links and maintain hearing function [106].
The majority of mutations identified in the PCDH15 gene have been point mutations,
whereas large deletions, which can escape routine screening methods, may also form a
significant proportion of PCDH15 mutations [65, 107].
USH1G (molecular subtype USH1G)
USH1G encodes a scaffolding protein that contains three ankyrin-like domains and a
SAM (sterile alpha motif) domain with a class I PDZ-binding motif at its C-terminal
end. USH1G is the smallest Usher gene comprising of only three exons, two of which are
coding. The SANS protein interacts with harmonin, myosin VIIa and whirlin. SANS has
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Figure 1.7: The scaffold protein SANS (USH1G) consists of three ankyrin domains
(ANK), a central region (CENT), a sterile alpha motif (SAM) and a C-terminal class
I PBM
been shown to be a critical component of the tip-link complex, a structure controlling
actin polymerization in stereocilia, where it interacts with CDH23 and PCDH15 [108].
Only a handful of mutations have been identified in Usher populations across the world,
suggesting that this gene makes a small contribution to the molecular cause of Usher
syndrome [49, 109, 110].
USH2A (molecular subtype USH2A)
The Usherin transcript was originally reported to be 5 kb [17], encoding a 170-kDa
protein which was predicted to be a secreted, extracellular protein. Since the start of
the work presented in this thesis, other researchers identified a further 51 exons were
discovered. This larger transcript predicted a 600-kDa protein which is predicted to be
anchored on the cell membrane with a large extracellular domain and a short C-terminal
PDZ-binding motif. The long Usherin isoform has been shown to be the predominant
form in murine photoreceptor cells. Usherin is thought to be required in the long-term
maintenance of photoreceptor cells, as USH2A null mice develop a normal retina which
subsequently degenerates [111].
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Figure 1.8: Isoform A of the Usher 2A protein (USH2A) contains an N-terminal
thrombospondin/pentaxin/laminin G-like domain, a laminin N-terminal (LamNT) do-
main, ten laminin-type EGF-like (EGF Lam) and four fibronection type III (FN3)
domains. In addition to this region, isoform B contains two laminin G (LamG), 28
FN3, a transmembrane domain and an intracellular domain with a C-terminal class I
PBM.
Usherin is expressed transiently in murine models and is postulated to have a role in the
postnatal maturation of cochlear hair cells [77, 111].
GPR98 (molecular subtype USH2C)
GPR98 is a large gene encompassing 605 kb. Three human GPR98 mRNA isoforms are
known, of which Isoform b is the largest and it contains all 90 exons. All three isoforms
are expressed during the development of the central nervous system and are also found
in the fetal retina. The translated GPR98 protein is one of the largest proteins found
in humans and belongs to the large N-terminal family B (LNB) of seventransmembrane
segment (7TM) receptors; specifically, to the subfamily with a G-protein-coupled prote-
olysis site (GPS) for G-protein signalling. The protein has several domains, each with
its own function [112].
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Figure 1.9: Isoform B of the very large G-coupled protein receptor, GPR98 (for-
merly known as VLGR1 or MASS1 ), contains a thrombospondin/pentaxin/laminin G-
like domain, 35 Ca2+-binding calcium exchanger (Calx) domains, seven EAR/EPTP
repeats, a seven-transmembrane region and an intracellular domain containing a C-
terminal class I PBM. (H) Clarin-1, the USH3A protein, only contains four (isoform
A) or one transmembrane (isoform C) domain.
WHRN (molecular subtype USH2D)
The most recent USH gene to be identified is WHRN that encodes the scaffold protein
Whirlin, previously reported to underlie non-syndromic deafness linked to the locus
DFNB31 and to cause deafness in the whirler mouse mutant [74]. Mutations in WHRN
(USH2D) were identified in a German USH2 family, previously excluded for all other
known Usher loci [52]. Prior to the identification of pathogenic mutations in WHRN,
it was proposed as a candidate gene for USH2 due to its reported interactions with
the other two USH2 proteins, Usherin and GPR98, as well as co-localizing with these
proteins in the retina and inner ear [74]. Whirlin is a PDZ scaffold protein and functions
similar to USH1C in the Usher protein interactome. It is expressed both in the ear and
the eye throughout development.
CLRN1 (molecular subtype USH3A)
CLRN1 belongs to a superfamily of four-transmembrane proteins that includes the
tetraspanin and claudin families. Tetraspanins are considered to be structural proteins
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Figure 1.10: Clarin-1, the USH3A protein, only contains four (isoform A) or one
transmembrane (isoform C) domain
that interact laterally with other membrane proteins such as ion channels, integrins,
and other tetraspanins [113, 114] Despite the genetic and phenotypic characterization
in humans, the molecular function of CLRN1 remains elusive [115].
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Molecular genetic advancements since the start of the study
Since the start of this study in 2003 research groups from around the world made sig-
nificant breakthroughs regarding the clinical and molecular aspects of Usher syndrome.
As many of these findings were significant and influenced the design of this study, some
are mentioned below in reverser chronological order.
A new locus for USH1
A new locus for USH1, designated USH1H has recently been reported following genome-
wide linkage scanning of a two large Pakistani consanguineous families [116]. This locus
overlaps the non-syndromic deafness locus DFNB48 raising the possibility that these
two disorders may be caused by the same gene, as is the case for other Usher genes see
1.1, [116].
USH Loci withdrawn
Two previously reported loci, USH1A and USH2B (3p23-24.2) were recently withdrawn
by their original authors. New pedigree information and additional molecular analysis in
the original French families used for the initial USH1A locus mapping studies identified
MYO7A as the causative gene in 7 of the 9 original families [117][75]. The USH2B locus
was also recently withdrawn [75].
1.2.4 The Usher “protein interactome”
The Usher genes encode proteins from different classes. The USH1 proteins include
the actin-based motor protein Myosin VIIa (USH1B), the cell-cell adhesion proteins,
Cadherin 23 (USH1D) and Protocadherin 15 (USH1F) and the scaffold proteins Har-
monin (USH1C) which contains PDZ domains and SANS (Scaffold protein containing
ANkyrin repeats and Sam domain, USH1G). The USH2 protein Whirlin (USH2D) is
also a PDZ domain-containing scaffold protein whilst the remaining two USH2 proteins
USH2A, termed Usherin and GPR98 (G Protein-coupled Receptor 98) representing USH
loci USH2A and USH2C respectively, are large transmembrane proteins. Clarin-1 is a
membrane glycoprotein with 4-transmembrane domains from the Clarin family and to
date is the only molecular cause of USH3.
PDZ (Post synaptic density, Disc-large, Zo-1 protein domains) domains are protein mod-
ules that interact via C-terminal sequences in other proteins to direct protein complex
assembly in multicellular organisms [118][119].
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Figure 1: Schematic diagram illustrating the deciphered interactions within the USH protein network interactome adapted from van Wijk
et al. [55].
proper alignment of outer segment disks of photoreceptors
and apical microvilli of RPE cells through interactions with
harmonin. However, none of the USH2 proteins have been
shown to be present in the RPE.
Most of the USH genes are responsible not only for Usher
syndrome but also for nonsyndromic hearing loss. To date,
however, only one gene (USH2A) is known to be responsible
for isolated RP, which suggests that usherin plays a main role
for the photoreceptor or that the rest of the Usher proteins
are not essential in the photoreceptor function.
6. Conclusion
6.1. Diagnosis. Usher syndrome is a clinically and genetically
heterogeneous disorder which is important from a public
health viewpoint because of the social isolation which Usher
patients must endure. The first step towards correct diagnosis
is proper differential diagnosis of the syndrome.
Initially, USH manifests as a sensorineural hearing
impairment, sometimes with vestibular dysfunction, with
RO onset occurring later in life. Several syndromes may
exhibit clinical signs which are similar to USH. Differential
diagnosis should take into account the presence of endocrine
abnormalities such insulin resistance, type 2 diabetes, hyper-
triglyceridemia, hepatic dysfunction, and/or renal failure, all
of them would indicate Alstro¨m syndrome or the presence
of obesity, mental retardation or cognitive impairment, and
postaxial polydactly and hypogenitalism, which may be
indicators of a Bardet-Biedl syndrome (BBS). If a family
history of X-linked inheritance is observed, or if signs of
dystonia or ataxia are detected, Mohr-Tranebjaerg syndrome
should be suspected.
Genetic tests could be a very powerful tool in differential
diagnosis of USH patients. However, there are many factors
that make the genetic study of this disease a complicated
difficult one. As explained in this paper, the genes identified
to date do not explain all the USH cases (this is true for
BBS and Alstro¨m syndromes as well), and the variable nature
of the proteins involved in USH and the complexity of the
USH interactome make identifying novel genes a difficult
task. This is due to genetic and allelic heterogeneity, which
contribute to the low rate of mutation detection, together
with the possible presence of large deletions, mutations in
noncoding regions, or isoforms in low concentration only
present in the affected tissues. Moreover, other complex
inheritance forms could modify the phenotype and its
expression, as recently shown by Ebermann et al. [54]. All
of these factors make the use of traditional techniques for
mutation detection difficult.
Application of new technologies based on DNA chips
could solve this problem; in fact, the recent creation of
a specific microchip for this disease [71, 72] permits the
Figure 1.11: Schematic diagram illustrating the deciphered interactions within the
USH protein network interactome adapted from van Wijk et al. 2006 courtesy of Millan
et al. 2011
The PDZ containing proteins Harmonin, Whirlin and SANS are thought to facilitate
such pr tein interaction . In the inner ear, H rmonin and Whirlin are thought to me-
diate th se interactions whilst in the retina Whirlin and SANS appear to fulfil this
role[77][69][71][72][74][75][76].
In addition, Harmonin [98][71], Whirlin [120], SANS [71] and possibly Myosin VIIa[75]
also form homodimers. The existence of differe t protein isof s sec dary t splicing
variations adds a further layer of complexity to these potential interacti ns, since some
isoforms appear to be much more abundant in some tissues than others. The only
known USH3 protein, Clarin-1 is less well understood than the other USH proteins. It
is the only USH protein in which the retinal cell and subcompartment localization are
unknown and does not yet fit in to the current USH interactome model [121].
1.2.5 The role of Usher proteins in the inner ear
The functional role of the Usher proteins in the inner ear concerns the morphogenesis
of hair cell bundles.
The stereocilia are the mechanosensory organelles present on the apical surface of cochlear
auditory and vestibular sensory hair cells, which are supported by an internal cytoskele-
ton of F-actin filaments. These bundles of stereocilia are neatly arranged in rows of
graded height and are tethered together by a number of fibrous connections or links,
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along their length (see Figure 1.1). These stereocilia are actually organelles whereas the
“true” hair cell cilium is the kinocilium, which is transient in mammals and responsible
for the orientation of the developing stereocilia. Normally, deflection of the hair cell stere-
ocilia results in mechanical opening of channels, inflow of potassium from endolymph
into the hair cell causing membrane depolarization, and release of neurotransmitter from
the ribbon synapse at the basal end of the cell [122][123][124].
The USH1 proteins have been localized to the developing auditory hair bundle, specif-
ically the growing stereocilia and/or the kinocilium in mouse models [69, 77, 101, 120,
125–127].
Protein interaction and localisation studies in mouse models have also suggested roles
for some of the USH proteins in the extracellular interstereocilia links, specifically the
extracellular regions of the USH1 transmembrane proteins Cadherin 23, Protocadherin
15 forming the tip links [101–103, 128, 129]. The three USH2 proteins Usherin, GPR98
and Whirlin are all transiently expressed during early cochlear development, as are the
interstereocilia ankle links which are vital for the postnatal development of cochlear hair
cells, supporting their involvement in the formation of a so called ankle-link molecular
complex (ALC)[74, 77, 111, 130, 131]. The current model is that these extracellular
interstereocilia links are anchored intracellularly by the scaffold proteins Harmonin, and
Whirlin which are in turn thought to link to the actin cytoskeleton directly or via
other proteins, such as Myosin VIIa (USH1B), Myosin XV, MYO1c and/or Vezatin
[69, 71, 120, 129, 131, 132]. In mouse models of USH, electron microscopy of the
sensory hair bundles in mutant mice demonstrate disorganised and disorientated hair
cell stereocilia due to a lack their characteristic cohesion and interstereociliary links
[16, 75, 76, 90, 133–136], supporting the role of the USH interactome in stereocilia
development.
The actin-based motor protein Myosin VIIa (USH1B) has been hypothesised to act as a
general transporter of the stereocilia USH proteins to their intended destination based
on the observation that the USH proteins Harmonin [69], Protocadherin 15 [73], GPR98,
Usherin, Whirlin, and Vezatin are misplaced or mislocalized in the hair bundles of the
shaker-1 (MYO7A mutant) mouse model [131], and that Myosin VIIa has also been
shown to interact with these proteins [132][69][71][120][131].
Unlike the other four USH1 proteins, SANS has not been localized to the stereocilia
in murine models, but instead to the apical region of the outer hair cell beneath the
cuticular plate at the base of the kinocilium [71]. It has been proposed that as SANS
controls the traffic of USH1 proteins along microtubules and the actin cytoskeleton
toward the stereocilia as it has been shown to colocalize and interacts with Myosin
VIIa and/or Harmonin [71]. Although USH proteins have been localized to the hair cell
Chapter 1. Introdution 20
synapse, the ribbon synapse has been examined in one mouse model and found to be
normal [137][75]
1.2.6 Mouse models of Usher syndrome
Mouse models of disease provide a useful tool to enable research and investigation of
human disease, although the use of live animals as a research tool remains a controversial
topic. Mouse models of the Usher genes have produced hearing defects analogous to
those observed in human USH, with sensorineural hearing loss and impaired vestibular
function, mouse models for the Usher genes have largely failed to demonstrate the visual
phenotype of photoreceptor cell loss as seen in human USH (see Figure 1.1). Previous
mouse models for USH display grossly normal retinas, although a mild peripheral retinal
degeneration been noted histologically in the USH1C dfcr mutant mouse [134]. In mouse
models with no gross retinal degeneration, some mutant alleles have been noted to have
a mild reduction of electroretinographic responses, suggesting photoreceptor rather than
synaptic dysfunction as none demonstrated an electronegative response (one in which
the b-wave is smaller than the a-wave).
The reason for the lack of a convincing retinal phenotype in these rodent models is un-
clear, with alternative splicing of genes, functional redundancy of the Usher proteins in
the murine retina and/or the slow disease progression making characterisation difficult,
all proposed as theories to explain this observation [127][111]. However Liu et al. [111]
recently reported the first murine model of any of the USH genes to demonstrate a clear
retinal phenotype. These USH2A null mice showed an essentially normal retinal pheno-
type at birth but went on to develop overt photoreceptor degeneration by age 20 months,
as demonstrated by light and electron microscopy and a decline in electroretinography
responses [111].
1.2.7 Usher protein function in the retina
The photoreceptor cell is a highly specialized sensory neuron that is capable of photo-
transduction.
The connecting cilium joins the metabolically active inner segment to the photosensitive
outer segment (which itself is actually a modified cilium) required for phototransduction
in the outer segment are synthesised in the inner segment and then transported through
the connecting cilium to the outer segment (see Figure 1.2) [138][76].
All three USH2 proteins and the USH1 proteins, with the exception of Harmonin,
have been localised at/around ciliary photoreceptor structures in the retina (as well
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as other ciliated tissues, such as olfactory epithelium and spermatozoa in the testis
[139][140][141][21][136].
The long ectodomains of the transmembrane protiens Usherin (USH2A) and GPR98
(USH2C) have been found to extend between the photoreceptor inner segment plasma
membrane and ciliary surface [111][76]. Both proteins have been proposed to form fibrous
links between these two membranes which are analogous to the ankle links between
adjacent stereocilia in cochlear hair cells mentioned above.
The scaffold proteins SANS (USH1G) and Whirlin (USH2D) have also been localized
to the periciliary collar of the apical inner segment and the adjacent connecting cilium
of murine photoreceptor cells and interact with the cytoplasmic domains of the long
isoforms of the large transmembrane proteins USH2A and GPR98 [76]. SANS may be
linked indirectly to microtubule-associated intracellular transport machinery [76].
There is some debate as to the localisation and function of USH proteins at
the ribbon synapse
In the photoreceptor cell, hyperpolarisation leads to a reduction of neurotransmitter at
the ribbon synapses in the outer plexiform layer of the retina. There have been reports
of localisation of the USH proteins to both the ribbon synapse and plexiform layers
of the retina [70][142][72][75][136][143][74]. However, other investigators have failed to
find evidence of expression at the synapse [111][34]. Furthermore no mutant mouse
phenotypes for any USH gene have demonstrated electronegative electroretinograms, as
might be expected if synaptic function were compromised [34].
In vivo studies of retinal function in humans harbouring mutations inMYO7A (USH1B),
PCDH15 (USH1F), USH2A and GPR98 (USH2C) have recently demonstrated that the
primary pathology in human cases of USH due to these genes is a primary photoreceptor
degeneration rather than a primary RPE or synaptic pathogenesis as has been previ-
ously suggested [144]. Evidence of synaptic dysfunction such as preserved photoreceptor
layer thickness relative to impaired visual function, electronegative electroretinograms
or dysplastic thickened retinas were not observed, arguing against the synapse being
the major site of pathology [144]. Liu et al. [111] are the only investigators to describe
an USH mouse model with a significant retinal phenotype and were unable to demon-
strate Usherin immunostaining in the inner retina, RPE or the photoreceptor synapses
and were unable to demonstrate defective synaptic transmission from photoreceptors to
second-order retinal neurons arguing against a significant function for Usherin at the
ribbon synapses.
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1.3 Human molecular genetics
1.3.1 Genetic linkage
Genetic linkage mapping compares the inheritance pattern of a phenotypic trait
with the inheritance pattern of chromosomal regions. By establishing pedigrees and
genotyping known chromosomal regions within a family, inheritance of these loci can be
traced. In a study such as this in order to determine whether certain genes might be
disease causing, variable DNA sequences (polymorphic markers) within or near the gene
in question one can be genotyped to help deduce inheritance within a family.
An important prerequisite for such genetic linkage analysis is that all individuals in a
pedigree should have distinct (and mutually exclusive) phenotypes, namely be affected
or unaffected. When employing such a strategy, an important caveat is that mendelian
inheritance may not always apply. Indeed there have been reported cases of uniparental
heterodisomy resulting in nonmedelian inheritance involving the gene USH2A [145].
Disease phenotypes may also arise from genetic mechanisms such loss of whole exon,
gene or chromosome.
Assuming Usher syndrome is a monogenic disorder with mendelian recessive inheritance,
the tracking of alleles in consanguineous and non-consanguineous pedigrees can be ex-
tremely useful as outlined below:
In consanguineous families
In a monogenic recessively inherited disorder in a consanguineous family, it would be
anticipated that due to the shared genetic material in the pedigree, the pathogenic allele
would be the same DNA sequence variant. In chromosomal terms this would mean that
two copies of the same stretch of chromosome (containing this pathogenic allele) could
have been inherited, resulting in two pathogenic alleles producing the disease phenotype.
If we assume that this pathogenic allele is the same, then so should a finite genetic
distance of chromosome encompassing the allele. Within this area, other polymorphic
sequence variants would by definition also be expected be identical, resulting in an area
of homozgosity delimited by crossovers at either end. Investigating chromosomal regions
that display homozygosity for alleles is termed homozygosity mapping and is a useful
way to determine or search for areas of the genome that are homozygous and thus in
consanguineous pedigrees good candidate regions for containing the putative pathogenic
allele.
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In non-consanguineous families
In cases where two different pathogenic alleles in the same gene are inherited from each
parent, which would be more probable in the case of families that are non-consanguineous,
the combination of different alleles inherited can be referred to as compound heterozy-
gosity.
The term haplotype is actually a concatenation of the term “haploid genotype”. It
can be used to refer to the inheritance of one of the two copies of a chromosome pos-
sessed by an individual. The inheritance of the region of chromosome can be deduced
by analysing polymorphic markers close to this particular locus. Within families, trans-
mission of genetic material is organised into a limited number of haplotypes delimited
by crossovers during meiosis and representing the independent assortment of stretches
of genetic material across chromosomes.
1.3.2 Polymorphic SNPs and microsatellite markers
A genetic mutation can be thought of as a DNA sequence change that deviates from
normal and/or that confers some form of deleterious effect. Often DNA sequence variants
at a particular locus do in fact vary in the normal population. These DNA sequence
variants occur commonly in a population can be referred to as genetic polymorphisms.
In the case of polymorphisms, no single allele can be regarded as the standard DNA
sequence for that species, instead there are two or more equally acceptable variations.
In terms of prevalence, mutations can also be thought of as a rare abnormal DNA
sequence variant, whereas a polymorphism a more common sequence variation. The
approximate frequency cut-off for a DNA sequence variant to be thought of as a common
polymorphism, is often regarded as being ∼1%, however, it must be stressed that this
figure is entirely arbitrary [146].
The identification and tracking of such non-disease causing DNA sequence variants (poly-
morphic alleles) in a pedigree, can allow the inheritance at these loci to be inferred. The
degree of informativity of such alleles depends on the degree of genetic heterogeneity at
these loci.
When attempting to deduce mendelian inheritance of alleles in a pedigree at a given
locus, if these alleles are the same, they can be referred to as Identical By State
(IBS). In classic mendelian inheritance, an individual receives one maternal and one
paternal allele. If the parents’ alleles are informative enough, it may be possible to
deduce from which of the four chromosomes (two maternal and two paternal) each allele
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was derived from. Thus if two siblings share alleles that can be identified as coming from
specific parental chromosomes they can be referred to as being Identical By Descent
(IBD).
SNPs
Single-nucleotide polymorphisms (SNPs) are variations in one base pair of DNA sequence
at the same locus between paired chromosomes of an individual or within a species,
that are not thought to be disease causing. These single base pair changes represent the
majority of DNA sequence variation between human individuals and are correspondingly
prevalent throughout the human genome. SNPs occur (on average) every 1,000 to 2,000
bases when two human chromosomes are compared [147–149]. The frequency of SNPs
has been shown to vary between different human populations [150].
Their frequency throughout the human genome can be used to advantage as SNPs can
be used to perform linkage analysis. Genetic polymorphisms such as SNPs can be used
to track inheritance of these polymorphisms
Technologies exist which enable genotyping in excess of 900,000 known SNPs throughout
the human genome such as the Affymetrix microarray platform (www.affymetrix.com).
If single base pair changes occur within non-coding regions they may not result in any
immediately obvious functional change, although they may potentially have an effect in
protein transcription or regulatory regions . Non-coding single base pair changes can
have a deleterious functional changes if they occur near intron/exon junctions where
they may affect mRNA splicing.
If single base pair changes occur the coding regions of genes, they do not always change
the amino acid sequence due to the degeneracy of the genetic code. They may however
result in the substitution of one amino acid to another. These single amino acid sub-
stitutions termed “missense” changes may or may not have a deleterious effect on the
protein they encode, depending on various factors such as the relative importance of the
amino acid involved and amino acid charge [151].
Deciding whether a sequence variant is pathogenic can be complicated process and can
be achieved using a number of different methods such as population studies to determine
the prevalence of these changes in control chromosomes (generally, the more common
it is, the less likely it is to be pathogenic). Investigation of the entire coding sequence
of the gene looking for other putative pathogenic changes can also be informative, es-
pecially when used in conjunction with segregation analysis of any putative pathogenic
changes within pedigrees. The relative importance (predicted functional significance) of
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a particular amino acid change also depends on the likelihood of the amino acid changing
the secondary structure of the protein it is part of, which can be inferred using software
programs [152], or looking to see whether the amino acid change lies within an important
functional domain of the protein by analysing DNA sequence motifs. Additional infer-
ences can also made by assessing the degree of evolutionary conservation within different
species and also the change in charge conferred by an amino acid change (conservative
vs. non-conservative).
In summary, a single-base pair substitution may simply represent a non-pathogenic
population polymorphism (when it is termed an SNP). If they do not cause disease by
themselves but influence disease only in tandem with other sequence variants, they are
termed genetic modifiers. A single base pair substitution may also be able to cause
disease as a splice-site change, missense change or by introducing a stop codon in to the
reading frame.
To obtain an estimate of the frequency of a given DNA sequence change (or “allele”) in
a population, one can assay the frequency of that change in a representative sample of
the population. The higher the sample size, the more accurate the resolution will be of
detecting the true heterozygosity rates in that population [153].
Thanks to large scale projects such as the Human Genome Project and the HapMap
Project over 10 million reported SNPs exist in public database repositories such as the
National Center for Biotechnology Institute single nucleotide polymorphism database
dbSNP. Approximately two-thirds of these SNPs are found with a minimum allele fre-
quency of 1% or greater, whilst over a third (38%) have a minimum allele frequency of
1% [154][155].
Microsatellite markers
Microsatellites, also termed Simple Sequence Repeats (SSRs), Short Tandem Repeat
Polymorphisms (STRPs) or Variable Number of Tandem Repeats (VNTRs) are
polymorphic sequences that consist of repeating units of 1-6 base pairs [156].
These repeated sequences are often simple, consisting of two, three or four nucleotides
(di-, tri-, and tetranucleotide repeats respectively) which can be repeated for a number of
units. They are found throughout the human genome and are often highly polymorphic.
For example, arrays of (CA)n repeats are very common, accounting for 0.5% of the
human genome. When n!12, the CA repeats are more likely to be polymorphic [146].
To calculate the n value for a polymorphic VNTR, PCR can be used to amplify a
DNA sequence containing the VNTR (see Figure 1.12). The length of the PCR product
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Figure 1.12: Schematic representing VNTR markerd for linkage analysis
(termed the amplimer) will vary in size depending on the number of VNTRs (n) in the
DNA sample amplified.
Practically this can be achieved by designing primers and labelling the 5’ end of the
forward primer with a fluorescent label. This fluorescent label becomes incorporated in
to the PCR product, which is then denatured prior to electrophoresis. The fluorescent
label enables sizing of the amplimers. Differences in amplimer sizes thus correspond to
differences in the n value for the VNTR which can be regarded as a polymorphic allele
at that locus.
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These VNTR alleles can then be used as linkage markers to track inheritance of chro-
mosomal loci in the same way as SNPs, but due to their high allelic heterogeneity they
are often more informative than SNPs [146].
1.3.3 Regional founder effects
When one particular mutation is the sole or most frequent mutation in a given population
as a result of genetic isolation, this phenomenon is referred to as a founder effect.
Regional founder effects in some populations contribute to this wide bandwidth of sub-
type prevalence.
The high prevalence of the USH3 subtype in Finland can be attributed to two mutations
in the USH3A gene which are both associated with a common ancestral haplotype. This
genetic enrichment from such founder effects is useful information; as the discovery of
common alleles within populations can lead to a methodical and efficient approach to
molecular diagnosis, carrier screening and genetic counselling as well as opening the door
to specific molecular therapies within these groups in the future [34].
To illustrate this point with a practical example: If these two most prevalent USH3A
mutations were assayed in a Finnish population with the Usher syndrome USH3 subtype,
confirmation of molecular diagnosis would be achieved in approximately 40% of this
population. A genetic diagnostic laboratory responsible for molecular diagnosis in this
population, would therefore be able to confirm genotype in 40% of cases. This has
significant implications as it reduces the time, cost and efficiency of such a service.
Similar examples exist in the Ashkenazi Jewish population, who have been found to seg-
regate their own founder mutations in USH3A as well as in PCDH15 (USH1F) [23][157]
and a recent molecular survey reported that four USH2A mutations accounted for 64
percent of all pathogenic alleles in Jewish families of non-Ashkenazi descent [158]. Other
populations such as the Acadians and Quebecois are now known to also segregate founder
mutations in USH1C as well as in USH2A due to shared ancestry [159, 160]. Neverthe-
less, despite these founder mutations, and the common c.2299delG mutation in USH2A
which is found in 16 to 77 % of USH2A families (depending on the populations studied)
there are a large number of private mutations in most populations [17][161][162][163][164]
[165][166][59][167][168][167].
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1.3.4 MassARRAY R©platform and MALDI-TOF R©mass spectrometry
Sequenom is a private company who have developed their own MassARRAY R©system
for DNA analysis. This system is able to yield accurate data from genetic target material
that is only available in trace amounts.
The Sequenom genotyping system is based on initial multiplexed PCR reaction, after
which the remaining nucleotides are deactivated by enzymatic (shrimp alkaline phospho-
tase) treatment. A single base primer extension step is then performed, and the primer
extension products analyzed using MALDI-TOF mass spectrometry.
Mass spectrometry
Mass spectrometry is an analytical technique employed to determine the elemental com-
position of a sample. It works by first ionizing chemical compounds generating charged
molecules which have their own mass and charge. The mass-to-charge ratio (m/z) of
these particles are based on the details of motion of the ions as they transit through
electromagnetic fields.
Conventional ionization methods can prove too aggressive in their ionisation of biological
molecules such as proteins, peptides and sugars and can cause fragmentation of these
more delicate organic molecules. To overcome this, a gentler form of ionization technique
termed Matrix-assisted laser desorption/ionization (MALDI) can be used to to ionize
intact biomolecules.
The biomolecule being interrogated is mixed with a UV-light absorbing matrix consisting
of crystallized molecules mixed with water and an organic solvent such as ethanol. This
mixture is then applied on the surface of a MALDI plate and dried, this is sometimes
referred to as a MADLIspot. The MALDIspot is then irradiated by a nanosecond
laser pulse. Most of the laser energy is absorbed by the matrix, preventing unwanted
fragmentation of the biomolecule. The ionizied paticles are then accelerated in an electric
field and passed through a flight tube toward a detector. Depending on the mass to
charge ratio of the ionized particles, they will be temporally separated, as they reach
the detector at different times. This allows each species to yield a distinct signal.
MassEXTEND R©reaction
To interrogate an allele located within the genome in a sample of genomic DNA an
oligonucleotide primer is designed adjacent to the site in question. A single base pair
termination reaction is then carried out to extend the primer by a single nucleotide. This
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The red boxes represent the nucleotide of interest on two chromosomes from a single individual. In
the above example the indivdual has a C/G heterozygous genotype. After PCR amplification of a
section of genomic DNA containing the allele, a 2nd set of primers are annealed adjacent to the allele.
Subsequently a single base pair extension reaction yields the addition of a G and a C, which are identified
by MALDI-TOF spectrometry by two separate peaks corresponding to the mass-to-charge ratio of these
two nucleotides.
Figure 1.13: Schematic representing the principles of Sequenom’s MassARRAY plat-
form for genotyping
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nucleotide is then analysed on a MALDIspot and the base pair added can be determined.
This process is summarised in Figure 1.13.
Chapter 2
Purpose and Aims
2.1 The National Collaborative Usher Study (NCUS)
The work presented in this thesis derives from The National Collaborative Usher study
(NCUS). This section presents an overview of the study prior to stating the aims of the
study.
2.1.1 What does the NCUS represent?
The NCUS was a large national study to investigate the clinical and genetic aspects
of Usher syndrome. It was set up in 2003 with funding from the Community Fund
(National Lottery) and the British Retinitis Pigmentosa Society (BRPS) to employ a
family coordinator at the charity Sense, a postdoctoral scientist and an audiologist. The
funding also paid for a full-time ophthalmology clinical research fellow (myself).
The main aim of the NCUS was to find out more about the genetic and clinical aspects
of Usher syndrome affecting families in the UK.
This was to be achieved by recruiting families with Usher syndrome from the UK,
performing detailed phenotyping of their ophthalmic and audiovestibular features and
interpret these findings alongside a molecular diagnosis (or genotype).
The study represented a unique collaboration between the different disciplines of clin-
ical medicine (ophthalmology and audiovestibular medicine), scientists in the field of
molecular genetics and deafblind specialists from the charity Sense.
The clinicians and scientists were based at two academic/clinical institutions from Uni-
versity College London (UCL). The clinical phenotyping was performed in London by
31
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myself and Dr Nell Rangesh (the part-time audiologist on the NCUS). The genetic anal-
ysis work was shared between the team of scientists at Institute of Child Health and
myself. The NCUS team also collaborated with the Wellcome Trust Sanger Centre,
(Cambridge, UK) who were able to provide the facilities and finance to undertake some
of the most comprehensive genetic analysis of any cohort of Usher families in the world
to date.
Collaboration with Sense, London, UK
The deafblind charity Sense have a long history of providing help to deafblind families
and consequently had established links with many of the families with Usher syndrome
in the UK. Aside from having a database of Usher families, Sense also maintain active
avenues of communication with Usher families by way of Usher groups, meetings, out-
ings and via their website. The operations at Sense were overseen by Mrs Mary Guest
Throughout the study newsletters were produced and distributed to the deafblind com-
munity via post and their website, keeping families informed of developments as the
NCUS progressed and also encouraging other families to participate in the study.
Miss Liz Cook (2003-2007) was employed as the family coordinator, who was based at
Sense. The family coordinator’s role was to explain the study to family members and
encourage participation by visiting as many families as possible either at home, or when
they attended London for clinical phenotyping, or through correspondence with families.
Sense were also able to inform clinical collaborators in the NCUS on deafblind culture
and offer practical help in meeting the communication needs of the deafblind study
population (e.g. lip-reading, sign language, hands-on signing and braille). They were
also able to offer their extensive experience to help with the production of all printed
or electronic communication material for optimum fonts, colours and contrast for the
Usher population.
Collaboration with Institute of Ophthalmology, (University College London)
and Moorfields Eye Hospital NHS Foundation Trust, London, UK
The Institute of Ophthalmology is an academic unit specialising in the research and
treatment of ocular disorders and was where I was based from 2003-2007 working in Dr
Andrew Webster’s laboratory, where part of the early genetic analysis was performed.
The Institute of Ophthalmology is associated with Moorfields Eye Hospital NHS Foun-
dation Trust, a tertiary referral ophthalmology hospital where many individuals with
Usher syndrome have at some point been referred to for assessment. Many of the Usher
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patients had at some point been under the care of either Prof Tony Moore and Dr An-
drew Webster’s clinics and Collaboration with Moorfields Eye Hospital thus provided
access to meet many Usher families in the UK and subsequently recruit them in to the
NCUS. All ophthalmic clinical examinations and phenotyping was performed by one
researcher (myself) at Moorfields Eye Hospital.
Collaboration with Institute of Child Health (University College London)
and Great Ormond Street Hospital for Children NHS Trust, London, UK
DNA samples were extracted and stored at the Institute of Child Health. Dr Maria
Bitner-Glindzicz was the primary investigator on the NCUS and oversaw part of the
molecular work under her team at the Institute of Child Health as well as working as
a clinical geneticist in Great Ormond Street Hospital for Children . Over the course
of the study two post-doctoral researchers Dr Elene Haralambous (2005-2007) and Dr
Polona Le Quesne Stabej (2006-2010) and a research assistant Dr Yasmin Hughes (2005-
2007) were employed in Dr Bitner-Glindzicz’s laboratory part-time to help out with the
molecular aspects of the study.
Prof Linda Luxon headed up the clinical audiovestibular analysis part of the NCUS with
Dr Nell Rangesh performing the audiovestibular phenotyping at the National Hospital
for Neurology and Neurosurgery Queen Square (UCL) London, UK.
Collaboration with the Wellcome Trust Sanger Institute, Cambridge, UK
For the first two years of the NCUS, the genetic analysis was being performed entirely
by myself at Institute of Ophthalmology and the part-time post doctoral scientist and
research assistant at the Institute of Child Health.
In 2005 we formed a collaboration with Prof Karen Steel’s team at the Wellcome Trust
Sanger Institute (Cambridge, UK) which provided the NCUS to obtain a vast amount
of genetic data that would have not been possible due to financial and manpower con-
straints at the start of the study. This collaboration afforded the NCUS the facility
to perform direct bidirectional DNA sequencing in nine of the Usher genes (and one
candidate gene) in the proband from each of the 180+ families recruited in to the study.
This generated approximately 264824 base pairs of DNA sequence traces in each of the
180 probands (totalling 47.6 million base pairs for the whole study) which had to be
manually analysed.
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Outsourcing of second round of molecular analysis to SequenomR©
DNA sequencing at the Wellcome Trust Sanger Institute identified 370 interesting DNA
sequence variants in each of the nine Usher genes that warranted further interrogation.
For each change, an assay was designed and run by the company SequenomR© (San
Diego, USA) on a panel of 1152 DNA samples comprising of DNA 770 affected and
unaffected family members recruited in to the NCUS and 600 control DNAs.
2.2 Why perform a study like the NCUS?
2.2.1 Questions a diagnosis of Usher syndrome raises
For a family who are already dealing with the challenges of having a deaf child, the
diagnosis of Usher syndrome and the resultant prospect of having to also deal with
visual loss can be a devastating blow. Understandably, when an individual or family
receive a diagnosis of Usher syndrome this will raise many questions such as:
• What type of Usher syndrome do I have?
• How long will my vision last?
• Will I go blind?
• Are there other related problems e.g. poor balance?
• Will my hearing deteriorate further?
• When I have children will they be affected?
• Are my hearing brothers and sisters carriers?
• Will my child benefit from cochlear implantation to help them develop speech?
• Will I be able to drive to work in 5 years time?
• I communicate using British Sign Language at present, but should I think about
learning hands-on signing before my vision deteriorates further?
• Will I be able to carry on my job as an electrician in 10 years time, or do I have
to think about another career?
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The families will seek the answers to these questions from a number of sources such as
their ophthalmologist, their clinical geneticist, teh internet, their audiologist or deaf-
blind workers who may have a working knowledge of Usher syndrome. Such prognostic
information can guide important decisions families make regarding life plans, accommo-
dation, education and job opportunities.
Due to the wide spectrum of hearing and visual phenotypes seen in Usher syndrome
delivering the much needed prognostic information to families is extremely difficult.
The resulting frustration felt by families and clinicians at the lack of reliable prognostic
information is one of the reasons behind performing a large study like the NCUS.
For scientists researching Usher syndrome
Outside the clinical setting, the wide clinical variability produced by mutations in the 9
Usher genes (see table 1.1) is a source of great interest for scientists.
Scientists attempting to understand the molecular pathways that underlie retinal func-
tion/dysfunction can learn from the clinical effects associated with dysfunction in the
Usher genes. This in turn can help contribute to the general understanding of retinal
function/dysfunction associated with molecular pathways in the retina. For those scien-
tists attempting to design therapies to prevent or retard the progressive visual loss seen
in Usher syndrome, knowing which retinal cells degenerate and different stages of the
disease process is a prerequisite. For example, a therapy designed to rescue retinal pho-
toreceptors would need to be initiated at a time before significant photoreceptor death,
which (by implication of the variable age of onset and severity of visual loss) probably
vary greatly amongst a cohort of individuals with a clinical diagnosis of Usher syndrome.
Any human therapy trials will require an idea of the normal rate of degeneration in or-
der to ascertain whether or not a treatment is actively influencing the natural course
of the disease. Whilst animal models are of some use in this area, there is a paucity of
good animal models of Usher syndrome that demonstrate a retinal phenotype (discussed
earlier 1.2.6) making in-vivo human studies like the NCUS important.
2.2.2 My role in the NCUS
I was employed full time as a clinical research fellow at Institute of Ophthalmology with
an honorary contract at Moorfields Eye Hospital from 2003-2007.
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My post was funded during this time Community Fund (National Lottery) the British
Retinitis Pigmentosa Society (BRPS) with additional help from the Special Trustees of
Moorfields Eye Hospital.
• I was solely responsible for performing the ophthalmic clinical phenotyping tests
on each of the 220+ affected individuals recruited in to the study.
• I was also responsible for finding and recruiting Usher families in to the study
along with the help of a the family coordinator from Sense.
• I took sole responsibility for the DNA sequence analysis of the USH2A gene in
our 182 probands. This involved manually analysing bidirectional DNA sequence
trace data in 100 amplimers per person.
• I designed and created a large multi-user database which was used by different
collaborators to input and store the vast amounts of administrative, clinical and
genetic data.
• I designed different database user interfaces for the different needs of our collabo-
rators
• I also created strategies to link and query the huge volume of genetic data generated
from the study and developed a system to interrogate the pathogenicity of all DNA
sequence variants identified from the second round of molecular experiments.
2.3 Aims of the NCUS
1. Identify a cohort of genotyped individuals with Usher syndrome in the
UK
Although no treatment exists for Usher syndrome at present, there are a number
of research groups around the world working on gene directed therapy of Usher
syndrome in animal models. Should these initial trials turn out to be successful,
the next stage would be to proceed to Phase 1 testing of these therapies in a subset
of human subjects with Usher syndrome and a formal molecular diagnosis would
be a mandatory prerequisite for this.
Most studies on Usher syndrome to date have concentrated on looking retrospec-
tively at clinical data, or genotyping a cohort of individuals with a particular
phenotype. This study aims to collect clinical data prospectively (reducing data
collection bias) and attempt to identify the causative gene in a cohort of individuals
with different phenotypes of Usher syndrome in the UK.
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2. Understand natural history of the disorder
In order to assess the benefit of any molecular therapies on altering disease course
in a progressive disease, one must first have an appreciation of the natural history
of the disease. Ideally this requires the collection of prospectively collected clinical
data over time (a longitudinal study). Although this study is a cohort study, by
performing standardised prospective clinical tests and interpreting these alongside
a genetic diagnosis we may begin to explore the similarities and/or differences in
disease phenotype that arise due to different mutations in different genes.
3. Facilitate subsequent longitudinal studies
By recording the results of standardised clinical tests in our cohort of affected indi-
viduals with a genetic diagnosis, these clinical tests could be repeated in the future.
This would generate longitudinal data documenting disease progression giving us
a clearer idea of the natural history of disease over time that are associated with
a particualr molecular diagnosis.
4. Help devise a strategy for subsequent molecular analysis in the UK
By performing genetic analysis on a representative sample of individuals with
Usher syndrome in the UK we will be able to identify which mutations in which
genes are responsible for the disease in the UK Usher population. This genetic
epidemiological information in tandem with the clinical information will help to
determine if genetic testing for USH can be directed by clinical findings, providing a
strategy for the subsequent molecular analysis of individuals with Usher syndrome
in the UK.
5. Investigate the possibility of digenic effects and unusual phenotypes
Most clinical and genetic studies in Usher syndrome to date have interrogated
specific genes in a subset of individuals with a particular clinical subtype of Usher
syndrome. This is the first study in the world to comprehensively analyse all nine
Usher genes in a population of clinically diagnosed patients with Usher syndrome,
regardless of their clinical subtype. This strategy will enable investigation of the
possibility of digenic effects and also see if mutations in genes commonly associated
with a particular clinical subtype of Usher syndrome may also be associated with
other clinical subtypes of Usher syndrome.
6. Identify which DNA sequence changes are disease causing
Many of the DNA sequence variants reported as disease causing in previous studies
of Usher syndrome are single nucleotide substitutions resulting in the change of
one amino acid to another, which are referred to as missense changes. Assaying
our putative pathogenic mutations in a large panel of control chromosomes as
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well as segregation analysis of these sequence variants will help determine the
pathogenicity of DNA sequence variants identified by this study. This molecular
genetic data is to be shared with other researchers.
7. Genetic counselling for individuals and families
Achieving a molecular diagnosis in families with a genetic condition can allow for
confirmation of the clinical diagnosis and subsequent genetic counselling of indi-
viduals, for example, with regard to the risk of transmission to future generations.
8. Genotype vs. Phenotype: inform clinicians
The genotype and phenotype information generated in this study may inform clini-
cians in making a clinical diagnosis of Usher syndrome (“Can the phenotype predict
genotype?”). It may also help clinicians deliver prognostic information to affected
individuals and their families (“Does the genotype predict the phenotype?”)
Chapter 3
Background to study methods
Devising a workable study methodology required consideration of the multidisciplinary
aspects of the NCUS and the challenges faced by working with deafblind study partici-
pants.
This chapter provides an overarching view of these challenges and other important con-
siderations relating to this study that influenced methodology. The details of actual
molecular and clinical techniques employed can be found in chapters4 and 5.
3.1 Patient recruitment
Recruiting deafblind study participants was one of the most challenging aspects of the
study and one which demanded a lot of thought and attention.
There are many difficulties faced when attempting to contact persons with dual sensory
impairment. Letters and telephone calls, the standard mode of communication which
most hospitals employ to contact patients, can prove unreliable, as visual impairment
may preclude letter reading and hearing loss may make telephone conversations difficult
or impossible.
By the end of the study, many different methods were used to recruit study participants.
This subsection provides an insight in to the communication requirements of the study
participants and the factors that needed to be considered during recruiting, consent and
phenotyping.
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3.1.1 Communication
The challenges presented to a person with dual sensory loss are greater than the sum of
the two senses that are lost, as outlined below:
Hearing impairment
Hearing loss in Usher syndrome can vary from moderate to profound. Generally indi-
viduals with USH1 communicate via sign language which relies heavily on good visual
function 1. Those with USH2 generally are able to communicate via speech with the
help of hearing aids and often relying heavily on lip-reading.
If an USH1 individual who communicates via sign language also has a reduced visual
field, this means that the area which they can see their signer (their visual frame) is re-
duced. Thus when using a BSL interpreter to communicate with someone with a reduced
visual frame the interpreter must be aware of this and modify their signing accordingly.
Additionally if they have deficient colour vision or reduced contrast sensitivity the colour
of the signers’ clothes relative to their hand colour can be important. If visual function
drops precluding adequate use of the visual frame, a technique based upon British Sign
Language called hands-on signing can be employed. The deafblind person places their
hands over those of the signer and interprets them by feeling the signs formed.
For USH1 patients we therefore had to arrange specialist BSL or hands-on interpreters
familiar with working with Usher syndome and these professionals had to be booked
and arranged for the phenotyping tests.
Some individuals with USH2 have sufficient hearing to manage to communicate via the
telephone, however many do not. If an individual who relies heavily on lip-reading looses
central visual function, their ability to lip-read can be greatly impaired thus making
communication difficult. Due to the high frequency hearing loss in USH2, individuals
often find picking out spoken voice in areas with ambient background noise extremely
challenging, requiring that all clinical examinations were conducted in a quiet place.
Visual impairment
In all individuals with Usher syndrome, reduction of visual field can make interpreting
the non-verbal cues of others difficult. Also many individuals with Usher syndrome are
troubled by glare, so optimum lighting conditions e.g. ensuring that bright sunlight is
1The exception being those young USH1 individuals who have undergone cochlear implantation al-
lowing them to communicate via speech.
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not streaming in through a window and the effects of their nyctalopia (by ensuring the
room is well lit, but not too bright) must be accounted for. In order to ensure that
someone is able to lip-read, special attention was paid to ensure a clear line of sight and
to enunciate words clearly without covering one’s mouth.
Each affected individual recruited in to the study was asked to state their preferred mode
of communication. This preference was then recorded on the NCUS database so that
all researchers were aware of the best method to contact individuals and their families
in the future.
Table 3.1: Table listing the various modes of communication used to contact individ-
uals with dual sensory impairment
Requires adequate visual function Requires adequate hearing
Text phone Yes No
SMS messaging Yes No
Printed material Yes No
Lip-reading Yes No
Email Yes No
CCTV Yes No
BSL Yes No
Telephone No Yes
Speech No Yes
Hands-on signing No No
Braille Phones No No
3.1.2 Locating Usher families for recruiting in to the NCUS
The task of recruiting up to 200 families with Usher syndrome was shared between the
author and the family coordinator based at the charity Sense, with smaller proportions
of families recruited from other sources.
Recruitment through Moorfields Eye Hospital (MEH)
The task of identifying and recruiting patients from Moorfields Eye Hospital was the
responsibility of the author. Many deaf patients who are suspected of having visual
problems or Usher syndrome are referred to MEH for formal ophthalmic examination.
Additionally many individuals with a clinical diagnosis of Usher syndrome return to the
clinics on an annual basis for routine ophthalmic check up. Moorfields Eye Hospital
has a large patient base which was an important source of identifying prospective study
participants. Recruitment from Moorfields Eye Hospital was approached in three main
ways:
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1. The majority of recruits from Moorfields Eye Hospital were identified through the
genetics database curated by Dr Andrew Webster. This database has acted as
a repository for clinical, administrative and where relevant, molecular data over
recent years. This database was queried for affected individuals with a clinical
diagnosis of Usher syndrome. Their hospital record number was then recorded
and their records accessed via the Hospital Patient Administration System (PAS).
The PAS system was then queried for the date and time of their next hospital
appointment, which was used as an initial point of contact to meet the affected
person and their families and give them information about the study. If they
expressed an interest, their preferred method for subsequent communication (e.g.
email) was established. This method worked well as in many cases sign language
interpreters were already booked for their clinic appointments.
2. The NCUS was publicised amongst clinicians working in the retinal clinics at
Moorfields Eye Hospital . Study information packs were also made available to
doctors to pass to patients.
3. Doctors working in the retinal clinics at Moorfields Eye Hospital would contact
the author to attend clinic to conduct the routine examination and pass on infor-
mation regarding the study. This helped to lighten the clinical load of each clinic,
particularly as many Usher syndrome patients required extra time to communicate
their dual sensory impairment.
Recruitment through Sense
A number of families with dual sensory loss are well known to the national deafblind
charity Sense, who offer support and advice to individuals and their families. Sense used
their records to contact UK Usher families to invite them to participate in the study.
Recruitment through Institute of Child Health Great Ormond Street Chil-
dren’s Hospital
Details of families with Usher syndrome who expressed an interest in the NCUS were
sent information packs by the family co-ordinator.
3.1.3 Deliver information and obtain informed consent
In many cases, deaf individuals who were unable to communicate via voicephone, indi-
cated that their preferred mode of contact was via telephone to another family member.
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For matters relating to organising dates for phenotyping appointments and other admin-
istrative matters this method of proxy communication was employed. For all matters
pertaining to consent and clinical examination direct communication was always ar-
ranged and if sign-language was required, a professional sign-language interpreter was
always employed. Often, family members of deaf individuals volunteered their sign
language skills for translation, however this was avoided in order to ensure that the in-
formation the affected individual received was entirely impartial and unbiased, allowing
them to give their own informed consent to participate in the study.
Ethical approval for the clinical and genetic aspects of the study including the collection
of DNA for research purposes, was obtained from the Multi-Centre Research Ethics
Committee (MREC) of England and local research ethics committees as appropriate
and informed consent was provided according to the Declaration of Helsinki.
Information sheets describing the study aims, purposes and methodology was also ap-
proved by MREC. These information sheets were required to be given to participating
individuals at least 24 hours prior to obtaining informed consent.
There were separate information sheets and consent forms for children and adults.
All affected individuals participating in the study were required to sign three consent
forms for clinical tests, genetic tests and for DNA analysis. All non-affected family
members who submitted blood samples for DNA extraction and subsequent analysis
were required to sign just one consent form for genetic testing.
The information sheets and consent forms can be found in the Appendix section.
3.1.4 Geographical challenges in performing a national study with
deafblind participants
Clinical pheotyping for the ophthalmic and audiovestibular parts of the NCUS were
carried out in London. Each phenotyping session required approximately half a day per
affected individual. For many families who were based outside of London, these two
phenotyping sessions were organised to take place on the same or consecutive days.
Many families from outside London required accommodation to be organised for them
to stay overnight.
Some deafblind study participants who travelled to London on their own, required as-
sistance in getting to the phenotyping centres and this was achieved with the help of
Sense supplying communicator guides to meet participants at their point of entry in to
London and return them to their point of departure from London after phenotyping.
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3.2 How to genotype a genetically heterogenous autosomal
recessive disease in a population?
The large number of genes associated with Usher syndrome (genetic heterogeneity) and
the large genomic size of some of these genes, makes screening these genes for pathogenic
changes both costly and time consuming. The GPR98 gene for example, is associated
with an USH2 phenotype (USH2C) and is one of the largest known human genes, com-
prising of 90 exons encompassing 605 kb (605000 base pairs) of genomic DNA, 19338
base pairs of cDNA which code for 6306 amino acids. In light of the ever present con-
straints of time and money, what approaches could be employed to achieve a molecular
diagnosis in a clinically and genetically heterogeneous condition like Usher syndrome?
3.2.1 Genotyping microarray
One possibility would be to use genotyping microarray platform which holds a finite
number of known mutations for all the Usher genes and run that on the proband for
each family. Any positive results could then be subsequently analysed on a family by
family basis. Such a platform actually exists and in 2006 the NCUS collaborated with
researchers in Holland to develop such a platform based on the arrayed primer extension
(APEX) method [169]. Whilst the relatively low cost of running a genotyping microarray
on the proband of each family is attractive, this method would fail to detect mutations
that were not previously known and included on the chip. Due to the difficulties in de-
termining the pathogenicity of alleles, many of the DNA sequence variants included on
the microarray are of uncertain pathogenicity. This uncertainty would result in equiv-
ocal molecular results and potentially misdirection of subsequent genetic analysis. In a
population where there are a high prevalence of known founder mutations were assayed
on an array platform, this would be a cost and time effective method of genotyping.
3.2.2 Stratify the molecular analysis
Of the nine known Usher genes, mutations in five are generally associated with an USH1
phenotype, three genes with an USH2 phenotype and one gene with the USH3 phenotype
(see table 1.1). Most previous molecular studies in Usher syndrome analysed one or more
genes in a selected population of individuals with the clinical subtype of USH usually
associated with that gene. The advantages of this would be the saving of cost and time
in screening other clinical subtypes who were unlikely to have mutations in that gene,
but this method would not detect the possibility of atypical phenotypes.
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Analyse genes in a logical order
Another possibility would be to order the nine Usher genes in predicted order of decreas-
ing frequency based on previous studies. Each gene could then be sequentially analysed,
one gene at a time, in order of decreasing frequency. After analysis on one gene was
completed, those families with a confirmed molecular diagnosis for that gene, could be
removed from the panel who would all then undergo analysis of the next gene in the
remaining subset. The disadvantage with this method is that atypical phenotypes for
a given gene would be missed as would the opportunity to interrogate possible digenic
effects.
Direct molecular analysis in each family to the subset of genes known to be
associated with that families phenotype
This stratified approach could be further expanded by analysing only the subset of
genes associated with the clinical subtype of the family in question, further reducing
the workload. Both these approaches make the assumption that gene frequency in one
population is the same as another, which we know is not the case in Usher syndrome
worldwide (see subsection 1.3.3).
Direct molecular analysis in each family based on the result of genetic
linkage analysis
Chromosomal linkage markers for each gene or locus could be run in all members of an
informative family to exclude or demonstrate linkage to one or more genes/loci and thus
reduce subsequent efforts by excluding further analysis of genes that could be confidently
excluded.
3.3 Molecular strategy prior to collaboration with Well-
come Trust Sager Institute
At the start of the NCUS in 2003, all genetic analysis was to be performed in-house by
two researchers, myself and a part time post-doctoral research fellow based at Institute
of Child Health, UCL, London.
The ultimate aim of molecular analysis was to identify the two pathogenic DNA se-
quence variants in the appropriate gene in each family. Bidirectional DNA sequencing
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Table 3.2: Table summarising split of molecular analysis for NCUS in 2003
Researcher Location Molecular analysis duties
Dr Elene Haralambous Institute of Child Health USH1 genes
Dr Zubin Saihan Institute of Ophthalmology USH2 and USH3 genes
currently represents the gold standard for identifying disease causing mutations. Per-
forming sequencing on all exonic regions in each of the nine genes associated with Usher
syndrome, by two individuals would have been impossible for the following reasons:
1. Time constraints: In-house DNA sequencing is time consuming.
2. Financial constraints: In-house DNA sequencing reagents were expensive
3. Practical resources: DNA sequencing machines were shared with other groups in
our respective workplaces and thus only available for limited use per week.
4. Genomic size: There are a large number of genes associated with Usher syndrome
(see 1.2) spanning a huge genomic area (see table 3.3)
5. Man hours: In addition to molecular analysis, my time had to be divided between
actively recruiting families and performing the ophthalmic phenotyping.
Accepting that we would be limited in our ability to perform bidirectional sequencing,
it was important to refine the disease causing loci in each family.
Table 3.3: The genomic size of the nine genes associated with Usher sydnrome
Gene Genomic size (base pairs)
MYO7A 86973
USH1C 50521
CDH23 419008
PCDH15 1825171
USH1G 7175
USH2A 800502
GPR98 605421
WHRN 103376
USH3A 46836
TOTAL 3944983
The initial plan was to collect DNA samples from affected individuals and unaffected
family members as they were recruited in to the study. Where possible, in-house chro-
mosomal linkage analysis using polymorphic markers would then be performed with the
aim of excluding or suggesting linkage to certain genes or loci, reducing the likely number
of genes that required subsequent interrogation in each family.
Chapter 3. Background to study methods 47
In consanguineous families, it would be anticipated that the affected individuals would
be homozygotes for the same pathogenic DNA sequence variant. In such consanguineous
families, homozygosity of linkage markers at a particular locus in affected individuals
would thus be used to point toward a molecular diagnosis.
In non-consanguineous families with an informative pedigree structure (DNA samples
from enough affected and unaffected siblings), providing the markers were informative,
we might expect to confidently exclude a number of genes by linkage analysis alone as
we would expect all affected siblings to be Identical By Descent for a genotype at a
particular locus compared to their unaffected siblings.
It was accepted that running chromosomal markers would be of little practical use on
non-informative pedigree structures such as simplex cases (those without siblings) or in
families without sufficient parental and/or sibling DNA samples.
After excluding or highlighting loci by linkage analysis, the next stage of refining molec-
ular analysis would be to amplify DNA coding regions by polymerase chain reaction
and perform a technique such as Single Strand Conformation Polymorphism (SSCP) or
use the WAVE analysis system (heteroduplex analysis) to further reduce the potential
number of amplified regions that might need to be sequenced in order to identify the
pathogenic sequence variants.
Challenges with this initial approach to molecular analysis
The main challenge with this initial approach was efficient use of laboratory time. Be-
cause recruitment in to the study was an ongoing process, DNA samples were collected
piecemeal. However linkage analysis for a marker set were only useful after DNA for the
whole family had been received and genotyped. In terms of laboratory time and cost, it
would have been more efficient to finish recruitment of all individuals and then run sets
of markers across the whole panel of DNAs, however due to the time constraints of the
study and time pressures resulting from my additional responsibilities of recruiting and
ophthalmic phenotyping, this was felt not to be a viable option.
3.4 Collaboration with Wellcome Trust Sanger Institute
In 2006 collaboration with Prof Karen Steel afforded the NCUS to gain access to the
high-throughput sequencing pipeline at the Wellcome Trust Sanger Institute.
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This new opportunity radically changed the genetic aspect of the study. The previous
strategy of piecemeal genetic linkage analysis with markers and in-house sequencing was
largely abandoned at this stage.
The high-throughput sequencing pipeline offered to manually re-annotate the nine Usher
genes (and one candidate gene) prior to direct bidirectional DNA sequencing on the
above ten genes in the proband from each family recruited in to the study.
At this point the entire genetic aspect of the project was re-evaluated and taken in a
different direction. The comprehensive genetic data on each of the Usher genes in every
family enabled the study to address questions that would not have been possible with
the initial approach to molecular diagnosis in addition to providing a broader overview
of Usher syndrome.
3.4.1 Why sequence all the Usher genes in each individual?
This strategy was employed for several reasons, outlined below.
• Due to the set up of the high-thoughput sequencing pipeline, DNA samples had to
be analysed in batches of exactly 48 (half a plate). At the time of collaboration,
less than 48 USH1 probands were recruited in to the study. Thus the initial 48
DNA samples analysed were a mix of USH1, USH2 and USH3 phenotypes.
• This method would give us the unprecedented opportunity to interrogate the pos-
sibility of digenic effects in Usher syndrome
• This method would give us the unprecedented opportunity to interrogate the Usher
genes for atypical presentations. This would enable us to answer the question,
“can mutations in a gene typically associated with one clinical subtype produce
phenotypes of a different clinical subtype?”
3.4.2 Summary of the final methods employed for molecular analysis
(Figure 3.1)
The genetic analysis aspect of this study was essentially in two stages. The first stage
involved bidirectional DNA sequencing of the nine known Usher genes in one affected in-
dividual (the index case) from each family. The sequencing experiments were performed
at the Wellcome Trust Sanger Institute by collaborators. The raw sequence data was
then ‘blindly’ analysed and interpreted by myself and other collaborators based at the
Institute of Child Health, UCL.
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DNA sequence variants identified from this stage were then interrogated further in fami-
lies by means of a series of allele specific assays which was genotyped in a larger panel of
DNA samples consisting of index cases, their affected siblings, unaffected family mem-
bers and a panel of ‘control’ DNA samples. The experiments were performed by the
private company Sequenom and the results validated and analysed by myself and other
collaborators based at the Institute of Child Health, UCL.
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Figure 3.1: Simplified schematic illustrating the main methods finally employed for
genetic analysis
3.5 Challenges in collecting, storing and analysing clinical
and genetic data for a large prospective collaborative
study
The NCUS required the secure storage of the vast amounts of clinical, molecular and ad-
ministrative information collected. I was solely responsible for creating and maintaining
a database for this purpose.
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Figure 3.2: Overview of NCUS database structure
The NCUS database had to house vast amounts of clinical and genetic data collected
from different sites over the course of several years. Access to the data had to be tightly
controlled to protect patient identity.
As the study was set to run for several years, the database had to be robust, secure and
flexible enough to allow the subsequent addition of different types of data as the study
progressed.
Prior to construction of the data storage, consideration was given to how the data
was stored bearing in mind that the data would at some point in the future, need to
be analysed in order to achieve study aims. Thus the database construction was an
important part of study methodology and is discussed in this section.
Database construction was essentially a dynamic process and structured in a hub and
spoke model, the hub being a main table called tblPerson. Each record in this table
corresponded to an individual (either an affected or unaffected family member) that had
been recruited in to the study.
Each person had a unique identifier number (termed the NCUS ID number) auto-
matically generated and assigned to them.
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The database was essentially a relational database which was constructed in a modular
fashion to enable the addition of new data tables to be added as required as the study
progressed. Each record in the other tables was linked back to the central table, such
that a person’s identity could be recorded by a simple anonymous number (NCUS ID
number).
Each individual was manually ascribed a Family number. Unlike the unique identifier
NCUS ID number, several individuals from the same family could share a Family number.
Data pertaining to the whole family, such as ethnicity and consanguinity were stored
under the Family number rather than the NCUS ID number.
Where possible, data entry was forced choice or binary rather than free text, to allow
for subsequent electronic filtering of results. Also care was taken to avoid duplication of
data in data tables in any form.
When a table was designed for the purposes of recording clinical data, a date of ex-
amination field was included, such that every clinical entry related exclusively to data
collected at a specific date and time. This was done so that if the same clinical data was
collected in the future, this could be added to the same table this enabling the collection
of longitudinal clinical data from the cohort using the same database.
3.5.1 Multi-user and software problems
Access to the database was required simultaneously by different collaborators at the
different sites in the UK listed below:
1. Institute of Ophthalmology, UCL, London
2. Institute of Child Health, UCL, London
3. Sense headquarters, London
4. At the home of the family coordinator (who worked partly from home) outside of
London
Because most collaborators ran Microsoft Windows XP operating systems, the database
had to be accessible using this operating system. The database also had to comply with
UCLs strict policy on data storage, with the confidential patient data encrypted and
password protected. Because a collaborator at one of the above five sites might enter
data that would need to be viewed collaborators at other sites, the database had to
house data that was live such that when data was entered it was updated immediately.
Chapter 3. Background to study methods 52
In order to maintain tight security to the data, each user could only access the database
from the specific known location of their PCs (using a static TCP/IP address) and they
were only able to gain access to the data after the correct username and password had
been entered. Registration of the database with University College London was manda-
tory under the data protection act (1998). Following successful registration, permission
was granted to house the data (UCL reference number Z6364106, Section 19, Research:
Medical Research).
Access to each table in the database had to be granted for each username by the database
administrator (myself). For example, scientists working on molecular analysis were not
granted privileges to view clinical data, but were granted privileges to view (but not
edit) relevant administrative data such as names and date of birth. This was done to
comply with data protection regulations and also to safeguard data from inadvertent
modification.
As most collaborators were familiar with the Microsoft Office software suite, using the
popular database program Microsoft Access seemed a sensible starting point. Initially
the web based networking software Citrix was trialled with Microsoft Access but this
did not work efficiently and the security levels were not tight enough to comply with
UCL’s policy for data storage.
To circumvent this, a host MySql server in the UCL computer network was set up. Each
researcher had access to the database restricted to a single IP address and access was
password protected.
The main problem with using MySql is that whilst the data is stored logically, the user
interface is not intuitive and entering data is a cumbersome process involving the use of
long strings of command lines.
To get round these problems, a Microsoft Access software “front-end” was created to
view the data stored remotely in the MySql database. The forms created were user
friendly and easy to navigate due to the incorporation of tabs and pages. Data entry
was facilitated by the creation of text boxes. Visual Basic commands were written and
embedded in the Microsoft Access front-end such that each time a patient record was
navigated to, or updated in any way, this updated the central MySql database and as
well as appropriately queried the central MySql database to display the correct live data.
Backup of data
Regular back up of the MySql database tables was performed and stored securely.
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Identifier Keys
In addition to theNCUS ID number and Family number keys which identified indi-
viduals and families by a unique integer, similar alphanumeric identifiers were ascribed
to aliquots of DNA samples.
When sending aliquots of DNA to collaborators at different research sites, these samples
were given unique DNA identifier keys.
3.6 How to determine if a DNA sequence change is pathogenic
or not
Identifying whether a DNA sequence change is pathogenic or not is not straightforward.
3.6.1 Rare SNP in a particular population or pathogenic variant?
Although pathogenic single base pair changes will be expected to be less prevalent than
non-pathogenic population variations like SNPs it does not follow on that all rare single
base changes will be therefore be pathogenic. As discussed earlier (1.3.2) one would
anticipate that over a third of all SNPs would occur at a frequency of less than 1%
depending on the population group studied.
Government figures in the UK suggest approximately 8 percent of the UK population
belong to a non-White ethnic group [170]. As our study participants were to be drawn
from the ethnically diverse population of the United Kingdom, it was anticipated that
many single base changes in our cohort may simply represent rare non-disease causing
alleles prevalent in ethnic groups.
One solution to this problem would be to assay the frequency of any rare sequence
variants found in a family of ethnic origin, in an ethnically matched control group of
chromosomes for that particular family. However, in such an ethnically diverse popula-
tion as the UK, this solution would be impractical and potentially a whole new study
in its own right. The compromise that was reached involved the assembly of a control
panel of 433 DNA samples (866 chromosomes) comprising of 376 unrelated UK blood
donors from the European Collection of Cell Cultures (ECCAC, UK) and 57 individu-
als of Pakistani origin (courtesy of Professor Eamonn R Maher, Birmingham, UK). See
table 4.2.
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3.6.2 Potential methods employed to determine pathogenicity
Deciding whether or not an allele is disease causing is often not straightforward.
The gold standard for deciding whether or not a particular DNA sequence variant is
disease causing or not would be to express it in an appropriate cell line and perform
functional protein analysis to determine of the suspected mutant allele confers a delete-
rious effect on protein function compared to the wild type allele.
In a disease such as Usher syndrome where the exact site and biological function of the
normal protein is not fully understood, this would present some problems in terms of
choosing an appropriate cell line and assay. Furthermore, in addition to their being sev-
eral different genes that are associated with the disease, many of the mutations reported
to date are private (specific to families, rather than populations) creating a huge volume
of different potential mutations to analyse.
A fairly robust method is assaying the frequency of the allele in question in a control
population. The limitation to this, as discussed above, is that there is the wide variation
in polymorphic allele frequency amongst different populations, requiring an ethnically
matched control group to the study sample (as discussed above) to interrogate allele
frequency.
Interpreting a sequence change in the context of Mendelian inheritance can also be of
use in some cases. The assumptions here would be that the disease in question is a
monogenic disorder, that is transmitted by Mendelian inheritance. Taking these two
prerequistes as given, in the case of an autosomal recessively inherited disease such as
Usher syndrome, one would expect an affected individual to inherit two disease alleles
in a gene (one from each parent) and this carry these alleles in trans. If this can be
demonstrated by segregation analysis, this would lend support to the hypothesis that
the two alleles in question are disease causing.
Interpreting a sequence change in the context of what we know about the structure
of genes can also be useful. For example a DNA sequence change in a coding region
of DNA is more likely to affect protein function and thus be disease causing than a
non-coding change. Furthermore, changes that cause disruption of the reading frame,
will result in all of the codons occurring after the deletion to be read incorrectly during
protein translation, which is more likely to affect resultant protein function that a single
nucleotide change within the coding region.
For missense changes, determining pathogenicity can prove more tricky. One can perform
multiple sequence alignment for DNA or proteins from different species with programs
such as clustalw2 which produces biologically meaningful multiple sequence alignments
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of divergent sequences. Clustalw2 determines the best match for selected sequences, and
aligns them so that their similarities and differences can be seen. The main hypothesis
for this form of analysis is that evolutionary conserved sequences across divergent species
are more likely to be important for proper protein function, suggesting that if the change
in question is conserved, it is more likely to be disease causing.
Clustalw2 requires that sequences for comparison are selected manually where as the
software program SIFT (Sorting Intolerant From Tolerant) processes the query se-
quence by first searching for similar sequences, then chooses closely related sequences
that may share similar function, performs alignment of these chosen sequences and then
calculates the probability for all possible substitutions from the alignment. If the nor-
malised probability calculation for a nucleotide is <0.05, the change is predicted to be
deleterious, whilst if the probability is 0.05≤ the change is predicted to be tolerated.
Because many of the DNA sequence variants will have been previously reported by other
researchers, some use can be made of the published allele frequency in controls as this
is an impartial statistic that can be useful in determining the minimum allele frequency.
By the same token, some care must be exercised in designating a particular allele as
disease causing simply because it has previously been reported as such.
3.7 Overview of study methods
A detailed schematic of the NCUS can be found in Figure 3.3 which aims to give the
reader an overall appreciation of the chronological order of events prior to the more
detailed exposition of molecular and clinical methods in the following chapters.
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Chapter 4
Molecular Methods
4.1 DNA collection and labelling
4.1.1 From NCUS participants
Blood samples for DNA extraction were collected from all affected individuals and un-
affected first degree family members where possible. In some pedigrees, with a con-
sanguineous or unusual family structure, second degree family members also had blood
taken for DNA analysis. Blood samples for DNA extraction were obtained in the fol-
lowing ways:
1. during attendance for phenotyping tests in London
2. by the family coordinator during visits to family homes
3. by posting blood packs to study participants which they took to their local GP or
Hospital phlebotomy service
Blood packs contained several items listed here 4.1 and were a useful way that individuals
could get their blood sample taken locally then posted directly to the Camelia Botnar
Laboratory for DNA extraction. The assembly and posting of blood packs was achieved
with help from the charity Sense.
4.1.2 Control DNA
Control DNA samples were employed in three areas of the study.
57
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Instruction letter for patient
Instruction letter for General Practitioner’s surgery or local Hospital Phlebotomy service
Consent form for DNA analysis to sign and return
x2 EDTA plastic tubes for blood sample and patient details label
Plastic tube to hold EDTA tube
Form with blood sample administrative details to complete and return
Padded envelope with address of DNA extraction laboratory
Biological hazard sticker on envelope
Table 4.1: Contents of blood packs used for collection of DNA via post
1. Optimisation of in-house PCR and in-house linkage analysis.
Control DNA samples were drawn from an in-house panel of individuals working
at the Institute of Ophthalmology, London, UK.
2. High throughput sequencing at the Wellcome Trust Sanger Institute,
Cambridge, UK
A panel of control DNA was used during high throughput sequencing at the Well-
come Trust Sanger Institute. The panel has been used extensively in previous
work done at this facility. The panel consisted of 48 individuals from the CEPH
families supplied by Coriell Cell Repositories. Full details of this CEPH panel can
be found at www.sanger.ac.uk/humgen/exoseq/DNApanel.shtml. The panel of 48
individuals (96 chromosomes) was not used in the final calculations of minimum
allele frequency but were used as a quick reference guide to assess whether a DNA
sequence change noted on direct sequencing was common or rare.
3. Allele specific assays performed by Sequenom, San Diego, USA
A panel of control chromosomes was assembled to interrogate DNA sequence
changes found in the NCUS cohort. This panel of 866 chromosomes was assem-
bled as outlined in table 4.2. A macro was written to generate the minimum allele
frequency of each sequence variant assayed.
Table 4.2: Control DNA samples used for 2nd round of genetic analysis, the allele
specifc assays performed by SequenomR©
Control DNA ethnicity/origin DNA samples (n) Chromosomes (n)
ECCAC controls 1 381 762
Pakistani controls 2 59 118
TOTAL 440 880
1 - from European Collection of Cell Cultures (ECCAC, UK)
2 - from Professor Eamonn R Maher, Birmingham, UK
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4.2 DNA extraction of NCUS participants
DNA was extracted from peripheral blood samples at the NHS Camelia Botnar
laboratory, located at the Institute of Child Health. Blood samples were cen-
trifuged at 4000 cycles per second for 15 minutes. Cells were suspended in PBS at
a concentration of 1 x 106 cells per 100 µL, double the volume of DNA lysis buffer
added, mixed and then incubated at 68 degrees centigrade for 5 minutes. The sam-
ple was then cooled, mixed with an equal volume of chloroform and centrifuged
at 2000rpm for 20 minutes. The upper layer, containing the DNA in solution,
was carefully decanted, added to an equal volume of 100 % ethanol and gently
mixed until the DNA precipitated. The DNA was transferred to a clean tube and
washed twice in 70% ethanol, then dissolved by end-over-end rotation at 4◦C in
an appropriate volume of ddH20. Samples were stored at 4◦C.
The DNA sample was stored in plastic Eppendorf tubes, labelled only with the
NCUS ID number and stored in labelled boxes. The storage location of a sample
(box reference number and location was then logged on to the NCUS database, to
enable DNA samples to be located easily.
4.3 In-house molecular methods
For the purposes of clarity, in the exposition of molecular methodology that follows,
the prefix “in-house” refers specifically to laboratory work that was performed by
the author in Dr Andrew Webster’s laboratory at the Institute of Ophthalmology,
UCL, London. This is to distinguish molecular work done by myself and that
performed by our collaborators from the Institute of Child Health, the Wellcome
Trust Sanger Institute and the experiments outsourced to the private company
SequenomR© (San Diego, USA).
4.3.1 In-house Polymerase Chain Reaction
PCRs were performed in-house prior to linkage analysis and in-house direct bi-
directional sequencing. They were also performed by the Wellcome Trust Sanger
Institute prior to high throughput sequencing.
In-house PCRs were designed with the program Primer3 [171]. Desalted primers
were synthesised on a 0.05µM scale by the company Sigma Aldrich.
Dry oligonucleotides were briefly spun for around 5 seconds at 1500 rpm and re-
constituted with sterile deionised water to a stock concentration of 100µM stock
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solution, which was subsequently stored at -20 degrees centigrade. For PCR reac-
tions, this stock solution was diluted down to a concentration of 10µM.
Table 4.3: Reagents for in-house PCR
Reagent Volume (µ L)
x10 NH4 buffer (No MgCl2; Bioline UK) 2
MgCl2 [1.5µM] (Bioline, UK) 1
dNTP [2mM] 2
Forward primer [5pM] 2
Reverse primer [5pM] 2
Taq polymerase (Bioline, UK) 0.1
dH2O 9.9
10ng DNA template 1
TOTAL VOLUME 20
The PCR conditions were optimised for each set of oligonucleotide primers using
a sample of control DNA of known quality and concentration (10ng/µl). To iden-
tify the optimum annealing temperature for each set of oligonucleotide primers,
reaction mixes were made as outlined in table 4.3 and run with 10ng of the same
control DNA using the “gradient” profile on an Eppendorf Mastercycler PCR block
(Hamburg, Germany). The settings for the gradient setting were entered as fol-
lows: annealing temperature=7 ◦C, ramp=3 ◦C/sec, gradient=7 ◦C on the
PCR block. After PCR amplification using the thermoprofile settings listed in
Table 4.4, 10µ of each PCR was run on a 1% agarose gel and visualised under
ultraviolet light with an appropriate molecular weight ladder. The strongest most
discrete band was identified and the annealing temperature corresponding to this
sample was used for subsequent PCRs for that particular oligonucleotide primer
pair.
Table 4.4: Thermoprofile for in-house PCR
Step Function Temperature in degrees C Duration
1 Hot Start 95 5 minutes
2 Denature 94 30 seconds
3 Anneal 50-62∗ 30 seconds 35 cycles
4 Extension 72 30 seconds
5 Final extension 72 10 minutes
∗ the annealing temparature for each PCR reaction was determined during PCR opti-
misation
In-house PCRs for in-house linkage analysis
Desalted primers for in-house linkage analysis were synthesised on a 0.05µM scale
by the company Sigma Aldrich and labelled with one of the three fluorescent
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fluorophores FAM, HEX or TET.
Fluorescently modified oligonucelotides were reconstituted to a stock concentration
as described above. They were stored at -20 degrees centigrade in eppendorf
tubes wrapped in aluminium foil to reduce exposure to light and prevent dye
photobleaching.
4.3.2 In-house Agarose gel electrophoresis
Agarose gels were used for analysing the products of in-house PCR.
A gel tank was prepared with end plates and placed in a freezer at -20 degrees
centigrade to cool. During this time, Agarose powder (Bioline, UK) was added
to 1.5%TAE buffer in a conical flask to a concentration of 1-2% depending on the
degree of resolution required and gently agitated manually for 30 seconds. This
suspension was heated gently to for 2-4 minutes in a microwave until all the agarose
powder had disolved. Ethidium bromide [50ng/ml] (Sigma, UK) was added to the
flask and agitated manually for 30 seconds.
The gel tank was removed from the freezer and a plastic comb was inserted. The
contents of the flask were then carefully decanted in to the gel tank and allowed to
set at room temperature for 30 minutes. The plastic combs were removed which
formed indentation wells in the gel and the end plates of the gel tank were also
removed.
The gel was then placed in a gel tank filled with 1.5% TAE buffer. For each row
of wells, one well was loaded with DNA ladder to mark out fragments of known
molecular size. Either 1µl of phiX174 DNA/HaeIII Markers DNA ladder [0.5
g/10/muL] (Promega, USA) or 0.5µl of HyperLadder TMIV [0.16g/10µl] (Bioline,
UK) was used for this purpose.
PCR products were mixed with bromophenol blue (BPB) loading dye at a ratio of
10:1 and 5-10µl were loaded in to the wells and a current of 200mW passed across
the gel tank for approximately 20 minutes or until the BPB dye had progressed
sufficiently along the gel. The gel was then imaged using ultraviolet illumination.
4.3.3 In-house genetic linkage analysis using markers
In-house genetic linkage marker construction
A set of markers were assembled for four genes/loci corresponding to the molecular
subtypes of Usher syndrome USH2A, USH2B, USH2C and USH3A which were used
to interrogate families segregating a non-USH1 phenotype.
Chapter 4. Molecular Methods 62
These markers consisted of a combination of previously published genetic linkage
markers alongside new markers that were created in-house.
Polymorphic markers were chosen a short genetic distance from the gene being
interrogated. In some cases, markers were located within the non-coding areas of
the gene being interrogated. The main criteria for marker selection was proximity
to the gene in question. A secondary criteria was a relatively high heterozygosity
score, as these markers were more likely to be informative. In-house markers
for a particular gene were created by downloading genomic DNA containing the
coding sequence of that gene from the human DNA sequence repository at The
National Center for Biotechnology. This section of genomic DNA was limited by 20
kilobases either side (both upstream and downstream) of the coding regions. These
sections of genomic DNA were then searched for contiguous repeat sequences of
CA/GT dinucleotides using a simple iterative program written in house. Flanking
oligonucelotide primers were then designed around the tandem repeat sequence
using the software program Primer3 and the primer pair labelled with a fluorescent
label as described above (see 4.3.1).
Genotyping markers
The PCR was optimised and then run on ten control DNAs. 1µl of each PCR
reaction was then suspended in 9µl of Formamide and run on the ABI 3100 geno-
typer. The fragment lengths were analysed using ABI Genotyper software ver 3.7
and fragment lengths were measured. If markers amplified reliably and had alle-
les were of sufficient heterozygosity that could be accurately scored on the ABI
PRISM 377 DNA Sequencer in a control panel of 10 DNA samples they were cho-
sen to add to the panel. The fluors used to label markers and the amplimer size
of in-house markers were chosen to allow multiplexing of the electrophoresis where
possible.
Figure 4.1 shows an example of the traces of one of 6 polymorphic linkage markers
that were designed for the USH2A gene.
4.3.4 In-house bidirectional DNA sequencing
PCRs were cleaned using Millipore montage PCR clean-up plates (Oxford, UK)
as described in table 4.6.
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Table 4.6: Method for in-house PCR clean up prior to in-house sequencing
STEP
1 Run 5µl of PCR product on an agaorse gel to check PCR success
2 Make up volume of remaining PCR to 100µl with H20
3 Transfer this 100µl to purple plate
4 Vacuum 10 mins
5 Check wells are empty
6 Add 25µl H20 to each well
7 Vacuum 3 mins
8 Wash bevelled plate and leave to dry
9 Add 20µl H20
10 Cover plate & cling-film
11 Vortex at 1000rpm for 10 mins
12 Transfer remaining (approx 15µl) to plate for storage
13 Mark out used wells on purple plate in order to re-use purple plate
14 Use 2 to 2.5µl of this cleaned product for sequencing reaction
Using Millipore PCR clean up montage plates
In-house sequencing reaction
In-house sequencing reaction was performed using cleaned PCR product and the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, UK) as per
Table 4.7.
Table 4.7: Reagents for in-house DNA Sequencing reaction
Reagent Volume (µl)
BigDye (Applied Bio, UK) 0.5
Sequencing Buffer 2.5
(Forward or Reverse) primer [5pM] 0.5
Clean PCR product 2
dH2O 4.5
TOTAL VOLUME 10
In-house sequencing thermoprofile
The sequencing reaction thermoprofile used for in-house sequencing is shown in
Table 4.8.
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Table 4.8: Thermoprofile for in-house sequencing reaction
Step Temperature in degrees C Duration
1 94 30 seconds
2 96 30 seconds
3 55 15 seconds 27 cycles
4 60 2 minutes
5 60 3 minutes
Table 4.9: Method for clean up of in-house sequencing reaction prior to in-house
sequencing
STEP
1 SEQ cleanup (BLUE plates)
2 Add 25µll Injection solution to each well
3 Transfer total volume ∼35µl to BLUE plate
4 Vacuum 3 mins
5 Check wells are empty
6 Add 25µlInjection solution to each well
7 Vacuum 4 mins
8 Wash bevelled plate and leave to dry
9 Add 25µl Injection solution to each well & tap it to the bottom of well.
10 Cover plate & cling-film
11 Vortex at 1000rpm 10 mins
12 Transfer remaining vol ( 11µl) to sequencing plate
13 Mark out used wells on blue plate in order to re-use purple plate
Using Millipore sequencing clean up montage plates
4.4 Wellcome Trust Sanger Institute
4.4.1 Sequencing work performed
The index case (“proband”) from each family underwent bidirectional DNA se-
quencing of the nine Usher genes and one candidate gene at the Wellcome Trust
Sanger Institute.
This group of individuals will subsequently be referred to as the Sanger cohort.
The annotation of each of the nine Usher genes and the one candidate gene, primer
design and sequencing reactions were performed entirely by collaborators at the
automated high-throughput pipeline at the Sanger Institute.
The raw sequence traces generated from these sequencing reactions were automat-
ically stored in an electronic repository.
Although the reactions were performed entirely by collaborators, the analysis of
the sequence trace data was performed manually using computational software
aids described in a later subsection 4.4.4. Due to the large volume of sequence
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trace data generated from ten genes in 186 families, this analysis work was divided
up between a group of six individuals (including the author) based at the Institute
of Child Health, Institute of Ophthalmology and at the Sanger Institute.
In addition to the panel of DNA samples from this study, each amplimer was also
sequenced in a panel of 30 control DNA samples from CEPH families (see 4.1.2 for
details). This panel of DNAs served as a screening panel to enable the detection
of common polymorphic changes. Prior to undertaking sequencing analysis for an
amplimer, the CEPH control panel was first analysed. Any sequence variants that
looked polymorphic (e.g. present in a significant proportion of control DNA sam-
ples) were marked by their position in the amplimer such that when the amplimer
was subsequently analysed in the USH index case panel, this information would
be available to indicate common polymorphic changes.
Any sequence changes identified were recorded by the amplimer name, the base pair
change, and the location of the sequence variant within the amplimer. All sequence
traces were aligned to a reference sequence that was defined and numbered in
relation to the forward and reverse primers. This is illustrated in Figure 4.2. Thus
if a sequence change was located at number 154 in a contig, the position of this
nucleotide could be subsequently by locating the forward primer and counting 154
base pairs downstream. This transformation of data was achieved by assembling
a contig of genomic DNA for the gene, which was aligned with sequence files for
the primers used as well as sequences for all coding regions. this was performed
using the software tools in DNASTAR v.8.0.2 (Lasergene Madison, USA).
A decision was made based on the position and frequency of a sequence vari-
ant identified as to whether it was recorded. Any sequence change that was in or
around a coding region was considered worthy of subsequent analysis and recorded
on a database. Only polymorphic changes (that were present in significant pro-
portions in he control DNA panel) were not scored in each individual.
The results from this initial round of sequencing was thus recorded in a largely
abstract format. Subsequently this ‘raw’ data was transformed in to meaningful
genomic and coding sequence data and recorded alongside the raw data on the
same database.
The sequencing analysis was a significant undertaking that took several years to
complete as it generated 278475 base pairs of sequence per individual, which totals
just under 53 million base pairs for the Sanger cohort.
The author was solely responsible for the analysis of the USH2A gene in each of the
index cases and 30 control DNAs that were also sequenced at the Sanger Institute,
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stSG1155388 
ins GA (154_155) 
Figure 4.2: Screengrab of a GA insertion between nucleotide numbers 154 and 155.
The pink bars in the reference sequence indicate that these nucleotides are coding in the
reference sequence. The amplimer reference is stSG1155388. This data would then be
used at a later stage to locate the position of nucleotides 154 and 155 on an alignment of
genomic DNA and revealed that this change represents the novel frame-shift sequence
variant p.Arg1946LeufsX22 (Family 173)
whilst the sequence trace analysis in the other genes was shared amongst the rest
of the team.
Following the conclusion of the second round of molecular experiments all individ-
uals with an USH2 phenotype and no putative pathogenic changes in addition to
index cases in whom only one putative pathogenic sequence change was identified
were reanalysed by another member of the team Dr Polona Le Quesne Stabej, who
rechecked the sequence trace files analysing raw electropherogram traces to double
check for missed sequence variants in this subset of individuals in whom another
disease causing allele in this gene were suspected.
Anonymity of DNA samples
DNA samples were submitted to the Sanger Centre labelled only with their (anonymised)
NCUS ID number. The Sanger Centre generated a new alphanumeric key to re-
fer to each sample. All DNA sequence trace analysis was undertaken using these
alphanumeric keys rather than patient names. This was done in order to comply
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with departmental policy as well as removing the potential bias of analysing DNA
from an individual in whom the phenotype was already known; i.e. the DNA
samples were analysed “blindly”.
Two probands had duplicate DNA samples sent and despite the clinical diagnosis
of some of the families with suspected non-USH were known soon after recruitment,
these DNA samples were left in the Sanger cohort and still underwent sequencing.
4.4.2 Vega gene re-annotation
Prior to sequencing each gene was re-annotated using the VEGA annotation al-
gorithms for predicting exon structure. These were compared against published
findings. The re-annotated genes can be found online in the VEGA genome browser
4.4.3 High-throughput sequencing pipeline
Primer Design
This was carried out using the program Primer3. Primers for all genes were de-
signed to cover all exonic regions and intron/exon boundaries as well as 3 prime
and 5 prime untranslated regions (UTRs) using the Primer3 to amplify the exon
and at least 125 base pairs either side of the exon to capture the splice sites and
regions and sequences that may be of other functional importance. The target
amplimer size was between 450 and 550 base pairs.
Primers with 1 base pair mismatches (or SNPs) in their sequence were excluded
and re-designed. Larger exons required several overlapping primer pairs to obtain
complete coverage of the exonic area.
Any exons that failed automatic primer design at this size range were re-designed
with an increased permitted product size of up to 700 base pairs. If primers failed
at this target amplimer size they were then designed manually.
Primers were checked for uniqueness in the human genome using the In-silico PCR
experiment simulation system (ipcress) software program.
Primers were screened for optimum amplification conditions . A full list of primers
can be obtained by searching using gene name at this location.
Primers with exact or 1 bp mismatches (or SNPs) in their sequence were excluded
and re-designed. For large exons a series of overlapping primer pairs were designed
to enable adequate coverage on sequencing.
PCRs and sequencing reactions were tested initially in a panel of 48 CEPH DNAs
(2). Those primers that failed to amplify successfully were redesigned.
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High throughput PCR
The Standard ExoSeq PCR reaction conditions and thermoprofiles used for PCR
are available online from the Wellcome Trust Sanger Institute at
www.sanger.ac.uk/resources/downloads/human/exoseq.html
Over 700 primer pairs were designed to cover the nine genes associated with Usher
syndrome and another candidate gene SLCA4. Each primer pair was given a
unique alphanumeric identifier code termed an STS number. Each panel of DNAs
sequenced for a particular STS number were given a unique numeric identifier
code termed GROUP ID. Both these identifiers were generated from the high
sequencing department at the Wellcome Trust Sanger Institute.
Sequencing reaction conditions
PCR products were sequenced with specific primers bidirectionally to produce
double-stranded sequence. Protocols are available at
www.sanger.ac.uk/humgen/exoseq/protocol-sequencing.shtml.
4.4.4 DNA sequence analysis using the Staden Package
DNA sequence traces were analysed using the open source software the Staden
Package.
Raw trace files from bidirectional sequencing at the Wellcome Trust Sanger In-
stitute were initially processed with the pregap4 program, prior to analysis with
the gap4 program in search of DNA sequence changes. I was responsible for the
analysis of sequence data for the 100 amplimers of sequence data for the USH2A
gene in all 180 probands, whilst several other researchers based at the Institute of
Child Health and Wellcome Trust Sanger Institute performed sequence analysis of
the other genes sequenced.
pregap4
pregap4 is a software program which is part of the Staden Package which provides
a graphical user interface (GUI) to the processing of raw trace sequence files.
As it’s name suggests it is used prior to analysing the sequences in the gap4
software program. pregap4 has the facility to perform several functions that can
be realised in gap4 and it also assembles files in to a contig. pregap4 can also be
used to convert file format, screen for contaminant sequences and perform repeat
searching. A useful feature of pregap4 is the integration of an algorithm which is
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used to assign a numerical value to sequence files to quantify base read confidence.
An overview for the stages of pregap4 processing are outlined in figure 4.3.
Figure 4.3: Overview of pre-GAP4 trace file processing
The configuration settings for pregap4 were set as indicated in figure 4.4. These
settings were important prerequisites in order to process the sequence data ap-
propriately to allow automated estimation of base accuracies and the highlighting
possible mutations when subsequently analysing the traces in gap4.
Importing sequence files in to pregap4 is achieved by selecting the files to process
tab. In addition to the sequence files for a group of individuals, reference sequence
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Figure 4.4: Screengrab of the pregap4 settings used for processing sequence trace files
traces (both forward and reverse) were added and in some cases a sequence file
containing the exonic sequence contained in the amplimer was also imported. This
was done so that when analysing the contig in gap4 one could easily view the
position of a particular sequence variant within a contig was exonic or intronic.
Sequence files that were of very poor quality or absent were excluded in the contig
selection.
Each time a set of samples was processed using pregap4, a new gap4 database was
generated, the name of which had to be chosen and manually entered as indicated
in Figure 4.5.
When a group of samples was successfully processed by pregap4 an experiment file
(extension .aux) was created with the same name as the database.
4.4.5 Analysis of DNA sequence files using gap4
Due to the vast number of electropherograms generated from the bidirectional
sequencing process, analysing millions of electropherograms by eye would be un-
likely to give a high pick up rate of subtle base pair changes such as substitutions
or indels, which is why gap4’s Graphical User Interface (GUI) was employed.
gap4 is a Genome Assembly Program. Its utility lies in the power of its GUI and
additional tools that can be used to interrogate DNA sequence trace files. gap4
can analyse each sequence trace individually and within the broader context of
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Figure 4.5: Screengrab of the pregap4 settings used for creating a new gap4 database
an assembled contig and highlight areas in the display window that warranted
closer inspection, which was then achieved by opening up a small proportion of
the electropherogams.
Because the purpose of sequence analysis in this study was to identify mutations
(i.e. differences to “normal” sequences) in each amplimer, we were only interested
in sequences that were different to the reference sequence for that section of DNA.
The Contig Editor window
Figure 4.6 shows the alignment of a group of DNA traces for the STS number
stSG1157243.
The display of base characters in the Contig Editor is generated from analysing
the sequence trace and ascribing them to the letters A, T, C or G. The traces are
aligned in rows, sandwiched between the reference sequence traces, located at the
top and bottom rows.
Electropherograms can be opened up for a particular trace by double clicking over
the appropriate letter or alternatively every trace can be
In order to interrogate this highlighted DNA sequence change the forward and
reverse traces were opened (see Figure 4.7) along with the un-highlighted trace
corresponding to the individual from the row above (individual USH0124). This
shows that the highlighted sequence change actually represents a heterozygous
C>A base pair change.
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Figure 4.6: he traces have been aligned by template, such that forward and reverse
traces (indicated by + and - signs respectively) for an individual are on adjacent rows.
The consensus (reference) sequence is displayed at the bottom of the screen. Asterisks
have been inserted to compensate for differences in one or more of the sequences in the
contig compared to that of the reference sequence.A red box has been superimposed
on the screengrab to highlight that trace on the 9th and 10th rows belongs to an
individual identified by the code USH0123. Following processing with pregap4, two
base pairs have been identified as differing from the reference sequence in individual
USH0123 and these have been highlighted in blue. The cursor has been positioned at
the position of position 294 in the contig
Opening a gap4 experiment file
On opening an experiment (.aux) file in gap4 a Contig Selector window (see Figure
4.8) appears in addition to an output window, the latter of which contains infor-
mation about the number of sequences, average sequence read length and number
of contigs created (which should be equal to one).
Missing sequences
A record was kept of how many and which sequence files were missing from a con-
tig. If a sequence was missing this could potentially be due to lack of amplification.
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Figure 4.7: Screengrab of an electropherogram trace showing an example of a het-
erozygous base pair change
The lower two traces show a heterozygous C>A base pair change on both forward and reverse strands
from individual USH0123, whilst the upper two traces show the wild type C nucleotide at this position
on both forward and reverse strands of individual USH0124
Figure 4.8: Screengrab of gap4 Contig Selector window
Right clicking on the Contig Selector (see Figure 4.8) opens up the the Contig Ed-
itor window which is the main window used for sequence analysis. If bidirectional
sequences from an individual were missing (or present from only one strand) their
absence was recorded, as this may represent evidence of a homozygous deletion
within that amplimer for that individual.
Estimation of read quality
The “read quality” setting is a very useful feature that graphically displays the
quality of the trace data by the grey-scale shading of the surrounding area to a
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Figure 4.9: Screengrab of the Contig Editor in gap4 demonstrating the use of the
read quality and base error calling
The graphical interface of gap4 makes spotting the missing sequence in individual USH0014 more obvious
and also highlights the G >A heterozygous base pair substitution at position 421. The darker grey
background colour corresponds to a poor read quality.
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base letter such that lighter the background the better the data and the darker
the background the poorer the sequence trace data is. This can be a useful tool in
analysing batches of sequences as illustrated in Figure 4.9.
In some cases where the read quality of a seqment of a sequence trace is very
poor, that part of the sequence might be ommitted altogether. For heterozygous
deletions this produces a characteristic pattern This is illustrated if Figure 4.10.
When the electropherogams for the individual (USH0049) with the deletion pattern are opened it can
be seen that in both directions, the sequence traces are clean up until the point where the deletion is
reached, after which the traces are superimposed from the normal strand and the deleted strand. This
example is the c.11875delC in USH2A causing p.Gln3959LysfsX25
Figure 4.10: Screengrab showing the characteristic pattern of a heterozygous deletion
Highlighting sequence conflicts
gap4 is able to highlight differences in bases when compared to the reference se-
quence by modifying the background colour in the Contig editor display window
(see 4.6). When surveying a contig, attention could thus be directed to opening
the relevant electropherograms.
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4.4.6 System of analysing a contig with gap4
As mentioned earlier each “contig” was created in pregap4 and consisted of a
reference sequence aligned with the forward and reverse strands from a group of
individuals (usually 48 individuals).
This main goal of surveying contigs was to identify any DNA sequence in an
individual when compared to the reference sequence.
When analysing the contigs in the Contig Eritor window, due to the large number
of traces and the size of the contigs (around 600 base pairs) the viewing window
would have to be scrolled to enable a survey of the full contig.
(a) The traces were grouped by template (DNA sample)
(b) The contig was checked for missing sequences and those that were absent
were recorded
(c) The contig was checked for unidirectional sequences and recorded
(d) The traces were grouped by strand (forward strands together and reverse
strands together)
(e) Both extremes of the contig were inspected for sequence changes.
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Clinical Methods
5.1 Family history
Detailed pedigrees were taken following consultation with the index cases and
where possible other members of their family.
In all families
Specific enquiry was made with regard to family history of visual or hearing
loss in other family members. Specific enquiry was also made as to whether
there was a history of consanguinity. Ethnicity was also ascertained by asking
the country of origin of grandparents
In some families
In families with a history of consanguinity, specific details with regard to the
nature of any consanguinity was made. This was done so that subsequent
molecular analysis could be interpreted accordingly.
5.2 Past medical history
A full past medical history was taken based around a loose structure:
5.2.1 Audiovestibular history
• Age that hearing loss was first suspected/noticed
• Age that hearing loss was diagnosed
• Did the patient feel their hearing loss was progressive?
• Was their any objective evidence for progressive hearing loss?
• Hearing aid/Cochlear implant history (where appropriate)
79
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5.2.2 Ophthalmic history
One important question we wanted to answer was if the age of onset of retinal
symptoms was different amongst the different clinical and molecular subtypes
of Usher syndrome.
Determining the age of onset of retinal symptoms objectively would be an
impossible task in a cohort study like the NCUS, because the time of onset
of retinal symptoms would be expected to have been in the past (this event
having precipitated the actual diagnosis of Usher syndrome)
Accepting that determining ago of onset would therefore have to be a subjec-
tive assessment, care was taken to standardize the questions asked in order
not to introduce further bias.
The questions were initially as open ended as possible and if the appropriate
information could not be gleaned from this initial response as series of further
questions were asked until a response was given.
i. Age that visual problems were first noticed
ii. The nature of the initial visual problems
iii. Age that nyctalopia was first suspected/noticed
iv. Age that visual field loss was first suspected/noticed
v. Age that a formal diagnosis of Retinitis Pigmntosa was first made
vi. Any history of previous ophthalmic problems, diagnoses or surgery
If an affected individual denied having problems seeing in the dark, further
clarification was sought by asking the following questions:
“Are you able to see the stars in the sky at night?”
“Have you ever had trouble finding you seat in a cinema when the
lights go down?”
If the answer was still negative, then this was recorded.
If an affected individual denied having problems with their visual field, further
clarification was sought by asking the following questions:
“Have you noticed that you have been bumping in to people or trip-
ping over things?”
If the answer was still negative, then this was recorded.
In the results chapters the term disease duration was used as a variable for
correlation analysis. Disease duration was an integer computed as a logical
function and only calculated in individuals in whom a value for ‘age of 1st
visual symptom’ was recorded as illustrated below.
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Disease duration = (age at time of examination)−(age of 1st visual symptom)
(5.1)
5.2.3 Medical History
A formal medical history including past or present medical diagnoses.
5.2.4 Surgical History
Enquiry was made with regard to any previous ophthalmic, audiovestibular
or general surgery
5.2.5 Drug History
Current medications were recorded.
Family History of dual sensory loss
Specific enquiry was made with regard to hearing loss, visual loss or any other
disorders in parents, grandparents and extended family members.
5.3 Visual acuity
Visual acuity (VA) was determined using a retro-illuminated ETDRS chart
using LogMAR optotypes at 4 metres. VA was checked with the patient’s
own distance refractive correction if appropriate first and then through a pin-
hole in order to reduce the artefact of uncorrected refractive error or media
opacity. The best corrected visual acuity was the best VA recorded by either
method.
If no letters on the chart were read at 4 metres, the test distance was reduced
to 1 metre and the appropriate correction (adding 0.6) made to calculate the
correct LogMAR VA.
For those individuals with severely impaired visual acuity, the LogMAR ap-
proximation of 2.6 was used to represent counting fingers vision and extrapo-
lated values of 2.7, 2.8, and 2.9 LogMAR to represent hand movement, light
perception, and no light perception, respectively.
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As a benchmark standard for “good” central vision, the minimum level of
visual acuity used by the DVLA was taken. Whilst this represents an arbi-
trary criterion, it is a level of vision that is understandable as it is in layman’s
terms and such is a meaningful criterion that can be imparted to patients.
The DVLA standards compatible with ‘driving vision’ is taken to approximate
to 6/10 Snellen (equivalent to logMAR " 0.22) [172]. Survival analysis was
performed using log-rank (Mantel-Cox) test.
5.4 Colour vision
Colour vision of the red-green and blue-yellow axes, were assessed using the
4th edition Harvey-Rand-Rittler (HRR) colour pseudoisochromatic colour
plates from Richmond products. These were used in preference to the more
commonly used Ishihara plates which only assess colour vision in the red-
green axis. The original HRR color vision test was developed 60 years ago
by LeGrand Hardy, M.D., Gertrude Rand, Ph.D. and M.Catherine Rittler,
B.A. at Columbia University USA with help from their colleagues Judd,
Farnsworth and Nickerson. The test was designed to screen for, diagnose and
quantify colour vision defects along the protan or deutan, tritan or tetartan
axes. Following modification of the test’s diagnostic accuracy and printing
accuracy the 4th edition is now most widely used.
Colour vision tests were performed directly after testing visual acuity to en-
sure that study subjects had not dark adapted in any way prior to testing.
They were thus performed in photopic conditions, after appropriate correction
of any refractive error.
Clear instructions were given prior to the start of the test and responses were
recorded on a proforma score-sheet see Figure 5.1 that is included with the
test book.
The HRR plates are a book of 24 pages, each page representing a plate (see
Figure 5.2).
The test is divided in to three parts.
1. Demonstration plates: (plates 1-4)
The first four plates of the test are demonstration plates and were not scored.
All subjects apart from those with poor visual acuity, total color deficient
vision or malingerers will be able to see the shapes on the first three plates
(the fourth is blank).
2. Screening plates (plates 5-10)
Plates five to ten inclusive are screening plates and if correct responses were
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Figure 5.1: Scorecard for the Hardy-Rand-Rittler (HRR) psudoisochromatic colour
vision test
supplied for these plates, the subject was deemed to have normal color vision
and no further testing need be done.
3. Diagnostic plates (plates 11-24)
If there were any incorrect responses from plates 1-10, or if there appearred
to be some difficulty in providing responses for the screening plates, the re-
mainder of the test using the diagnostic plates was undertaken.
5.4.1 HRR Test instructions
The study subject was given a clean brush to hold and instructed with the
following:
INSTRUCTION 1 : “I am going to show you some coloured symbols.
Without touching them, how many do you see?”
INSTRUCTION 2 : “What are they?”
After naming the symbol the subject was asked the question..
INSTRUCTION 3 : ‘’Where are they?”
and asked to trace out any shapes seen using the hand-held brush used as
a pointer. The test subject was requested not to touch the plates directly
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Figure 5.2: A HRR diagnostic plate showing symbols made from coloured dots on a
grey background testing for deficiencies on the protan/deutan axis
with their finger to avoid marking the test plates and adversely affecting
the validity of their subsequent use. Finally the remainder of the test was
explained to the test subject:
INSTRUCTION 4 : “The test itself is made up of just these three
symbols with either two, one, or none on each page. Some of them
will be harder for you to see as they may be less strong in color.
Draw round the outline of any shape you see on each page”
In cases where study subjects communicated by sign language the instructions
were modified so as to communicate the test requirements appropriately using
a sign language interpreter.
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5.4.2 HRR Test scoring
If the subject gave the correct response to questions 1, 2 and 3 for each plate
they were scored as correct with a
√
placed in the appropriate box on the
score-sheet (see Figure 5.1). If they gave an incorrect response to any of the
three questions, the box was left blank.
The diagnostic plates (plates 11-24) are split in to those that test for colour
defects on the protan/deutan (red/green) axis (plates 11-20) and those that
test the tritan/tetartan (blue/yellow) diagnostic plates (plates 21-24).
The diagnostic plates from each axis are further subdivided in to three subsec-
tions indicating mild, medium and severe defects for the red/green axis and in
to two subsections testing for medium and severe defects for the blue/yellow
axis.
At the conclusion of the test, the binary responses to each box were then
analysed to determine the nature and severity of colour vision defect. Figure
5.3 is a schematic representing the method of scoring.
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Figure 5.3: Schematic representing the scoring system for responses of the HRR
colour vision plates
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Examples of three individuals are given to illustrate the scoring system in
Figure 5.3. In Example A, all responses were correct and it is likely that the
responses to the screening plates (5-10) were also correct. In Example A the
test subject has normal colour vision for the red/green and blue/yellow axes.
In Example B the subject makes an error in the mild red/green subset
(plates11-15) and provides correct responses for the medium red/green (16-
18) and strong red/green (19-20) subsets. They thus have a mild defect on
the red/green axis. In Example B the subject also makes an error in the
medium blue/yellow subset (plates 21-22) and provides correct responses for
the strong blue/yellow (23-24) subsets. They thus have a medium defect on
the blue/yellow axis.
Example 3 demonstrates a strong blue/yellow defect and medium blue/yellow
defect.
Although not indicated on the schematic in Figure 5.3, it is actually possible
to further categorise the nature of a colour visual defect by counting which
of the two columns present on the score-sheet (see Figure 5.1) have the most
correct responses . For example if more
√
responses were entered in the
“Protan” rather than “Deutan” column then the subject had a ProtanDeutan
defect.
Although this detail was available, for the purposes of clarity colour vision
responses were simply recorded in terms of the overall deficiency on red/green
and blue/yellow axes.
5.5 Visual fields
Visual Fields were obtained using kinetic Goldmann perimetry. This method
of visual field testing was used in preference to other more standard and ar-
guably easier methods of visual field testing such as the automated Humphrey
visual field 30-2. The benefits of the using Goldmann kinetic perimetry were
essentially threefold. Firstly the Goldmann perimeter was able to test a
significantly larger area of visual field than other methods. Secondly, the in-
teractive nature of the test, allowing mid-peripheral scotomas (often present
in RP) to be delineated more accurately and thirdly, the ability to map out
isotpers of visual field sensitivity at standardised levels of luminance afforded
the opportunity to compare standardised visual field areas between individ-
uals better than using data from static perimetry which is much harder to
compare between individuals.
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The Goldmann perimeter was calibrated prior to use, initially calibrating the
target to 1000 asb followed by calibration of the background to 31.5 asb.
5.5.1 Calibration of Goldmann perimeter
This was performed daily prior to performing testing in order to standardise
test conditions. This was done in a darkened room with the door nearly fully
closed with the ambient room lights off (i.e. same conditions for testing).
Figure 5.4: Orientation lines (blue arrows) and target locking position (red arrow)
for calibration of Goldmann perimeter
Below is the process followed to calibrate the machine:
i. Turn the machine on.
ii. Paper inserted in to the machine and aligned in horizontal and vertical
meridians (see blue arrows in Figure 5.4).
iii. The pantograph arm (sometimes called the target light projector arm) of
the machine was placed in the locking position (see red arrow in Figure
5.4) and pressed forwards to lock the pantograph handle in position. This
causes the pantograph to direct the target light toward the slot on the
left side of the machine.
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iv. All filter handles were turned to their far right producing the largest
brightest target V4e.
v. The light meter was inserted into slot on the left side of machine.
vi. The small bulb on left side of bowl was turned on to illuminate the light
meter screen.
vii. The photometer screen was opened by pushing the white flag up and out
the way of the light path allowing it to measure the brightness of the
target.
viii. Luminosity was adjusted such that the target light was 1000 apostilbs.
ix. If unable to obtain maximum luminosity, the main bulb could be removed
and rotated or replaced.
x. Light meter screen was switched off.
xi. The handle of photometer screen (the white flag) was pulled down.
xii. The target light will now be directed on to white flag.
xiii. The light filters at the operator side of the machine were adjusted to the
V1e setting.
xiv. Walking round to the test subject’s side of the machine and looking
through the aperture obliquely, the brightness of the target light was
equated to that of the photometer screen by sliding the rheostat at the
top of the machine until brightness was judged to be the same as that on
the white flag.
xv. This should be equivalent to a background luminance of the perimeter of
31.5 apostilbs.
xvi. After calibration the pantograph arm was unlocked and placed in a safe
position prior to bringing the patient to the machine.
5.5.2 Instructions to study subjects prior to Goldmann visual
field testing
Due to the deafblind population being studied, prior to seating the study
subject at the machine, the test procedure and purpose of the test was fully
explained verbally or via a sign language interpreter as appropriate. Another
important consideration at this stage in the clinical examination testing was
that subjects would be changing from the photopic conditions used to test
visual acuity and colour vision, in to a dark environment. Due to the nature
of their RP, this often adversely affected their vision subsequently for an
indefinite time dependant on their retinal disease. Thus prior to measurement
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of visual fields, time was taken to summarise the following battery of tests
that would be performed in the session for the benefit of study subjects.
The following points were clearly explained to the patient:
i. The purpose of this test is to determine the area in each eye in which
you are able to see different sized targets of light
ii. You should be seated comfortably at the machine, so that you can keep
your head still for the duration of the test.
iii. If you get tired during the test or want a break, that is fine, but they
should indicate this to the tester (myself) by means of a prearranged
signal
iv. One eye would be tested at a time, whilst the other is covered with a
patch
v. You should only look directly at the target in the centre of the bowl and
keep your gaze fixed here for the duration of the test
vi. If you are unable to clearly see the target in the centre of the bowl then
the test would be abandoned.
vii. You will be given a hand held device with a button (connected to a
buzzer), which you should press down only when they can see a light
viii. Lights will appear and disappear throughout the test
ix. If you see a light during the test, press and hold the button
x. The button should be held down for the entire duration of time that they
were able to see the light
xi. When the light disappears, they should immediately let go of the button
xii. The lights will be of different sizes and brightness
xiii. Not to worry too much about the test as they would not be expected to
see lights all of the time
xiv. No matter where the lights appear/disappear their gaze should remain
fixed firmly on the target in the centre of the bowl
xv. I (as the examiner) will be viewing your eye (the test subject) from behind
the target to ensure that their gaze was fixed firmly on the target in the
centre of the bowl
The patient was seated at the machine and the table height and chin rest was
adjusted to optimise the subjects comfort and body habitus. The eye not
being tested was occluded up with an eye patch.
Each eye was tested separately starting with the eye with better visual acuity.
Gaze fixation was constantly monitored through the viewing telescope on
the device. The largest isopter (V4e) was tested initially moving from the
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periphery of the visual field toward the centre. Scotomatous areas identified
within the visual field were interrogated more closely by moving the light
target from a non-seeing (scotomatous) to a seeing area, to delineate the
borders of the scotoma.
If the visual field was able to be measured for the V4e isopter, the middle sized
target (II4e) was then tested in the same fashion, followed by the smallest
sized isopter (I4e) where possible.
In most cases the visual field was taken with an individuals appropriate re-
fractive correction. In some cases the central 30 degrees was re-checked using
the appropriate lens correction as calculated by using Goldmann’s near add
table
Table 5.1: Goldmann’s near add table
Age in years Dioptres of near add
40-45 +1.5
45-50 +2.0
50-55 +2.5
55-60 +3.0
60+ or pseudophakes +3.25
5.5.3 Calculation of visual field area
The paper for each Goldmann visual field for each eye, was scanned as a
digital image (.tif file) which was subsequently analysed with the planimetry
software ’Retinal Area Analysis Tool’, a package designed by Fred Fitzke
and Anthony Halfyard (2002) to calculate the two-dimensional area from the
visual field plot and convert this in to degrees squared units. Calibration of
the two-dimensional image file was performed by using the central point of
fixation and the centre of the blind spot as the eqivalent scaling factor between
fovea and optic nerve head. In eyes where deliniation of the blind spot was
not performed or not possible (see Figure 5.5) the approximate location of
the centre of the blind spot was 15 degrees temporal to the point of central
fixation.
When calculating the area of visual field for each of the three isopters V4e,
II4e and I4e, the area of central contiguous islands of visual field was recorded
in addition the the area of any peripheral islands of visual field, the total area
of visual field size for each isopter being the sum of central and peripheral
islands. This meant that for each isopter, three variables were recorded (cen-
tral, perihperal and total area in degrees squared). This was done for both
eyes resulting in a maximum of 18 data variables per individual. For brevity
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The blind spot for this individual (with a severely constricted visual field) lay outside the area of their
visual field and was impossible to map. The fovea-optic disc calibration required for calibration of the
software was therefore performed by using the central target (fovea) and a point 15 degrees temporal to
this point (estimated location of blind spot) as an approximation
Figure 5.5: Screengrab of the planimetry software retinal analysis tool developed by
Fitzke and Halfyard, used to calculate the area of Goldmann visual fields
these variables were ascribed a categorical label, prefixed by R (right) or L
(left) to indicate laterality. These labels are summarised in Table 5.2.
Table 5.2: Table illustrating the system of naming categories of visual field area. Each
value label was prefixed by R or L to indicate laterality
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5.6 Refractive error
Refractive error was assessed either from the individual’s most recent glasses
prescription or by focimetry of their distance glasses.
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Figure 5.6: Visual fields taken in the right eye of two individuals with (above) a normal
visual field; (below) an individual with USH2 due to disease in USH2A restricted to a
central 10 degrees. The isopters represented are for the different target sizes used to
map visual fields. Largest (V4e) - black, Intermediate (II4e) - green, Smallest (I4e) -
red
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5.7 Colour fundus photography
Colour photographs of the retina were obtained after pupil dilatation with
tropicamide 1 %. Where possible the fundus was surveyed in all nine positions
of gaze. The images were taken with the Topcon TRC-501X digital camera
using the IMAGEnet 2000 software used to collect and store the images.
Images were cropped and assembled as a montage using Adobe Photoshop
CS2 and the open source program GIMP (The GNU Image Manipulation
Program, for X Windows systems software).
5.8 Fundus autofluorescence
Fundus autofluorescence imaging was performed using the Heidelberg con-
focal scanning laser ophthalmoscope (SLO) system (Heidelberg Retina An-
giograph, Heidelberg Engineering, Dossenheim, Germany). Images of fundus
autofluorescence were recorded after pupillary dilation with a 30 degree field-
of-view mode. The ametropic corrector was employed to correct for refractive
error. An argon blue laser (wavelength of 488 nm) was used for excitation
and the emitted light of greater than 495 nm was detected with a barrier
filter. To amplify the autofluorescence signal, a flash mode was used (i.e.
laser power was increased 2-fold for 32 milliseconds). At least 24 single aut-
ofluorescence images of 512 x 512 pixels were acquired in series mode with
a frequency of 12 images per second. The best 10 images were selected for
automatic alignment, and the creation of a single mean image for each eye.
5.9 Optical coherence tomography
Optical coherence tomography images were taken using the Zeiss OCT3 ma-
chine (Stratus OCT3; Carl Zeiss Meditec, Dublin, CA). 6mm scans centred
on the fovea were obtained employing firstly the ’fast macular’ preset followed
by a horizontal cross hair scan.
High resolution optical coherence tomography images were also available on
some individuals and were taken with the Spectralis HRA+OCT (Heidelberg
Engineering, Germany), Camera version 1.6.0.0 and OCT camera version
1.45.0.0, acquisition software version 4.0.2.0.
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Figure 5.7: Fundus autofluorescence imaging in a normal right eye. The area of
hypofluorescence corresponding to the fovea can be seen. There is no autofluorescence
produced at the optic disc and there is total masking of autofluorescence by the retinal
vessels, which are seen as branching curvilinear lines from the optic disc
5.10 Statistical Analysis
Statistical analysis was performed with SPSS for Windows, Rel. 16.0.2 2008,
SPSS Inc. (Chicago, USA) and GraphPad Prism version 4.00 for Windows,
GraphPad Software, (San Diego California USA) www.graphpad.com.
If variables were not normally distributed, bivariate correlation analysis was
performed using Spearman’s rank coefficient. For all statistical tests signifi-
cance was assumed at levels of P <0.05.
5.11 Terms used to describe study subsets
In subsequent chapters, the term affected NCUS cohort will be used to
refer to all affected individuals from USH families. These individuals have a
diagnosis of USH1, USH2, USH3 or ARRP 1
Chapter 6
Results - Molecular Results
6.1 Demographics
This chapter describes the breakdown of the demographic of the NCUS study
cohort. Individuals with a clinical diagnosis consistent with Usher syndrome
type 1, type 2 or type 3 are referred to as USH1, USH2 and USH3 respec-
tively. Each family had received a diagnosis of Usher syndrome at some point
prior to recruitment in to the study. However, during the course of the study
it became clear that a small subset of families had clinical phenotypes or
pedigree structures that were not consistent with a diagnosis of either USH1,
USH2 or USH3. These non-USH families are discussed in a later section.
Where the causative gene was identified in a family, this was referred to as
their “molecular diagnosis”.
6.1.1 Total numbers recruited
This study recruited affected individuals with a diagnosis of Usher syndrome
and their unaffected family members in to the study. A total of 734 individ-
uals from 190 families were recruited in to the study. Of the 734 individuals,
242 were affected.
Not all individuals consented for all aspects of the study. Some unaffected
family members did not want to, or were unable to give a blood sample
for DNA analysis. Some affected individuals were happy to submit a DNA
sample, but did not wish to carry out the clinical phenotyping tests either in
their entirety or at all.
At the conclusion of the study, 673 DNA samples (236 of these were from
affected individuals) from this NCUS cohort were collected for analysis and
ophthalmic data was available on 209 affected individuals.
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Table 6.1: Clinical diagnosis of all 190 families recruited in to the NCUS
!"#$"%&
!"#$#%&"'(#&)$*+#+ ,&-#"#.+'/$0
'()"*+,-."& /0
&12'()"*+,-."3 &45
'()"*+,-."4 3
!"6$7*%89%:;<%!=>?>% &
&3
:$-.#6:@%AB%.)";7$-." 4
!=?>%C;7%*"$#;:@%<#(":("D 3
&
&
E;F;7G;+(-;<*7H#6+6:E(" &
>:$"%7;("$%!=?>%I%A889 &
&
&
,J,A> &K5
!" !"#$%&'()$*"+,-
#$ .')$/$)$(01$23'/)%(,
%&'( 4'/(%-$/'"-,+05',-$/206%((
!##$ !")%(%3,+0.'7'(($&'0.')$/$)$(01$23'/)%(,
!)#$ !")%(%3,+08%3$/,/)0.')$/$)$(01$23'/)%(,
1.)2.)&3#*$'
4&33.2$
,&-#"#.+'/$0'
5#36'718
,&-#"#.+'/$0'
5#36'$*$9718
:#+;&"'"*++'&$('
6.&2#$)'"*++'
&44&2.$3"<'
+.)2.)&3#$)'&+'
36.'+&-.'
(#+*2(.2
:$-.#6:@%*"$#;:@%.)";7$-."%C;7%
AB%<:$:%:L:#@:M@"D
A@($*7H%(-;<*7H"
:#+;&"'"*++'&$('
6.&2#$)'"*++'
+.)2.)&3#$)'&+'
35*'+.4&2&3.'
(#+*2(.2+
A6NE#*"<%!=?>%%%%%%%%%%%%%%%%%%%CO
.7($%H";#;P#$#(D%I89
!=?>I%AQ89%("P*"P:$#;P%:(%
%(".:*:$"%<#(7*<"*(
6.1.2 Total numbers analysed
As per study protocol, individuals and families reserved the right to withdraw
from the study at any point.
Of the initial 190 families recruited, three families Family 156 (USH1); Family
186 (USH2); and Family 167 (non-USH) withdrew from the study altogether
and did not undergo clinical or molecular analysis. The affected individual
NCUS 276 (Family 84) consented to undergo clinical phenotyping, but with-
drew consent for genetic analysis.
This resulted in clinical and genetic cohorts of slightly different sizes. For the
purposes of clarity, the total number of families that were recruited, under-
went ophthalmic examination and those that underwent molecular analysis
are shown in Table 6.2.
219 individuals from 188 families underwent ophthalmic phenotyping. Each
of the 219 individuals did not perform every ophthalmic test modality. In
the following chapters when reporting ophthalmic test results, the distinction
between individuals who did not perform a particular test, and those that
were unable to perform the test due to severe visual dysfunction is made. If
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Table 6.2: Number of families that were recruited into the study and the subsets of
these families that underwent clinical and molecular analysis
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∗ = families with visual and hearing dysfunction attributable to causes other than Usher syndrome
an individual lacked the visual function to perform a test (e.g. central vision
too poor to test colour vision) the numbers of these indivduals are stated as
they represent an important clinical finding. When stating the outcomes or
relative proportions of test performance for different subgroups, the number
of individuals performing the test are stated.
Individuals from 186 families were submitted for bidirectional DNA sequenc-
ing analysis and their clinical diagnoses are outlined in table 6.2.
A total of 175 families had a clinical diagnosis of USH1, USH2 or USH3.
11 families were subsequently identified as having their hearing and visual
loss attributable to other causes. Only one of these eleven ‘non-USH’ fami-
lies were found to have disease causing mutations in any of the Usher genes
sequenced, reaffirming the clinical findings. This family (Family 142) had
an atypical phenotype due to mutations in the USH1C gene, representing a
novel phenotype for USH1C.This sibling pair along with the other non-USH
families are discussed in greater detail in a separate section 10.1.1.
Of the 178 families with a diagnosis of Usher syndrome, just under a quarter
were USH1, and 70% were USH2, with only two USH3 families identified
(Figure 6.3).
Paucity of USH3 families
Of the 188 families available for clinical analysis, 176 families were identified
with a clinical diagnosis consistent with either USH1, USH2 or USH3. During
recruitment it became apparent that many individuals reported progressive
hearing loss, raising the possibility that they had USH3. During the early
stages of the study, other researchers published findings documenting progres-
sion of hearing loss (greater than could be explained by simply presbyacusis
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Table 6.3: Piechart representing the proportion of families available for ophthalmic
clinical examination
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alone) in individuals with a clinical diagnosis of USH2, a subset of which also
had a molecular diagnosis of USH2A [173].
This important finding suggested that the clinical distinction between USH2
and USH3 was less clear-cut than reported previously. A number of individ-
uals recruited into this study reported a history of subjective and in some
cases objective progression of hearing loss. Of this subset of ’non-USH1’ in-
dividuals, most were subsequently found to have disease due to USH2A, one
individual was subsequently identified as not having Usher syndrome, leav-
ing only three individuals from two families with a molecular diagnosis of
USH3A. Due to the small numbers of USH3 families identified in this study,
they have been omitted in some sections of subsequent chapters, as the small
sample size precluded useful statistical analysis when comparing this small
group against the larger USH1 and USH2 groups.
6.1.3 Gender (Figure 6.1)
The gender spread was similar in the USH1 and USH2 groups, resulting in an
equal mix of males and females in each clinical group . The three individuals
with USH3 were all male
Statistically, there was no significant difference between males and
females in the USH1, USH2, USH3 and non-USH groups (chi-
squared test, alpha <0.05).
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Figure 6.1: Barchart displaying gender per clinical group
6.1.4 Age (Figure 6.1.4)
Unlike gender, the ages of affected individuals amongst the clinical
groups varied significantly, with the USH1 cohort having a younger
median age than the USH2 cohort.
The significant difference in ages between USH1, USH2 and USH3 (Kruskal-
Wallis test, P<0.0001) most likely represents a recruitment bias.
The median age of affected individuals was 28yrs for the USH1 and 41yrs
for USH2.
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(b) Box and whisker plot
Figure 6.2: Scattergraph (above) showing the age in years at the time
of ophthalmic examination and Box and whisker plot (below) showing the
range, interquartile range and median ages per clinical subtype
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6.1.5 Recruitment
Time course of families recruited
The progress of recruitment of families to the study is displayed graphically
in Figure 6.3.
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Figure 6.3: Graph showing the number of families recruited in to the NCUS over the
course of the study
Sources of recruitment (Figure 6.4)
The NCUS had ethical approval for recruitment on a nationwide basis and
families were recruited from throughout the UK.
The majority of participants were recruited through three main channels.
Moorfields Eye Hospital (MEH), the charity Sense and self-referral. A smaller
but important contribution from the amalgamated London paediatric centres
Great Ormond Street Hospital (GOSH) and the Institute of Child Health
(ICH) who referred the majority of younger index cases
Approximately a quarter of families with Usher syndrome self-referred after
hearing about the study through friends, family, the deaf-blind community
and/or the Sense website illustrating the importance of awareness of the study
in the deafblind community in helping recruiting numbers.
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Figure 6.4: Piechart showing sources of recruitment of families with Usher syndrome
Preferred contact mode
Following initial contact with families, each affected individual was asked to
state their preferred mode of contact. Whilst this may seem a trivial point to
detail in the results section of this study, it is included here because these data
may be useful for similar studies conducted within the UK Usher population
in the future. Due to the dual sensory impairment in individuals with Usher
syndrome face, establishing a reliable mode of communication is extremely
important. Figure 6.5 illustrates the differences in the preferred modes of
communication such as the reliance of non-verbal modes such as email, via a
relative or SMS in the USH1 cohort and by voicephone in the USH2 cohort.
Whilst this data is from a UK population with Usher syndrome recruited
from c.2003-2006, such data may also be of use for other researchers around
the world.
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Figure 6.5: Bar chart showing the number of families requesting different types of
communication as their preferred mode of contact. The categories are not mutually
exclusive
6.1.6 Ethnicity
The majority of families recruited in to the study had index case grandparents
who originated from the United Kingdom or Europe.
The ethnicity of index case grandparents is displayed graphically in Figure
ref{fig:clusterbaretnicityush123whichshowsnumbersforbroadethnicgroups.
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Figure 6.6: Cluster bar chart showing ethnicity of the grandparents of each index
case
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6.2 DNA sequencing analysis of the nine USH genes
The direct bidirectional sequencing of the nine known Usher genes and one candidate
gene generated a vast amount of raw electropherogram data to analyse. The volume of
sequence data generated is summarised in Table 6.4.
Table 6.4: Breakdown of the bidirectional DNA sequencing performed on each DNA
sample submitted to the Wellcome Trust Sanger Centre
GENE Number of Amplimers Total number of base pairs
MYO7A 60 28106
USH1C 34 14739
CDH23 97 45328
PCDH15 54 25494
USH1G 13 6702
USH2A 105 51819
GPR98 123 61392
WHRN 27 13209
USH3A 13 6195
SLC4A7 52 25491
TOTAL 578 278475
6.2.1 Data collection from sequence analysis
The data presented pertains to the sequencing data of one of the above genes, USH2A
for which the author was solely responsible for screening.
Each amplimer was analysed and entered in to a database consisting of 22169 records.
Each record pertained to a result of sequencing in each index case for each amplimer.
Of the 22169 records, no sequence trace was produced in 670 cases (3%). Unidirectional
traces were noted in 372 cases (1.7%). 936 instances of sequence variants of interest were
identified (4%) across the panel of DNAs analysed. From these 936 individual sequence
changes, a total of 142 sequence variants were identified for subsequent analysis with a
second round of molecular experiments in the form of an Sequenom allele specific assays
for that particular variant in a larger panel of DNAs. In the remainder (>90%) of the
records, the sequenced amplimer was no different to the reference sequence. Within
this last group, many records were noted to have common polymorphisms noted from
prior analysis of that amplimer in the CEPH panel of control DNAs. Because all these
sequence variants were by definition prevalent and polymorphic, most were not recorded.
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6.2.2 Results of Sequenom allele specific assay data
The return rate for successful genotypes was >95% in successful assays. A summary of
assays passing validation are summarised in Table 6.5
Table 6.5: Summary of allele specific assays after validation
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Of the 323 assays that passed assay validation, a third had a MAF of greater than
0.246% and were thus considered polymorphic. The genotype calls pertaining to these
assays were mainly used for segregation analysis in families to determine phase as well
as to exclude or confirm possible linkage of loci amongst informative families.
6.2.3 Assays of rare sequence variants
The remaining two-thirds of assays (n=212) had an MAF <0.246%. Table 6.6 lists the
predicted effect of each of these changes.
Table 6.6: Rare sequence variants with an MAF <0.246%
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Analysis of the predicted effect of each of these changes in some cases was instructive in
ascribing a pathogenicity score. Sequence variants that were predicted to result in stop
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codons, affecting invariant acceptor/donor splice sites, insertions, deletions, duplications
or any similar classes of sequence variant that were predicted to cause frameshifts were
designated as pathogenic alleles and ascribed a pathogenicity score of 4. However this
was only possible for around a fifth of assays (n=46) the remaining assays were to
interrogate sequence variants of equivocal pathology.
This was the case for the majority of assays within this subset of rare sequence variants
(n=166), the majority of which were missense changes (n=109).
Table 6.7 presents the breakdown of the predicted effect of the sequence variants that
were analysed by assays and found to have an MAF of <0.246%. This illustrates the
high proportion of missense changes in USH2A, MYO7A and GPR98.
Table 6.7: Predicted effect of the sequence variants that were analysed by assays and
found to have an MAF of <0.246%
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Each missense change was analysed using segregation data generated from the assays.
Rather than present the mass of data relating to this work, some examples of the types
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of results analysis could yield are illustrated using three representative cases of rare mis-
sense changes identified by direct sequencing and further interrogated by allele specific
assays in the gene USH2A.
Rare missense changes - straightforward example of disease causing change
The c.1036 A>C (p.Asn346His) sequence variant in USH2A was one of the rare mis-
sense changes initially identified by sequencing analysis and subsequently assayed.
The assay returned a positive result of wild type (AA) in 437 control DNA samples (874
chromosomes) and thus had a MAF of 0%.
Table 6.8: Genotypes and family structure for p.Asn346His specific assay. Segregation
analysis of this variant in each family reveal that although only families 74 and 95 are
fully informative, segregation of the rare variant (C) would be consistent with disease
in families 162 and 181. The other significant sequence variants identified in the index
cases from each family are shown in bold italics on the top left of each family structure.
The number in brackets following the sequence variant represent represents the ascribed
pathogenicity score
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Direct sequence analysis of the Usher genes in all index cases had identified this change
heterozygously in four index cases (NCUS 225, 385, 591, 680). The allele specific assay
returned positive results for all the above four individuals who were positive controls. In
addition to the above index cases, the assay also returned a heterozygous result for an-
other index case, NCUS 321). In order to validate this assay, the direct sequence traces
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were revisited for NCUS 321 and revealed that they did indeed carry the change het-
erozygously, but this had been missed because the sequence trace was unidirectional (one
strand failed to amplify around the region) and as the change had not been highlighted
by the GAP4 software it had been missed by visual inspection.
Table 6.8 lists the relevant genotype calls for the assay in the relevant five families. In
each family the index case had an USH2 phenotype. In four of the families, another
putative pathogenic allele had been identified.
This illustrates some of the benefits of performing the allele specific assays across the
large panel of DNAs used as it afforded the opportunity to validate the results of se-
quencing, highlight potential errors in sequence trace analysis, confirm segregation of
the allele in four of five families who carried the variant is consistent with disease and
determine that the allele is rare in the control population.
This allele has also previously been reported by other research groups [161, 168, 174,
175], who all independantly determined the allele was disease causing, lending further
support to the conclusion that p.Asn346His was pathogenic. This variant was ascribed
a pathogenicity score of 3.
Rare missense changes - not disease causing
The c.2844 C>G (p.Cys948Trp) sequence variant in USH2A was one of the rare mis-
sense changes initially identified by sequencing analysis and subsequently assayed.
Table 6.9: Genotypes and family structure for the p.Cys948Trp specific assay. Pu-
tative pathogenic sequence variants identified in the index cases from each family are
shown in bold italics on the top left box of each family structure. The number in
brackets following the sequence variant represent represents the ascribed pathogenicity
score
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Direct sequence analysis of the Usher genes in all index cases had identified this change
heterozygously in three index cases (NCUS 14, 32, 171). All three index cases had an
USH2 phenotpe and their grandparents were of all of white European origin. The allele
specific assay for p.Asn346His confirmed each index case (acting as the positive control
for the assay) carried the change heterozygously and did not identify it in any other
index case. The assay also returned 434 genotypes in the control group all of which were
wild type (CC) yielding an MAF of 0%.
Table 6.9 presents the genotype data relating to this assay as well as the interesting find-
ing that all three individuals also carry the common frameshift change p.Glu767fsSerfsX21
in the same gene.
Moreover, in addition to the common frameshift change, each index case also had another
truncating (and likely pathogenic) sequence variant in the same gene. In light of this
finding it would be reasonable to assume that the missense change p.Cys948Trp is not
the cause of the disease in these three families. The more parsimonious explanation to
account for this finding would be that p.Cys948Trp is in linkage disequilibrium with the
common p.Glu767fsSerfsX21 in these families.
Rare missense changes - rare population ‘polymorphism’
The c.13984 C>G (p.Gln4662Glu) sequence variant in USH2A
Table 6.10: Genotypes and family structure for the p.Gln4662Glu specific assay.
Putative pathogenic sequence variants identified in the index cases from each family
are shown in bold italics on the top left box of each family structure. The number in
brackets following the sequence variant represent represents the ascribed pathogenicity
score
!"#"$% &'#()*%'% +#,'-. /01!23&2
!"#$%&'()*+*,-./
04 1)#5567"68 9: 3)86;<=*">6? @AB
00 1)#5567"68 9: 3)86;<+#">6? @A@
00 C5567"68 1%>6?<D.E6@ 9: 3)86;<7#%6 @@F
00 C5567"68 1%>6?<D.E6@ 9: 3)86;<!'G<C5567"68 @F:
01"2.3&345*6789'(:4; 01<2=&34>?20(:@;(-/(ABCD<
04 C5567"68 1%>6?<D.E6@ HF 3)86;<7#%6 @IA
00 C5567"68 1%>6?<D.E6@ HF 3)86;<!'G<C5567"68 @:J
C!!CK2
(6)*".E6
L6-#"'*)%>'E2D*23)86;2
0#%6
was one of the rare missense changes initially identified by sequencing analysis and
subsequently assayed.
Direct sequence analysis of the Usher genes in all index cases had identified this change
heterozygously in two index cases NCUS 182. Although initial sequence analysis was
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performed ‘blind’ (masked to the identity of the index case) subsequent review of the
data revealed that the index case had an USH1 phenotype and was of African origin.
The results from the p.Gln4662Glu assay are presented in Table 6.10.
The USH1 index case NCUS 182 was found to already carry two pathogenic mutations
in the MYO7A gene accounting for her disease. The p.Gln4662Glu assay genotype for
her affected sibling was wild type. In summary the two affected siblings had an USH1
phenotype, did not both carry the allele and ad two two putative pathogenic mutations
in another USH1 gene.
The assay also identified the p.Gln4662Glu change heterozygously in the mother of an
index case in Family 35. The mother did not pass the variant to either of her affected
siblings which provides evidence to suggest that the variant is not responsible for disease
in this family. Such examples of non-transmission of alleles suggest that they are unlikely
to be disease causing. Although no pathogenic changes were identified in the two USH1
sibs from Family 35, they are suspected of having disease due to PCDH15 gene for
which they may be homo/hemizygous (see Figure 6.7). They are scheduled to undergo
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis to investigate this
further.
Figure 6.7: Haplotype analysis for the PCDH15 gene in Family 35
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6.3 Molecular diagnoses for USH families
Table 6.11: Molecular diagnoses for the entire study cohort (a total of 175 families)
that underwent genetic analysis. The percentage contribution of each gene is detailed
in the table and the corresponding number of families is annotated on the piechart.
The segment of USH2A labelled E767fs, pertains to the proportion of families (n=52)
who carry at least one allele of the common pathogenic allele p.Glu767SerfsX21
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175 families with a clinical diagnosis consistent with USH1, USH2 or USH3 were available
molecular analysis. A molecular diagnosis was achieved when at least one putative
pathogenic sequence variant (pathogenicity score of 3 or 4) was confirmed.
The molecular diagnosis achieved per family is represented in table and piechart 6.11.
This illustrates that over half of all cases of USH in our UK cohort are due to disease
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in the USH2A gene. This represented the largest molecular group identified (n=98).
The majority of this group (53%, n=52) carried the common pathogenic sequence vari-
ant p.Glu767SerfsX21 on at least one allele, six of these families carrying the variant
homozygously.
In 18% of families no molecular diagnosis was achieved. This empty molecular group was
the second largest category when subdividing the study cohort on the basis of genotype.
Disease due to theMYO7A gene (12%) was the third largest molecular group. Of the six
families with an USH1 phenotype due to USH1C, the previously reported invariant splice
site change c.496+1 G>A [160] was identified in five families and present homozygously
in four.
In the entire cohort we were unable to identify disease due to the two genes USH1G and
WHRN. No putative pathogenic changes were identified in the candidate gene SLCA4
in any family.
Across the cohort no convincing evidence of digenic effects were identified, in that no
affected individual had sequence variants of pathogenicity score 3 or 4 in two different
genes.
6.4 Molecular diagnosis per subtype
Just under half of USH1 families have disease due to the MYO7A gene (47%), with
13% of families due to USH1C and relatively smaller contributions made by the two
cadhedrin family USH1 genes, CDH23 and PCDH15. No family had disease due to the
USH1G gene.
Over three-quarters of USH2 families (76%) had disease due to USH2A with much
smaller contribution from the GPR98 gene (6%). No disease causing mutations were
identified in WHRN, the other gene known to cause an USH2 phenotype.
No molecular diagnosis was achieved in 22% of USH1 and 18% of USH2 families.
Figure 6.4 illustrates that this 20% is equally split between the USH1 and USH2 groups.
!"#$"%&
!"#" $%&' !"#" $%&( !"#" $%&)
*#+#,-# (./..0 *#+#,-# '1/210 *#+#,-# ./..0
!"#$% 34/410 &'()% 15/160 &'(*% '../..0
&'(+, '5/540 -(./ ./..0
,0()* ''/''0 12.34 4/(50
2,0(+5 4/410 6
&'(+1 ./..0
6./..0 6(/.)0 '../..0
(./..0 7 '1/210 ./..0
8#9":7;<="=7->?@7A"#"?>;7
9><A#,=>=
8#9":7;<="=7->?@,*?7<7
A"#"?>;79><A#,=>=
B<CD"7<#97E>";@<F?7=@,->#A7G<H>D>"=7->?@7<7H,D";*D<F79><A#,="=7="E<F<?"97CI7;D>#>;<D7=*C?IE"=7$%&'J7$%&(7<#97$%&)
'()(*+(
,-./0
1!2&3
34256
7342&8
1!2&9
'()(*+(
1!250
:2;<
97;=>
'()(*+(
1!260
Chapter 6. Results - Molecular Results 115
6.5 Number of alleles identified per subtype
For this section, only alleles that were were considered disease causing were included in
the summary figures. These were alleles with a pathogenicity score of 3 or 4. Although
there were alleles identified achieving a pathogenicity score of 2.5 and may well be
disease causing, as the pathogenicity of these variants has not yet been verified they
were omitted. The figures below therefore represent conservative estimates.
In an autosomal recessive disease such as Usher syndrome two disease-causing alleles are
thought to be required to cause disease. The proportion of families with two, one and
zero alleles identified is displayed in Table 6.12.
Chapter 6. Results - Molecular Results 116
Figure 6.8:
Table 6.12: Number of two, one and zero alleles identified per family subdivided by
clinical subtype
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6.6 Number of alleles identified per gene
Figure 6.9 displays the number and percentage of families within each molecular category
in whom one or two disease causing alleles were identified.
Of those with a molecular diagnosis of USH1C, PCDH15 and USH3A both disease caus-
ing alleles were identified in each family. in the remaining genes, a significant proportion
(30-60%) of second alleles remained unidentified.
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Figure 6.9: The number of pathogenic alleles (pathogenicity grade 3 or 4) identified
per gene. The percentage of one or two alleles from the total pathogenic alleles identified
in each gene is detailed in the table. The corresponding number of families is annotated
on the bar chart.
Chapter 6. Results - Molecular Results 118
6.7 Molecular results per clinical subtype
6.7.1 USH1
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6.7.2 USH2 and USH3
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6.8 Novel sequence variants
6.8.1 Novel pathogenic sequence variants identified
6.8.2 Novel changes of uncertain pathogenicity with in-silico analysis
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Figure 6.10: Novel pathogenic sequence variants identified
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In silico analysis was performed on variants of uncertain pathogenicity (UV2-UV4) as
presented earlier in 6.8.2. The results of the analysis clearly demonstrate the trend that
UV4 variants were more highly conserved, predicted to be involved in secondary con-
formational structures and on 3D analysis, were more likely to be predicted to interfere
with hydrogen bonding or steric effects than UV3 or UV2 variants, lending support to
our classification.
Of note, the two variants USH2A:p.Leu1378Pro and USH2A:p.Arg1578Cys were found
to less highly conserved and neither predicted to affect secondary or tertiary structure,
however they still fitted our criteria to be classified as UV4.
USH2A:p.Leu1378Pro was identified in trans in proband NCUS 545 (Family 154)
along with the common frameshift mutation USH2A:p.Glu767SerfsX21. The missense
change was not observed in 876 control chromosomes.
USH2A:p.Arg1578Cys was identified in proband NCUS 644 (Family 171) in trans
with the novel frameshift USHA:p.Asn1967TrpfsX5 . This missense change was not
identified in 878 control chromosomes.
Conversely many of the UV2 changes were found to be less highly conserved than the
UV4 changes, supporting the hypothesis that these changes are less likely to be disease
causing.
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6.8.3 Novel polymorphic changes (UV1) identified
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6.9 System for determining pathogenicity
An overview of the methods used to determine the pathogenicity of alleles were discussed
earlier in subsection ??.
6.9.1 minimum allele frequency for most prevalent pathogenic allele
After reviewing the results for the allele specific assays, one previously reported mutation
in the USH2A gene stood out as being the most prevalent allele returned in all families
regardless of clinical subtype. This change, c.2299delG (p.Glu767SerfsX21) has been
well reported as disease causing and is a common disease causing allele prevalent in
other populations studied across Europe [66, 164, 168, 175] [167] the prevalence of this
allele in the control population served as a benchmark.
The inherent limitations of assembling a control group for an ethnically diverse popula-
tion such as the NCUS cohort were discussed earlier in subsection 3.6.1.
Accepting these limitations and assuming that our control population is representative
of the NCUS cohort, being the most prevalent allele in out NCUS cohort, one would also
expect its prevalence in the control population (carrier frequency) would be the greatest
of all USH alleles in all USH genes.
The allele specific assay for the c.2299delG allele in our control population of 440 DNA
samples failed to return a genotype in 17 samples, 421 samples were returned as wild type
and 2 samples were returned as heterozygous (carriers). Using the formula for calculation
of minimum allele frequency described earlier (??) and excluding the samples that failed
the assay, the MAF was calculated as below:
2
(421 + 2)× 2 =
2
846
= 0.00236 = 0.236% (6.1)
French investigators reported the prevalence of the same allele as 1 in 1080 control chro-
mosomes (of unknown ethnic origin) which is equivalent to a minimum allele frequency
of 0.046%. This figure is significantly less than our figure (approx 20% of our value of
0.236%.
Even if we assume that our control population is enriched for the c.2299delG allele and
that our estimation of allele frequency is an overestimation, it would be fair to assume
that it would be very unlikely for another pathogenic allele in any of the Usher genes to
be present in the control population at a greater frequency than 0.236%.
This assumption was incorporated in the final algorithm devised for assaying the pathogenic-
ity of alleles identified.
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Figure 6.11: Algorithmic approach to determining the pathogenicity of DNA sequence
changes identified. The pathogenicity grades used in this study are shown in yellow, and
the corresponding nomenclature used to upload the variants to the USHbases database
is shown on the second row
6.9.2 Grading systems to determine pathogenicity of alleles
NCUS pathogenicity grading system; numerical grades from 1 - 4
An algorithm was created to rank the estimated pathogenicity of all DNA sequence
changes identified. This algorithm was based around the benchmark frequency of the
most prevalent disease causing allele in the entire study population (0.236%) as the
upper cut-off frequency for what was considered to be likely to be a pathogenic allele.
The algorithm also employed segregation data obtained from the allele specific alleles
where possible. Other important factors that were considered in the algorithm were the
predicted effect of the sequence change and segregation with disease as outlined in table
??.
Each allele was given a numerical score for its predicted pathogenicity ranging from 1 to
4. A pathogenicity score of 1 indicates a polymorphic non-disease causing allele. Con-
versely an allele with a pathogenicity score of 4 indicates an allele that was confidently
predicted to be disease causing. For the purposes of clarity, this simple grading system
has been used in the clinical results chapters 7, 8 and 9.
Pathogenicity grading system; USHbases
In order to conform with other researchers and submit our DNA sequence variants to the
USHbases database, the above pathogenicity grading system was reclassified as follows.
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Sequence variants were graded using two definite pathogenicity grades, i.e. pathogenic
(equivalent to NCUS pathogenicity grade 4) and neutral (equivalent to NCUS pathogenic-
ity grade 1). Variants which could not be confidently classified as either pathogenic or
neutral were called unclassified variants (UV1-UV4), with UV4 being probably pathogenic
and UV1 being probably neutral. A full description of the grading system is outlined in
table ??
Frame-shift mutations, nonsense mutations and mutations of the first two nucleotides
of canonical intron splice acceptor or donor sites have been classified as pathogenic. A
missense or intronic change was described as pathogenic if it fulfilled all of the following
criteria: it occurred in controls with a frequency <0.236%, was identified in trans to
a pathogenic or probably pathogenic mutation and it was either novel and segregated
with USH in more than two families, or was previously published as pathogenic/likely
pathogenic.
The benchmark frequency of 0.236% was determined based on the minimum allele fre-
quency of the most common USH mutation USH2A:p.Glu767SerfsX21 in 846 control
chromosomes assayed in this study (see 6.9).
If a novel variant fulfilled the above criteria, but segregated with USH in only one family,
it was deemed to be probably pathogenic and was classified as UV4. Missense variants
were classed as UV3 (likely pathogenic) if the frequency in control chromosomes was
<0.236%, but phase of the variant could not be ascertained due to missing family data.
Missense and silent changes of the last nucleotide of the exon that are likely to affect
splicing were also described as UV3 if they were found in the same gene as another
Pathogenic or UV4 variant. Our determination of a variant as pathogenic, is therefore
stringent.
Variants with uncertain pathogenicity were described as UV2. UV2 variants fulfilled the
criteria described for UV3, but were only genotyped in 96 CEPH control chromosomes. A
missense variant was also classified as UV2 if it was the only possibly pathogenic variant
in the gene. Furthermore, novel intronic variants residing three nucleotides from the
start/end of the exon and not found in 846 control chromosomes were also classified as
UV2. UV1 (probably neutral variants) variants were found in patients who already had
two other pathogenic/probably pathogenic mutations or did not segregate with disease.
The MAF of UV1 in control chromosomes was either <0.236% or was not assessed. We
cannot exclude the possibility that such variants may modify disease phenotype. Neutral
variants did not segregate with disease, were either previously published as neutral or
were found in controls with a frequency 0.236%<.
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Definition of “molecular diagnosis”
Using the grading system to determine pathogenicity of alleles described earlier, alleles
with a pathogenicity score of 3 or 4 were taken as disease causing. Although alleles with
a pathogenicity score of 2.5 might well be disease causing, for the purposes of defining
a confirmed molecular diagnosis these alleles were ignored. This conservative approach
was also employed to ensure that the subsets of individuals analysed when performing
phenotype vs. genotype correlations between individuals with disease due to different
genes, did not include individuals who might subsequently be identified as not having
disease due to that particular gene.
6.10 Challenges encountered
6.10.1 Limitations of sequencing
Whilst the strategy of DNA sequencing the nine Usher genes in each family is an ex-
tremely comprehensive method of molecular analysis, it has its limitations.
Conceptual errors
The DNA sequencing performed in this study was restricted to the exonic and in-
tron/exon boundaries of all the Usher genes (see 6.4 for a breakdown of this). It was
expected that screening these regions would pick up the majority of disease causing
changes in these genes. Determining whether DNA sequence changes in exonic se-
quences is not always straightforward, but the role that DNA sequence changes play
in non-coding areas is even less clear.
Thus, by omitting sequencing these large non-coding areas of the Usher genes we would
not detect any intronic sequence changes which may well be disease causing.
Employing direct sequencing might make heterozygous deletions difficult to detect.
Inaccurate annotation of genes
Gene prediction and manual annotation was performed initially by computational anal-
ysis an subsequently checked manually by collaborators at the Sanger centre.
6.10.2 Human error
When undertaking a large study such as the NCUS, there is always a possibility of
human error leading to DNA sample mix up or contamination. This could occur at
any stage such as blood sample labelling, DNA extraction, DNA storage, a mix up in
the alphanumeric identifier codes used to identify DNA samples, error in labelling the
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DNA aliquots that were sent to the different collaborator sites or practical errors at the
experiment stage of sequencing or the allele specific assays.
6.10.3 Software error
Software used to screen sequence data for base calling missed
Missing heterozygous missense changes Ignoring poor sequencing read quality
6.10.4 Sequencing errors and artefacts
Sanger sequencing has inherent errors which mainly occur as a result of errors in DNA
amplification (PCR). Repetitive sequences, SNPs under primer sites and the possibility
of missed pseudogenes interfering with sequence reads are all potential pitfalls in DNA
sequencing.
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6.11 Haplotype analysis on families with no pathogenic
sequence variants identified
Polymorphic marker data from SNPs genotyped during the Sequenom allele specific
assays part of this study were available on all study subjects and used in many families
to help establish linkage to a gene or in some cases to establish phase. Identification of
one or two putative pathogenic alleles to some extent makes much of this data redundant.
The polymorphic marker data however is useful when looking at those index cases in
whom were were unable to identify even one putative pathogenic DNA sequence change.
In some of these families, linkage analysis was not helpful due to family structure, specif-
ically the lack of other genotyped family members. The following section presents data
pertaining to some of the families in whom no putative pathogenic DNA sequence vari-
ants were identified.
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6.12 Summary of molecular data per family
This data is a summary of the molecular data as it pertains to each family recruited
in to the study and can be found on the electronic appendix attached to this
thesis. Each page represents data from one family. The top section titled Family
structure and ethnicity lists the family number and the ethnicity of the four index
case grandparents as well as if the family was consanguineous. The uppermost table lists
all family members that were recruited in to the study and indicates whether a DNA
sample was available for analysis.
The lower half of each page titled Index case genotype data, summarises the clinical
diagnosis of the index case, the causative gene, the two disease causing alleles identified
in the index case following the bidirectional DNA sequencing of the nine Usher genes.
In some cases, the genotypes of other family members that were determined by allele
specific assays are also included.
6.13 Discussion - Genetic Epidemiology
This study represents an original contribution to the knowledge of Usher syndrome, as
it is the first prospective clinical study to sequence the coding regions of each of the nine
genes associated with this disorder in families with Usher syndrome regardless of clini-
cal subtype. This comprehensive strategy of molecular analysis has afforded the unique
opportunity to interrogate the possibility of digenic effects, for which no supporting evi-
dence was found. This approach has also lead to the discovery of hypomorphic mutations
in the USH1C gene associated with sector RP and milder hearing loss representing a
novel phenotype for this gene.
USH2A was the most common molecular diagnosis of the study cohort, accounting for
76% of USH2 families and more than half of all families with Usher syndrome in this
study.
Of those families with disease due to the USH2A gene (n=98) over half carried the
common p.Glu767SerfsX21 (n=52) mutation on at least one allele. Aside from the
missense change p.Cys419Phe identified in 6 families and the three sequence variants
p.Asn346His, p.Trp3521Arg and p.Glu2288X each identified in four families, all other
mutations in USH2A were private.
After USH2A, the USH1C gene was the only other gene in which a pathogenic sequence
variant was common to more than three families. USH1C mutations have been reported
in the UK [95] and from other populations [54, 94]. In this study the c.496+1G>A
sequence variant USH1C was found in five families, four of whom were homozygous,
making it the most common pathogenic sequence variant resulting in an USH1 phenotype
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from our UK study. The second most prevalent change resulting in the USH1 phenotype
was p.Lys1255fs in the MYO7A gene which was identified in three families.
Due to the nationwide recruitment for this study, it is likely to be representative of the
clinical and genetic mix of Usher syndrome in the UK. Some degree of ascertainment
bias against recruitment of USH1 families is possible due to the extra communication
obstacles to overcome when recruiting this group due to their severe dual sensory im-
pairment. In this study USH1 represented around a third of all cases of Usher syndrome
which is comparable to previous reports of the relative prevalence of this clinical subtype
as a proportion of all Usher syndrome [7, 24, 176].
Ascertainment bias in this study was evident and resulted in the recruitment of a sig-
nificantly younger aged cohort of USH1 index cases, the reasons for this were unclear.
No putative pathogenic changes were identified in the USH1G or WHRN gene and only
two families with mutations in USH3A were identified suggesting these are rare in the
UK population.
The relatively high proportion of single alleles identified in families with disease due
to the most prevalent genes USH2A and MYO7A, suggest that sequencing methods
alone failed to identify the second allele. The reasons for this are unclear but might
be due to factors such as unidentified or missed heterozygous deletions, non-coding
variants or other potentially digenic effects with as yet unknown genes. The large number
of families with no molecular diagnosis (n=30) despite this comprehensive molecular
analysis strategy, suggest that more disease-causing genes are yet to be identified for
this disorder.
The challenges of determining the pathogenicity of the large number of rare DNA se-
quence variants assayed in a control population were illustrated. Many of these sequence
variants were missense changes that remain of uncertain pathogenicity and will be sub-
ject to further analysis. The in silico analysis of missense changes showed that most
variants classified as UV4 were highly conserved at their amino acid position and many
were also predicted to effect secondary and tertiary structure. Conversely the UV2 vari-
ants were less well conserved and were generally not predicted to effect secondary or
tertiary structure. These findings highlight the utility of in silico analysis as another
method of gathering evidence to support hypothesis regarding the pathogenicity of al-
leles, but their robustness is not as yet sufficient to be confidently integrated in to an
algorithm to assess the pathogenicity of alleles. This also highlights the fact that sim-
ple tests to measure allele frequency in a population are still important when deciding
whether a DNA sequence change is pathogenic or not.
A molecular algorithmic system was devised and implemented to help the grading of
putative pathogenic alleles for this study. This system is transferable to other genetic
studies of autosomal recessive disease.
Chapter 7
Results - Onset of retinal disease
This chapter presents an overview of the subjective responses given by affected individu-
als regarding their initial visual symptoms. The results are presented when dividing the
NCUS cohort of the basis of clinical subtype for 57 individuals from 45 USH1 families,
163 individuals from 129 USH2 families and three individuals from two USH3 families.
Results are also presented for the subsets of individuals with a confirmed molecular
diagnosis, which was taken as at least one putative pathogenic allele (pathogenicity
score 3 or 4) identified in one of the Usher genes.
7.1 Age of reported first visual symptom
When an individual with hearing loss notices visual problems this may prompt
an ophthalmic referral and examination. If their visual symptoms are due to
previously undiagnosed retinitis pigmentosa their diagnosis will change from simply
‘hearing loss’ to ‘Usher syndrome’.
The age at which individuals with Usher syndrome report their visual symptoms
is thus relevant to clinicians and families with deaf children.
The results will be presented by analysing the different subsets of the study cohort,
both clinical and molecular.
7.1.1 Clinical subtypes of Usher syndrome
The reported age of onset of the first visual symptom was significantly different
between the three clinical subtypes USH1, USH2 and USH3 (Kruskal-Wallis test,
P<0.0001)
Individuals with a clinical diagnosis of USH1 experienced onset of their first visual
symptom at a younger age than those with USH2 (Mann Whitney test, P<0.0001)
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By 14 years of age, all USH1 individuals in this study had experienced visual
symptoms suggestive of RP. By the same age, less than half of the USH2 individuals
had experienced any visual symptoms.
The median age of reported first visual symptom was 9yrs for the USH1 cohort,
and 17yrs for USH2 cohort .
Due to the small number of individuals with USH3 in the UK, achieving statisti-
cally significant conclusions was not possible.
37% (n=63/170) of individuals with all subtypes of Usher syndrome and half of
all USH2 (n=61/123) reported adult onset (aged 18 years of age or older), of their
retinal symptoms.
The range of reported age of onset of visual symptoms was much narrower for the
USH1 cohort compared to the USH2 cohort.
Table 7.1: Table showing median and mean age of onset of visual symptoms across
the clinical subtypes of Usher syndrome
USH1 USH2 USH3
Number of values 41 124 3
Minimum 3 2 10
25% Percentile 6 13
Median 9 17 11
75% Percentile 11 22
Maximum 14 45 12
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7.1.2 Age of first visual symptom vs. molecular subtype (Figure
7.2)
Figure 7.2: Scatter graph showing the age of the 1st visual symptom of individuals
with Usher syndrome grouped by molecular diagnosis
The clinical subtype pertaining to each gene is shown on the right
USH1 genes - MYO7A, USH1C, CDH23 and PCDH15
The median age of the first reported visual symptom did not differ significantly
between individuals with a molecular diagnosis of MYO7A, USH1C, CDH23 or
PCDH15 (Kruskal-Wallis test, P<0.05).
USH2 genes - USH2A and GPR98
The median age of first reported visual symptom did not differ significantly be-
tween individuals with a molecular diagnosis of USH2A and GPR98 (Mann Whit-
ney test, P<0.05)
USH1 genes vs. USH2 genes
There was however a highly significant difference between those with a moleulcar
diagnosis in the USH1 genes (MYO7A, USH1C, CDH23 and PCDH15 ) and the
two USH2 genes USH2A and GPR98 (Mann Whitney test, P<0.0001).
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Does the pathogenicity grade of mutations in the USH1 genes influence
age of onset of visual symptoms?
There was no difference between the median age of reported first visual symptom
for those with two identified “severe” alleles (pathogenicity score=4) compared to
the those with one or less severe alleles (Mann Whitney test, P<0.05).
Does the pathogenicity grade of mutations in the USH2 genes influence
age of onset of visual symptoms?
When subdividing all individuals with a molecular diagnosis associated with an
USH2 phenotype,individuals with two “null” alleles (where the pathogenicity score
for both alleles was 4) reported their first visual symptom at a younger age when
compared to others with one or less null alleles (Mann Whitney test, P=0.0345).
USH2A subgroup analysis: p.Glu767SerfsX21 vs. all other USH2A
alleles
Amongst the USH2A molecular group, there was a highly significant difference
between reported median age of onset of visual symptoms, which were reported
earlier in those that carried the common allele p.Glu767SerfsX21 compared to
those who did not.
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Figure 7.3: Scattergraph and median (vertical line) of age of first reported visual
symptom comparing individuals with the common p.Glu767SerfsX21 allele (E767fs+)
in USH2A vs. all other USH2A alleles
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7.2 Nature of first visual symptom
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Figure 7.5: Cluster barchart showing the nature of the first reported visual symptom
in each clinical subtype
Nyctalopia was the most common initial visual symptom reported by the whole cohort
across all clinical subtypes of USH (Figure 7.5) and when dividing affected individuals
in to molecularly diagnosed cohorts (Figure 7.6).
The second most frequent response recorded across all groups was that no clear visual
symptom was recalled or recorded. These “no answer” responses consisted of some
missing data sets (the question was not asked/the answer not recorded) in addition to
cases where affected individuals were unable to provide an answer due to inability to
recall a specific initial visual symptom.
There was no statistically significant difference in the relative proportions of the four
responses (nyctalopia, no answer, nyctalopia and visual field loss and visual field loss
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Figure 7.6: Cluster barchart showing the nature of the first reported visual symptom
per molecular diagnosis
alone) between the clinical subtypes of USH or the different molecular cohorts (chi-
squared test, alpha <0.05)
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7.3 Summary - Onset of retinal disease
The prospective data collected in this study shows that the subjective report of onset
of visual symptoms occurs at a significantly younger age amongst the USH1 group
compared to USH2.
A more interesting finding is that when dividing the cohort in to molecular groups, the
reported age of initial visual symptom is statistically similar amongst the four USH1
genes and amongst the two USH2 genes, but quite different between these two groups.
This suggests that there is some phenotypic similarity amongst the USH1 genes and the
USH2 genes respectively with regard to the subjective onset of visual symptoms.
It is interesting to note that despite the statistically significant earlier age of onset of
USH1 individuals, there was some overlap between the USH1 and USH2 groups with
both groups containing individuals with childhood onset of visual symptoms. All USH1
individuals reported onset of their first visual symptom by the age of 14 years, along
with approximately 40 % of USH2 individuals.
As none of the USH1 individuals reported age of onset of first visual symptom later
than 14 years of age, from these data, it seems unlikely that if a child with profound
hearing loss does not develop any visual symptoms by their mid-teens they would be
unlikely to go on to develop RP (i.e have USH1). This represents an important finding
for clinicians.
Conversely, half of all USH2 individuals did not report visual symptoms until the age
of 18 or older with many reporting onset of their visual symptoms in to their thirties
or even forties. This is a significant and unexpected finding which ophthalmic clinicians
might consider when assessing adults with moderate hearing loss.
Unlike USH1, adults with USH2 are able to communicate with spoken language and
with the use of hearing aids their significant hearing impairment may not be obvious
to others. This flags the importance of specific enquiry with regard to the presence of
hearing impairment in adults who present with symptoms or signs suggestive of RP.
Confounding factors in reporting onset of disease
An important consideration for any scientific methodology is to attempt to reduce bias
and confounding factors as much as possible. In clinical medicine one way of reducing
bias is to use objective rather than subjective measures wherever possible. Determining
the age of onset of retinal symptoms in a cohort study such as this, requires the use of
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such subjective data, as many study participants’ visual dysfunction actually precipi-
tated their diagnosis of Usher syndrome. Steps were taken to reduce the response bias
such as prospectively asking the same questions to all individuals and questions were
kept clear, precise and short which would be subject to less bias than a retrospective
review of medical case notes as has been the source of previous studies regarding the
onset of visual symptoms in this disorder.
Despite these steps, the main limitation to the data presented in this chapter is that
it is derived from the subjective responses given by affected individuals, in some cases
with help from their parents, regarding the onset of visual symptoms.
Considerations in difference in symptom reporting of USH1 and USH2
Due to the profound hearing loss in USH1 affected individuals rely heavily on their vision
for communication, navigation and social interaction more than USH2 individuals who
use their residual hearing for these tasks. This heavy reliance on visual function in the
profoundly hearing impaired might prompt an earlier recognition of visual pathology
than in the hearing USH2 group. The increased contact with healthcare professionals
that USH1 individuals encounter due to their severe audiological dysfunction may also
prompt an earlier discovery of visual symptoms by others.
Chapter 8
Results - Central retinal function
8.1 Visual Acuity (VA)
For the purposes of clarity, the term NCUS cohort refers to the affected individuals
(n=224) from the 178 families with Usher syndrome. The clinical subtypes are USH1,
USH2, USH3 and one case of ARRP who is the sister of an index case with USH2 (Family
141). The results for this section are presented in three subsections. Firstly the whole
NCUS cohort of affected individuals with Usher syndrome, secondly the cohort after
subdivision in to clinical subtypes and finally after subdivision in to molecular subtypes.
8.1.1 VA - Entire NCUS cohort
8.1.1.1 VA between left and right eyes
There was a high degree of correlation between the logMAR visual acuity between the
right and left eyes per individual (Spearman’s rank coefficient 0.799, P <0.01) across
the whole study population as illustrated in Figure 8.1. The outliers on the plot were
all individuals with advanced disease associated with either small islands of remaining
central retina or an atrophic macular appearance.
The remainder of this section on VA results will present data relating to the logMAR
VA in the better seeing eye per individual.
8.1.1.2 VA correlations with age and disease duration
When analysing all affected individuals from families with Usher syndrome, there was a
statistically significant correlation between visual acuity in the better seeing eye and age
198
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Figure 8.1: Scatterplot of visual acuity in left right eyes of all NCUS affecteds
Table 8.1: Correlation matrix for visual acuity across all NCUS affecteds. The highly
significant correlations between age and disease duration are highlighted in red text
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(Spearman’s rank coefficient 0.400, P <0.001) as well as disease duration (Spearman’s
rank coefficient 0.485, P <0.001).
The degree of correlation between VA and either age or disease duration was not signif-
icantly different (Z-test value=0.81).
8.1.1.3 VA regression analysis with age and disease duration
Age vs. VA regression analysis
A Linear regression model for age vs. VA for all NCUS affected individuals was highly
significant in predicting VA as a function of age . The regression model was y=0.01x
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+c (r2=0.117, 195 d.f., P <0.001). Age as a variable accounted for 12% (r2=0.117) of
the decline in VA. The rate of decline in VA was 0.01 logMAR units per year of age
(P <0.001). The regression calculation was unable to predict the baseline logMAR VA
when age=0 (P=0.565).
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Figure 8.2: Scattergraph and linear regression line showing the relationship between
age and visual acuity for the entire cohort of NCUS affected individuals. For comparison
with the cohort, the different clinical subtypes are highlighted on the scattergraph to
demonstrate their relationship to the overall regression line
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Disease duration vs. VA regression analysis
A Linear regression model for disease duration vs. VA for all NCUS affected individuals
was highly significant in predicting VA as a function of disease duration . The regression
model was y=0.013x +c (r2=0.177, 166 d.f., P <0.001). Disease duration could explain
18% (r2=0.177) of the decline in VA. The decline in VA per year of disease duration
was 0.013 logMAR units per year. The regression calculation was unable to predict the
baseline logMAR VA with significance (P =0.623) when disease duration=0.
Although the degree of correlation was greater and the linear regression model a better
fit for disease duration compared to age, the difference between these two variables as a
predictor of VA was not statistically significant (P <0.05).
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Figure 8.3: Scattergraph and linear regression line showing the relationship between
disease duration and visual acuity for the entire cohort of NCUS affected individuals.
For comparison with the cohort, the different clinical subtypes are highlighted on the
scattergraph to demonstrate their relationship to the overall regression line
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8.1.2 VA - Clinical subtypes
8.1.2.1 Ranges of VA seen per clinical subtype
There was a statistically significant difference between the median visual acuity in the
better seeing eye between the three clinical subtypes USH1, USH2 and USH3 (Kruskal-
Wallis test, P <0.05).
There was a highly significant difference between USH1 and USH2, with the USH2 group
having the better median visual acuity of 0.18 logMAR whilst the USH1 group median
was 0.3 logMAR (Mann Whitney test, P <0.001).
The spread of VA for all NCUS affecteds is shown in Figure 8.4. It is important to
appreciate that this figure does not take age into consideration. This highlights that
despite the USH1 group having a significantly younger age than the USH2 group ( see
Figure 6.1.4), they still had worse visual acuity. The effect of age as a predictor of visual
acuity is considered later with regression analysis.
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Figure 8.4: Boxplot (median and interquartile range) and whisker (data range) figure
demonstrating the distribution of visual acuity in the better eye for all NCUS affecteds.
The results are shown per clinical subtype. Outliers are annotated with their NCUS
ID number
8.1.2.2 Survival curves for USH1 vs USH2
Survival plots (Figure 8.5) were generated to determine the percentage of each clinical
group who retained ‘driving vision’ as per DVLA standards, taken to approximate to
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6/10 Snellen or better (equivalent to logMAR " 0.22).
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Figure 8.5: Survival curve for visual acuity USH1 and USH2 clinical groups. The end
point for this was taken as a VA not compatible with driving standards (logMAR VA
of 0.22<)
The difference between the two curves was highly significant (Mantel-Cox Test P<0.0001)
with half of USH1 individuals maintaining driving vision’ until the age of 35 years and
half of USH2 maintaining a similar level of visual acuity until the much later age of 55
years.
8.1.2.3 VA relationships with age and disease duration per clinical subtype
When splitting the affected individuals of the entire NCUS cohort in to subgroups based
on clinical subtype, similar levels of correlation were identified between age and disease
duration. Correlation coefficients for VA and age and disease duration were not statisti-
cally different between the USH1 and USH2 groups, suggesting the relationship between
VA and these two variables is similar. The RP and USH3 groups were too small in size
to permit useful conclusions to be drawn.
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8.1.2.4 VA regression analysis with age and disease duration
Age vs. VA regression analysis
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Figure 8.6: Scattergraph and regression lines for age vs. VA for USH1 and USH2.
The regression line (dotted) for the entire NCUS cohort is also shown for comparison
After splitting the NCUS affecteds cohort in to groups based on clinical subtype, regres-
sion analyses was repeated.
When analysing age as a predictor of VA, age was able to account for 11% (r2=0.105) of
the decline in VA observed in USH1, which was comparable to the regression model for
the entire NCUS cohort. For USH2, age was able to account for 26% (r2=0.255) of the
decline in VA observed, however the difference between these figures for r2 (‘goodness
of fit’) for USH1 and USH2 groups were not significantly different.
Linear regression analysis for age vs. VA for USH1, USH2 and USH3 groups all yielded
statistically significant models using age as a predictor for VA. Regression analysis
yielded significant results for the USH3 group, despite the extremely small sample size
(n=3) however these data are not discussed further due to the limited conclusions that
can be drawn from this small sample size.
The USH2 model was able to confidently predict baseline logMAR VA of -0.226 (95%
confidence intervals -0.372 to -0.081), P =0.03 ) when age=0, but a similar statistically
significant prediction was not possible in the USH1 group.
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The regression models for age vs VA were:
USH1: y=0.011x + c (r2=0.011, 46 d.f., P <0.03)
USH2: y=0.012x - 0.226 (r2=0.012, 143 d.f., P <0.01)
The slope of the regression lines was not significantly different between the USH1 and
USH2. The elevations of USH1 and USH2 regression lines were significantly different
from each other (P <0.01) This suggests that the overall elevations were identical, there
is a less than 0.01% chance of randomly choosing data points with elevations as different
as those observed.
Both models predicted a decline of 0.01 logMAR units per year of age (P <0.05). The
significance of this is discussed at the end of this section.
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Disease duration vs. VA regression analysis
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Figure 8.7: Scattergraph and regression lines for disease duration vs. VA for USH1
and USH2 groups. The regression line (dotted) for the entire NCUS cohort is also
shown for comparison
After splitting the NCUS affecteds cohort in to groups based on clinical subtype, regres-
sion analyses was repeated for disease duration vs. VA.
The regression models were:
USH1: y=0.015x + c (r2=0.140, 40 d.f., P=0.014)
USH2: y=0.012x - 0.014 (r2=0.244, 120 d.f., P <0.0001)
The linear regression models for disease duration for USH1 and USH2 groups both
provided a statistically significant predictors of VA. The slope of the regression lines
was not significantly different between USH1 and USH2 (P=0.62).
The elevations of USH1 and USH2 regression lines were significantly different from each
other (P <0.0014). This suggests that if the elevations were identical for the two lines,
there is a less than 0.001% chance of randomly choosing data points with elevations this
different.
When analysing disease duration as a predictor of VA, disease duration (years) was able
to account for 14% (r2=0.140) of the decline in VA for USH1 which was comparable to
the linear regression model for the entire cohort. For USH2, age was able to account
for 24% (r2=0.244) of the decline in VA in this group, however the difference between
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these figures for r2 (‘goodness of fit’) for USH1 and USH2 groups were not significantly
different. The model coefficients predicted a decline in VA of 0.015 logMAR in USH1
and 0.012 logMAR per year of disease.
The USH2 model was able to confidently predict a logMAR VA of -0.014 (95% confidence
interval -0.119 to +0.091) when disease duration=0 in the USH2 group, but a similar
statistically significant prediction was not possible in the USH1 group.
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8.1.3 VA - Molecular subtypes
8.1.3.1 Ranges of VA seen per molecular subtype
The ranges of VA per molecular group are shown in figure 8.8. There was a statistically
significant difference between the four USH1 genes and the two USH2 genes (Mann
Whitney test, P<0.001), however as there was also a significantly significant difference
between the median ages (Mann Whitney test, P<0.0001) this demonstrates that these
two subgroups were drawn from different age ranges.
VA in molecular groups
0 1 2 3
MYO7A
USH1C
CDH23
PCDH15
USH2A
GPR98
USH3A
logMAR VA
Figure 8.8: Boxplot and whisker showing the median, interquartile range and data
range for VA amongst all molecular groups identified
The USH1 genes - MYO7A, USH1C, CDH23 and PCDH15
There was no significant difference between the ages of individuals with a molecular
diagnosis of each of four USH1 genes (Kruskal-Wallis test, P=0.52).
There was no significant difference between the visual acuity in the better seeing eye
amongst the four USH1 genes (Kruskal-Wallis test, P<0.05).
The USH2 genes - USH2A and GPR98
There was no significant difference between the ages of individuals with a molecular
diagnosis of each of the two USH2 genes (Mann Whitney test, P=0.51).
There was no significant difference between the visual acuity in the better seeing eye
between the two USH2 genes (Mann Whitney test, P<0.05).
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The USH3 gene USH3A Only three individuals with USH3 were identified in the
study. A sibling pair in their twenties had good central visual acuity and one 48 year
old individual who had hand movements vision in both eyes.
8.1.3.2 Survival curves for MYO7A vs USH2A
Survival plots were generated to determine the percentage of each of the two largest
molecular groups MYO7A vs USH2A who retained ‘driving vision’ as per DVLA stan-
dards, taken to approximate to 6/10 or better Snellen (equivalent to logMAR " 0.22).
The difference between the two curves was highly significant (Mantel-Cox Test P<0.0001)
with half of the MYO7A individuals maintaining driving vision’ until the age of 36 years
and half of USH2A group maintaining a similar level of visual acuity until the much
later age of 55 years.
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Figure 8.9: Survival curve for visual acuity in MYO7A vs USH2A molecular groups.
The end point for this was taken as a VA incompatible with driving standards (logMAR
VA of 0.22<)
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8.1.3.3 VA regression analysis with age and disease duration
Age vs VA regression analysis
After splitting the NCUS affecteds cohort in to groups based on molecular diagnosis,
regression analyses was repeated. The raw data is presented in Figure 8.10. Individuals
from the NCUS cohort who did not have a confirmed molecular diagnosis were placed
in a category and included with the analysis.
Linear regression models only provided a significant result for two molecular groups,
USH2A and USH3A. Due to the small sample size of the USH3A group these data are
not discussed further due to the limited conclusions that can be drawn from this small
sample size (n=3).
For the USH2A molecular group, age was able to account for 30% (r2=0.297) of the
decline in of the decline in VA observed in this group. The USH2A model was able to
confidently predict baseline logMAR VA of -0.273 (95% confidence intervals -0.446 to
-0.1), P =0.02) when age=0.
The regression model for age vs VA was:
USH2A: y=0.012x - 0273 (r2=0.297, 106 d.f., P <0.001)
Comparing the linear regression models for USH2A and the entire NCUS cohort, the
slope and elevation of the regression lines are not significantly different.
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Figure 8.10: Scattergraph of age vs. VA in the USH1 genes (above) and the USH2
and USH3 genes (below). Linear regression models to fit this data were only significant
for the USH2A molecular group (USH2A regression line not shown)
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Disease duration vs. age regression analysis
After splitting the NCUS cohort in to groups based on molecular diagnosis, regression
analyses was repeated. Individuals from the NCUS cohort who did not have a confirmed
molecular diagnosis were placed in a category and included with the analysis.
Linear regression models only provided a significant result for the USH2A molecular
group.
For theUSH2Amolecular group, disease duration was able to account for 26% (r2=0.264)
of the decline in of the decline in VA observed in this group. The USH2A model was
not able to confidently predict baseline logMAR VA when age=0 (P=0.567).
The regression model for age vs VA was:
USH2A: y=0.014x + c (r2=0.26, 90 d.f., P <0.001)
Comparing the linear regression models for USH2A and the entire NCUS cohort, the
slope and elevation of the regression lines are not significantly different.
8.1.4 USH2A subgroup analysis: p.Glu767SerfsX21 vs. all otherUSH2A
alleles
Due to the large numbers in the USH2A group and the significant proportion who carried
the common allele p.Glu767SerfsX21, subgroup analysis was performed after dividing
up all individuals with a diagnosis of USH2A in to two groups; the p.Glu767SerfsX21
group (who carried the change heterozygously or homozygously) and those that did not.
There was no significant difference between the regression models for both groups when
models were constructed for age vs. VA (shown in Figure 8.11) and disease duration vs.
VA.
The regression model for the p.Glu767SerfsX21 sub-group was slightly (but not signifi-
cantly) a better fit for the data for age (r2=0.33, 53 d.f., P <0.0001) compared to the
non-p.Glu767SerfsX21 group (r2=0.30, 51 d.f., P <0.0001).
Similarly, the regression model for the p.Glu767SerfsX21 sub-group was slightly (but not
significantly) a better fit for the data for disease duration (r2=0.32, 45 d.f., P <0.0001)
compared to the non-p.Glu767SerfsX21 group (r2=0.29, 42 d.f., P <0.0001).
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Figure 8.11: Scattergraph and regression lines for visual acuity in the USH2A
molecular group after subdivision in to the group carrying the common allele
p.Glu767SerfsX21 (labelled “1”) and those that did not (labelled “0”)
8.2 HRR Colour vision
8.2.1 Colour vision per clinical subtype
There was a significant difference between the proportion of normal vs. abnormal (errors
in the test or unable to perform the test) between the USH1 and USH2 groups, with
USH2 having more abnormal responses (Mann Whitney test, P<0.001).
This result should be interpreted with consideration to the older age of the USH2 group
in the study population. The median ages of those with a recorded result for HRR
testing were 27.5 years old for USH1 and 40 years old for USH2. From this data alone
it is not clear if the greater proportion of ‘abnormal’ responses seen in the USH2 group
was a function of their diagnosis or the older median age of the USH2 group.
To answer this question, the data on HRR testing was filtered to a smaller data set
which excluded analysis of individuals in whom HRR testing was not performed or
disease duration was not determined. This was done to remove missing cases that would
prevent logistic regression. The results of analysis in this smaller subset of individuals
is reported in subsections 8.2.1.1 and 8.2.1.2.
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Figure 8.12: Cluster barchart showing results of HRR colour vision testing per clinical
subtype
Note the greater proportion of abnormal vs. normal colour vision tests in the USH2 group and the
opposite for the USH1 group. Note this barchart does not consider age
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8.2.1.1 Colour vision vs. age
HRR test results were correlated negatively with age (r=-0.296, P<0.0001) and disease
duration (r=-0.192, P<0.0001). Initial analysis performed in subset of individuals with
complete dataset for HRR result, age and disease duration (n=144) is presented below.
It was important to remove these individuals from analysis in order to construct a logistic
regression model. An ‘abnormal’ HRR test result was scored for those individuals who
were unable to score a result due to poor visual acuity.
To determine whether the greater proportion of abnormal colour vision test results seen
in USH2 were due to the diagnosis of USH2 or the older age of this sample population,
the data was split in to two groups, those with normal colour vision and those with
abnormal colour vision. The median ages of USH1 and USH2 subsets within each group
were then compared.
In both the abnormal and normal groups, the median age of USH1 and USH2 were
significantly different. (Mann Whitney test, P<0.01), as well as in those with a normal
result. This confirmed that the USH2 group was older than the USH1 group regardless
of HRR test performance.
8.2.1.2 Colour vision vs. disease duration
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Figure 8.13: Bar chart displaying the mean disease duration of groups divided on the
basis of HRR colour vision testing and clinical .diagnosis
The USH2 group were significantly older in the normal and abnormal colour vision test
result groups as as shown above. It is noteworthy that it in chapter 7 it was shown
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that the onset of retinal disease occurs later for USH2 compared to USH1. To attempt
to reduce the influence of the later disease onset on the results for HRR testing, the
subgroup analysis was repeated comparing the median value of disease duration between
the USH1 and USH2 groups in those with a normal colour and those with an abnormal
colour vision HRR test result. Disease duration was calculated by (age at exam - age
at reported first visual symptom). Figure 8.13 shows the relative proportions in each
group.
The medan disease duration was not significantly different between the USH1
and USH2 subsets in those with an abnormal HRR colour vision test result
(Mann Whitney test, P>0.667), as well as in those with a normal result
(Mann Whitney test, P>0.554).
This strongly suggests that when accounting for the earlier age of onset of visual symp-
toms reported in the USH1 group, there was no difference in HRR test performance.
8.2.2 Colour vision logistic regression
To test this hypothesis further, binary logistric regression models were constructed using
the primary outcome variable as HRR test result and the covariables age and working
diagnosis.
Formulating the null hypothesis that all HRR test results were abnormal (the majority
of test results in the entire study population were abnormal) and the reference group as
USH1, the observed data would be predicted 54% of the time.
Of the covariables; age and diagnosis, only age was statistically significant at predicting
the outcome of the test result. The Exp(B ) effect of age was 0.933 (95% confidence
interval 0.904 - 0.962) which suggests that for every advancing year of age, the odds ratio
of attaining a normal HRR test result is 0.933; i.e. there is a 6.7% chance per year of
age of getting an abnormal HRR test result. This model had a non-significant Hosmer
Lemeshow test (P >0.6) and thus provided a good fit for the observed data. This model
increased correct prediction of the outcome from 54% (the null hypothesis) to 71%.
Adding the interaction of working diagnosis (USH1 or USH2) to the model did not
provide a statistically significant improvement in prediction of outcome.
These data suggest that age alone was likely responsible for the increased proportion of
abnormal HRR test results observed in the USH2 vs. USH1 subset.
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8.2.3 Colour vision survival curve
The difference between the survival curves plotted for the proportion of USH1 and USH2
maintaining a normal colour vision test with age was equivocal, achieving statistical
significance using the log-rank (Mantel-Cox) Test but not the Gehan-Breslow-Wilcoxon
Test. Figure 8.14 demonstrates how close the curves mirror each other until the paucity
of data points for USH1 for older individuals skews the data. The 95% confidence
intervals for both curves are overlap for their entirety of the curves. This data supports
the findings from logistic regression, that age is more of a predictor of colour vision test
performance than clinical subtype.
0 20 40 60 80
0
50
100
150
USH1
USH2
Age (years)
P
e
rc
e
n
t s
u
rv
iv
a
l
Figure 8.14: Survival curve representing the percentage of individuals who achieve a
normal result on HRR colour vision testing. The curves for USH1 and USH2 are similar.
The median survival point indicated by the broken black line intercepts the survival
curves at a point where there 95% confidence intervals (lines not shown) overlap
8.2.4 Abnormal HRR test results
Whole NCUS cohort
Of the individuals with abnormal HRR colour test results, defects on the blue-yellow
axis were significantly more common than defects on the red-green axis (Mann Whitney
test, P<0.05) This is illustrated in Figure 8.15. This suggests that blue-yellow colour
vision is affected earlier in the disease, with red-green colour vision defects occurring
later.
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Figure 8.15: Data spread of the ages of individuals who had an abnormal test result
on HRR testing
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8.3 Cystoid Macular Oedema (CMO)
8.3.1 CMO prevalence all NCUS affected individuals
OCT data was available for 75% (n=167) of the entire cohort of NCUS affected individ-
uals (n=222).
Of the 167 affected individuals with an OCT scan available for review 75% (n=125) had
no evidence of CMO. 38% (n=15/40) of USH1 and 22% (n=28/125) of USH2 affected
individuals had CMO in one or more eyes, this difference was close to statistical signifi-
cance with two-tailed Chi Squared Test P=0.04 and with Fisher’s exact test P=0.07.
8.3.2 Age vs. CMO prevalence
Age vs. CMO prevalence in all NCUS affected individuals
CMO occurrence was independent of age There was no significant difference between the
median age of all NCUS individuals with CMO in one or more eyes, than those without
CMO (Mann Whitney test, P>0.05).
8.3.3 CMO prevalence vs. Clinical subtype
Table 8.2: Proportion of individuals with cystoid macular oedema in one or both eyes
per clinical subtype
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Of the 25% of individuals from the NCUS cohort (all subtypes) with CMO, it was
found unilaterally in a third of cases and bilaterally in two-thirds of cases, irrespective
of clinical subtype.
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8.3.4 Visual significance of CMO
The median VA of individuals for USH1 with CMO was logMAR 0.38 (n=13) and in
the absence of CMO was logMAR 0.33 (n=26). This difference was not significantly
different (Mann Whitney test, P=0.69). This lack of a significant difference in median
VA was maintained when repeating analysis after the removal of outliers with poor VA
(logMAR VA >1.0) (Mann Whitney test, P=0.39).
Figure 8.16: Scattergraph showing the logMAR VA for the RIGHT eyes in USH1
(top) and USH2 (bottom). Individuals with cystoid macular oedema are shown in red
and those without in blue. Within each clinical group the difference between median
visual acuity of those with/without CMO was not statistically significant. A number
of individuals maintained good visual acuity despite having CMO
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The median VA of USH2 individuals was worse in those with CMO at logMAR 0.4
(n=23) and in the absence of CMO was logMAR 0.2 (n=101) but this difference was
not statistically significant (Mann Whitney test, P=0.11). This difference remained
insignificant after the removal of outliers with poor VA (logMAR VA >1.0).
8.3.5 CMO per gene
Table 8.3 shows the proportions of individuals with CMO in each molecular subtype.
CMO was identified in each molecular subtype.
Table 8.3: Table showing that CMO was found in all molecular subtypes
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8.4 Fundus Autofluorescence (AF)
Fundus AF images were obtained on 154 individuals in the NCUS and a further nine
non-USH individuals. 16 individuals had such poor fundal fluorescence, no discernible
retinal landmarks could be identified. The characteristics of these individuals with poor
AF are described separately at the end of this section 8.4.6.
8.4.1 Foveal Hyperfluorescence
Foveal hyperfluorescence was a common finding, present in the majority of individuals
with AF images. It was found to be highly symmetrical. Of all NCUS affected individuals
with FAF images that were analysed (n=154), bilateral scans were available in over 95%
of cases (n=147). The presence or absence of foveal hyperfluorescence was found to be
100% concordant between left and right eyes. For the purposes of clarity, the remainder
of this subsection will consider analysis of variables related to the right eye only.
Foveal Hyperfluorescence - prevalence
Foveal hyperfluorescence was present in 58% (n=19) USH1 affected individuals, 53%
(n=62) USH2 and was present in an individual with a diagnosis of RP (NCUS 491)
who’s affected sibling was an USH2 index case (NCUS 490) both belonging to Family
141. Of note, the USH2 sibling from this family did not manifest foveal hyperfluores-
cence. There was no significant difference between the proportions of those with foveal
hyperfluorescence in USH1 vs USH2 (Fisher’s exact test P=0.56). Of the two USH3
families, AF was of such low fluorescence the image could not be characterised in one
individual (NCUS 82, Family 26, Age 48yrs); foveal hyperfluorescence was absent in the
two siblings from the other USH3 family (NCUS 49 and 50, Family 16, Aged 22yrs and
25yrs respectively).
High resolution OCT imaging of foveal hyperfluorescence
Figure High resolution AF and OCT scanning of foveal hyperfluorescence revealed opti-
cally dense deposits identifiable in the inner retina; specifically around the photoreceptor
and outer nuclear layer. The retinal pigment epithelium later appeared to be contiguous
intact, suggesting that the origin of the signal may be inner retinal, rather than pigment
epithelial.
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Figure 8.17: Image montage of fundus autofluorescence images. A normal AF image
is shown above for reference. The images A through D demonstrate abnormal areas
of hyperfluorescence at the fovea. All images also demonstrate varying amounts of
patchy hypofluorescence around the vascular arcades. Panel A: Arrow indicates area
of hyperfluorescence. Panel B: Discrete areas of hyperfluorescence within the foveal
area. This ‘petalloid’ appearance was due to the presence of CMO Panel C: Area
of contiguous hyperfluorescence at fovea associated with areas of parafoveal hyperfluo-
rescence. Panel D: Area of contiguous hyperfluorescence at fovea associated with an
annulus of parafoveal hyperfluorescence
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Figure 8.18: High resolution infrared image (top left) and autofluorescence image
(top right). The horizontal arrows represent the point at which the high resolution
OCT scan (bottom) was taken. Areas of hyperintense signal are seen in the inner
retina corresponding top of the areas of foveal hyperfluorescence. The retinal pigment
epithelim (RPE) apperas intact. The vertical arrow in the lower picture delimits the
outer nuclear layer
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Foveal Hyperfluorescence - association with visual acuity
Figure 8.19: Scattergraph showing the logMAR VA (x-axis) in the right eyes of all
NCUS affected individuals with and without foveal hyperfluorescence (FHF)
The median VA was significantly worse at logMAR=0.4 (n=80) amongst individuals
who had foveal hyperfluorescence compared to those who did not (logMAR VA=0.1,
n=70) (Mann Whitney test, P<0.0001).
Of those with foveal hyperfluorescence, there was no difference between median VA in
USH1 (logMAR=0.42, n=19) vs. USH2 (logMAR=0.40, n=59).
However when considering the VA of those without foveal hyperfluorescence , the me-
dian VAs were significantly different between USH1(logMAR=0.23, n=12) vs. USH2
(logMAR=0.08, n=57). This difference is likely due to the baseline difference in VA
already noted between USH1 and USH2 groups reported earlier.
Foveal Hyperfluorescence - association with age and CMO
Representative images are shown to illustrate the finding of foveal hyperfluorescence
with CMO (Figure 8.21) and in the absence of CMO (Figure 8.22).
The median age of those with foveal hyperfluorescence was 43.5 yrs (n=80) which was
significantly older that individuals in whom foveal hyperfluorescence was absent, who
had a median age of 30 yrs (n=71). This difference was highly significant (MannWhitney
test, P<0.0001).
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Figure 8.20: Scattergraph showing the logMAR VA in the right eyes of USH1 and
USH2 individuals with and without foveal hyperfluorescence (FHF)
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Figure 8.21: Montage of images from the left eye of an USH2 affected with foveal hy-
perfluorescence and cystoid macular oedema. Images are colour fundus photos (above),
AF imaging (below right) and OCT3 scanning (below left)
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Figure 8.22: Montage of images from the left eye of an USH2 affected with foveal
hyperfluorescence with no cystoid macular oedema. Images are colour fundus photos
(above), AF imaging (below right) and OCT3 scanning (below left)
It can be stated that foveal hyperfluorescence is significantly correlated with poorer
visual acuity and is found in higher prevalence in older patients with USH1, USH2
and an affected USH2 sibling with RP. As the pathogenesis of the hyperfluorescence is
uncertain it remains unclear whether this finding is a cause of poor visual acuity or a
secondary finding in the retinal pathogenesis of Usher syndrome.
As was shown earlier, when analysing USH1 and USH2 groups separately, there was no
significant difference in median VA between those with or without CMO.
Table 8.4: Crosstab table showing number of individuals with foveal hyperfluorescence
and cystoid macular oedema for all NCUS affecteds
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Figure 8.23: Scattergraph showing the assoiation between age and foveal hyperfluo-
rescence
Table 8.23 shows that CMO accounts for 28/74 cases of foveal hyperfluorescence, but a
larger proportion 46/74 had foveal hyperfluorescence in the absence of CMO. Interest-
ingly, of the two individuals who had CMO but no foveal hyperfluorescence, one (NCUS
42, Family11, disease due to MYO7A gene) had been on long term oral acetazolamide
therapy daily for many years to treat her chronic CMO.
Table 8.5: Crosstab tables showing number of individuals with foveal hyperfluores-
cence and cystoid macular oedema in USH1 and USH2 clinical groups!"!#$%#&'(#)%*+,-
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Foveal hyperfluorescence per gene
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Figure 8.24: Crosstab table showing number of individuals with foveal hyperfluores-
cence per disease causing gene
Table 8.24 shows the proportions of foveal hyperfluorescence per gene. No striking
pattern is seen. foveal hyperfluorescence appears to be present/absent in roughly equal
numbers and no obvious pattern is seen, however the small numbers of individuals in
most molecular categories makes drawing statistical conclusions from these data difficult.
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Figure 8.25: High resolution infrared image (top left) and autofluorescence image (top
right). The horizontal arrows represent the point at which the high resolution OCT
scan (bottom) was taken. Areas of hyperintense signal are seen in the inner retina on
high resolution OCT scans
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8.4.2 Parafoveal hypofluorescence
Normal 
Parafoveal   
Hypofluorescence 
A 
C D 
B 
Figure 8.26: Image montage of fundus autofluorescence images. A normal AF image
is shown above for reference. The panels A through D demonstrate abnormal areas of
parafoveal hypofluorescence. All images also demonstrate varying amounts of patchy
hypofluorescence around the vascular arcades and relatively preserved autofluorescence
at the posterior poles. Panel A: Arrow indicates area of hypofluorescence (dark area)
inferotemporal to right fovea which is continuous with an annulus of patchy hypofluo-
rescence just external to a ring of hyperfluorescence (bright area). Panels B and C:
Both show parafoveal hypofluorescence external to a hyperfluorescent ring.Panel D:
Shows patchy areas of parafoveal hypofluorescence restricted to superiorly and inferior
to a hyperfluorescent ring
Of all the AF images that were available for analysis from all NCUS affecteds (n=154),
parafoveal hypofluorescence was identified in about a third (n=55). Similarly to hyper-
foveal hyperfluorescence, it was a highly symmetrical finding. Of the individuals who
had AF images for both eyes available for analysis (N=147), the presence of parafoveal
Chapter 8. Results - Central retinal function 232
hypofluorescence had 100% concordance between left and right eyes. Due to the highly
symmetrical nature of the finding, data is presented in relation to parafoveal hypofluo-
rescence and related variables on the right eye only.
Parafoveal hypofluorescence - prevalence
R_FAF_HYPO_perifoveal
yesno
C
o
u
n
t
80
60
40
20
0
102
45
73
9
24
RP
Usher_Type3
Usher_Type2
Usher_Type1
WorkingDiagnosis
Page 1
Figure 8.27: Barchart showing number of individuals with parafoveal hypofluores-
cence per subtype
Parafoveal hypofluorescence was identified in 27% (n=9) of USH1, 38% (n=45) of USH2
individuals. It was also identified in the individual with a diagnosis of RP (NCUS
491) who’s affected sibling was an USH2 index case (NCUS 490) both belonging to
Family 141. Of note, the USH2 sibling from this family did not manifest parafoveal
hypofluorescence. There was no significant difference between the proportions of those
with parafoveal hypofluorescence in USH1 vs USH2 (Fisher’s exact test P=0.31).
Of the two USH3 families, AF was of such low fluorescence it could not be characterised
in one individual (NCUS 82, Family 26, Age 48yrs) and parafoveal hypofluorescence was
absent in the two siblings from the other USH3 family (NCUS 49 and 50, Family 16,
Aged 22yrs and 25yrs respectively).
8.4.3 Parafoveal hypofluorescence - associations
Of the variables analysed only VA and CMO were correlated with parafoveal hypofluores-
cence. No correlation was identified between the presence of parafoveal hypofluorescence
and visual acuity, disease duration, visual fields or foveal thickness.
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Age vs. parafoveal hypofluorescence
For the NCUS cohort as a whole, the median age was significantly higher in those with
parafoveal hypofluorescence (48yrs, n=53) compared to those who did not manifest
parafoveal hypofluorescence (30yrs, n=98) (Mann Whitney test, P<0.0001).
Figure 8.28: Scattergraphs of the relationship between age and the presence/absence
of parafoveal hypofluorescence. The top figure shows the significantly older age of those
manifesting parafoveal hypofluorescence. The lower figure represents the same data, but
after subdividing in to USH1 and USH2. This shows that the majority of the age effect
was contributed by the USH2 group
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Figure 8.28 shows that parafoveal hypofluorescence was identified in an older group of
USH1 and USH2 individuals, however this difference was only statistically significant
for the USH2 group (Mann Whitney test, P=0.0001).
CMO vs. parafoveal hypofluorescence
Table 8.6: Incidence of parafoveal hypofluorescence and cystoid macular oedema for
whole study group
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Table 8.6 highlights that parafoveal hypofluorescence was found more frequently amongst
individuals without CMO although the difference between these proportions was not
statistically significant (Fisher’s exact test P=0.14 ). The relative proportions remained
similar and did not achieve statistical significance after subdividing the NCUS cohort
in to two groups of USH1 and USH2. The relative proportions following subdivision
are shown in Table 8.7. Although not statistically significant, it is noteworthy that
in contrast to foveal hyperfluoresence, parafoveal hypofluorescence was less prevalent
amongst individuals with CMO.
Table 8.7: Incidence of parafoveal hypofluorescence and cystoid macular oedema for
USH1 and USH2
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Parafoveal hypofluorescence per disease causing gene
Table 8.8 shows that parafoveal hypofluorescence was identified in all molecular groups
apart from PCDH15 and USH3A.
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Table 8.8: Parafoveal hypofluorescence per molecular group
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8.4.4 AF hyperfluorescent rings
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Figure 8.29: Montage of images showing hyperfluorescent rings seen on autofluores-
cence imaging
Prevalence of AF hyperfluorescent rings per subtype
Of the total number of AF images available for review (n=154), hyperfluorescent rings
were a common finding present in 73% (n=112) of the NCUS cohort. The rings were
only identified by AF imaging and did not generally correspond to any obvious visible
features on slit lamp biomicroscopy.
Hyperfluorescent rings were found at a prevalence of 85% (n=28) in USH1 and 69%
(n=81) in USH2 with the proportions being statistically similar between these two groups
(Fisher’s exact test P=0.12). Of the two USH3 families, AF was of such low signal the
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image could not be characterised in one individual (NCUS 82, Family 26, Age 48yrs);
the two siblings from the other (Family 16) both manifest hyperfluorescent rings at 22yrs
and 25yrs.
Like other AF features described in earlier subsections, the presence of hyperfluorescent
rings was highly symetrical. Of those with AF images available for analysis from both
eyes (n=147) the presence of hyperfluorescent rings showed 100% concordance between
left and right eyes.
Age vs. Prevalence of AF hyperfluorescent rings
Considering the NCUS cohort as a whole, the median age of those with hyperfluorescent
rings was significantly younger at 30.5yrs (n=112) compared to those without hyperflu-
orescent rings 49yrs (n=42) (Mann Whitney test, P<0.0001).
Table 8.9: Number, percentage and median age of individuals who manifest hyper-
fluorescent rings on AF imaging when subdividing by clinical subtype
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Table 8.10: Number, percentage and median age of individuals who manifest hyper-
fluorescent rings on AF imaging when subdividing by molecular diagnosis
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Table 8.11 represents the distribution of AF rings by molecular diangosis. Note that
AF rings were found in each molecular subtype identified from this study. Although
only small numbers of subjects were available for study in USH1C, (n=6) AF rings were
present in all cases. They were also present with a striking and unique morphology
in Family 142 who had an atypical phenotype due to mutations in the USH1C gene
(discussed in a later chapter 10.1.1).
Amongst the most common molecular group USH2A, rings were identified in 68%
(n=60/88) of cases.
Table 8.11: Table showing presence of AF rings by molecular diagnosis
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Hyperfluorescent rings - associations
Hyperfluorescent ring status - association with age and disease duration
Hyperfluorescent ring status refers to whether or not an individual manifests an hy-
perfluorescent ring on AF imaging. This is to be distinguished from Hyperfluorescent
ring area, which is covered later.
The younger median age of those that manifest hyperfluorescent rings remained highly
significant when comparing USH1 and USH2 groups separately (Mann Whitney test,
P<0.0001) (see Table 8.9).
After further subdivision in to molecular groups (see Table 8.10), only the two largest
groups,MYO7A and USH2Amaintained a statistically significant difference of a younger
median age for the subgroup with hyperfluorescent rings (MannWhitney test, P<0.0001).
Hyperfluorescent ring status - association with visual acuity
In USH2 median VA was significantly better in those with hyperfluorescent rings log-
MAR=0.17 (n=81) than in those without logMAR=0.49 (n=37) (Mann Whitney test,
P<0.0001). In USH1, although the median VA was considerably better at logMAR=0.3
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Figure 8.30: Boxplot and whisker representation showing the younger median age of
those with manigest hyperfluorescent rings on AF imaging. The two outliers (NCUS
203 and 204) are siblings from Family 63
(n=28) in those with hyperfluorescent rings, due to the small number of individuals
(n=5) who did not have hyperfluorescent rings with a median VA of 0.55, this difference
was not statistically significant (Mann Whitney test, P=0.62).
Due to the younger median age of those with hyperfluorescent rings in both USH1 and
USH2 subtypes, the better VA seen in these groups is perhaps not surprising.
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Figure 8.31: Boxplot and whisker showing the median, interquartile range and total
range of visual acuity. Outliers are indicated by their NCUS ID number
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Hyperfluorescent ring status - association with visual field parameters
Analysing all NCUS affecteds together, the presence of a hyperfluorescent ring correlated
significantly and positively with all central, peripheral and total areas from each of the
three visual field isopters V4e, II4e and I4e. Their correlation coefficients ranged from
r=0.38 to r=0.81 (all P <0.05) indicated significant positive correlation between visual
field and the presence or absence of a hyperfluorescent ring.
There was no evidence of correlation between hyperfluorescent ring presence and CMO
status, age at first visual symptom or average macular thickness in the central 1mm2
(from OCT scans).
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Hyperfluorescent ring AREA - laterality
There was a high degree of correlation between the AF ring area in the left vs the right
eye (Spearman’s rank coefficient 0.979, P <0.001). A linear regression model was highly
significant at predicting left from right ring area (r2=0.992, 104 d.f., P <0.001).
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Figure 8.32: Scattergraph showing the high degree of correlation between right and
left AF ring area. The linear regression line predicting left from right AF ring area is
shown
Due to this high degree of symmetry between both eyes, subsequent analysis was per-
formed using the one eye (the right eye) only.
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Figure 8.33: Boxplot and whisker showing AF ring area for each clinical subtype.
The outliers are labelled with their NCUS ID number
There was a highly significant difference between median hyperfluorescent ring area
between USH1 and USH2 clinical groups. The median hyperfluorescent ring area was
116.5 degrees squared (n=57) for USH1 and 71 degrees squared for USH2 (n-163) (Mann
Whitney test, P<0.01). The mean and median ring area in the two siblings with USH3
(Family 49) was 68.5 degrees squared and thus comparable to the USH2 group.
Figure 8.33 highlights the disparity in not only the median ring sizes between USH1 and
USH2, but also the narrow range of ring area observed in USH2, d spite the greater
number of individuals in the study and the wider spread of ring areas seen in USH1
despite having fewer individuals in this group.
As hyperfluorescent ring status has been shown to be associated with a younger median
age and through recruitment bias in to this study, the USH1 population is of significantly
younger median age than the USH2 population. It might be reasonable to assume that
this larger ring area in USH1 might be due to this group having a younger median age.
However, age alone is unlikely to be able to explain this difference due to the magnitude
of this difference. This is illustrated in Figure 8.34 which shows age plotted against
hyperfluorescent ring area.
p50 vs AF ring area
The p50 value indicating macular function on retinal elctrodiagnostics was highly cor-
related with AF ring area (r=0.712, P<0.0001).
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Figure 8.34: Scattergraph showing the relationship for AF ring area in the right eye
with age. Note the general trend to smaller ring sizes with increasing age in USH2.
Although not significant, there appears to be a trend toward larger AF ring size in
USH1 with increasing age
A linear regression model for predicting AF ring area on p50 provided a good fit for the
data (r2=0.26, 20 d.f., P=0.01).
When restricting this analysis to just USH2A molecular group a much better fit was
achieved (r2=0.435, 31 d.f., P=0.003) which was able to achieve statistical significance of
the gradient +61.963 (95% confidence intervals 29.033 to 94.892) but not the y-intercept.
y=61.963 (29.033 to 94.892) + c
8.4.5 Regression analysis for AF hyperfluorescent rings
Linear regression model for USH2: Age vs. AF ring area
Following from the finding that AF ring size correlated with age in USH2, this re-
lationship was examined by constructing a linear regression model, which was highly
significant in predicting ring size as a function of age.
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Figure 8.35: Scattergraph showing relationship and regression line of AF ring area
vs p50 for all study participants with ERG data who manifested AF rings
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Figure 8.36: Scattergraph showing relationship and regression line of AF ring area vs
p50 for individuals with a molecular diagnosis of USH2A with ERG data who manifested
AF rings
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The sample used were USH2 affected individuals with documented AF ring area of less
than 600 degrees squared. One individual from this subset was excluded as they were
an outlier (NCUS 110, Family 31) with a ring area much larger (1300 degrees squared)
than the rest of this sample, the next largest ring area being 568 degrees squared. Of
note, this outlier did not have a confirmed molecular diagnosis despite screening of the
nine Usher genes.
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Figure 8.37: Scattergraph and linear regression line showing age vs. AF ring area for
molecular groups with an USH2 phenotype
The regression model for this subset (Figure 8.37) was y=-2.694x + 206.668 (r2=0.141,
77 d.f., P <0.001). The model suggested that age as a variable may account for 14% of
the decline in ring size seen. The rate of decline in ring size for per year for this model
was 2.7 degrees squared per year (95% confidence intervals 1.2 - 4.2). The regression
model suggested a ring area of 206.7 degrees squared (95% confidence intervals 143.3 -
270.0) when age=0 (P=0.0001).
The above subset was further reduced in size and genetic heterogeneity by only including
individuals with USH2 and the USH2A molecular subtype, which improved the fit of
the model.
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Linear regression model for USH2A genotype: Age vs. AF ring area
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Figure 8.38: Scattergraph and linear regression line showing age vs. AF ring area
and regression line for USH2A molecular group
Figure 8.38 shows the regression line through the data points. The model for the USH2A
molecular subset was y=-2.895x + 212.412 (r2=0.185, 58 d.f., P <0.001). This model
was a better fit for the data, that the previous model including individuals with a
molecular diagnosis of GPR98 or unknown genotype. The regression model suggested
that age as a variable, may account for 19% of the decline in ring size seen and that ring
size may decrease by 3 degrees (95% confidence intervals 1.3 - 4.5) squared per year.
The regression model suggested a ring area of 212.4 degrees squared (95% confidence
intervals 146.6 - 278.2) when age=0 (P=0.0001).
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Age vs. AF ring area in MYO7A
Due to small sample size no statistically significant correlation or regression analysis was
identified in the above subgroups. Figure 8.39 shows the scatterplot of age vs. AF ring
area. Although statistically inconclusive, it is worth remarking that unlike the USH2A
molecular group, the MYO7A group appear to show a positive correlation, that is larger
ring sizes are noted in older individuals. Note the magnitude of the y-axis has changed
to reflect the larger AF ring areas seen in this group.
Figure 8.37 shows a similar trend for GPR98 molecular group, however as all points lie
close to the USH2A cluster and regression line it would be unwise to make assumptions
regarding trends in this small group.
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Figure 8.39: Scattergraph showing age vs. AF ring area and regression line for
MYO7A molecular group
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8.4.6 Poor AF signal precluding image acquisition
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Figure 8.40: Table listing details of individuals with poor signals on AF imaging
Figure 8.40 shows the clinical characteristics of the 16 individuals in whom poor AF
precluded analysis of features. The majority of poor signal AF images precluding image
acquisition were due to advanced disease (n=14) and two young individuals (both aged
under 5 years), may have been influenced by difficulty in test cooperation.
The median age for this group was 38.5 years and most had poor VA (median logMAR
0.46), only four individuals had normal colour vision.
8.5 Discussion of results - central retinal function
8.5.1 VA summary
Data from this large prospective cohort study show that VA was significantly different
between the two largest clinical groups USH1 and USH2.
VA - differences between USH1 and USH2
When considering median VA (without making allowances for age) the USH1 group were
found to have significantly worse VA than the USH2 group, despite the latter having
a significantly older median age. This is a significant finding and on its own would be
sufficient to conclude that USH1 carries a worse visual prognosis than USH2.
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To interrogate this relationship further, linear regression models were constructed to
account for the effects of both age and disease duration. It is important to appreciate
that as this data was from an observational cohort study, not longitudinal, the regression
models should not be used to attempt to predict an individuals’ VA in the future, as this
would assume the rate and character of decline within each (genetically heterogeneous)
clinical group is the same. They can however be used to make generalisations and to
characterise apparent relationships from the data collected.
The apparent rate of decline in VA extrapolated from the cohort data suggested that
this was similar between USH1 and USH2, however for a given age, VA was worse in
USH1 compared to USH2 (significant difference in the elevation of regression lines).
It is possible that this difference in age vs. VA between USH1 and USH2 could be
explainable by the earlier age of onset of visual symptoms in the USH1 group reported
in the previous chapter? To answer this question, VA was modelled against disease
duration, rather than age. The results suggest that despite efforts to correct for the
different age of onset (on an individual basis) the USH1 group still appeared to have
worse VA for a given age, as demonstrated by the statistically significant difference
between the elevation of regression lines for disease duration vs. VA.
There are three possible explanations for this. Firstly that this result was achieved
by chance, which statistically would be expected to occur in 0.14% of cases. Secondly
assuming that the variable ‘disease duration’ represents an accurate representation of the
length of time since the onset of retinal symptoms, this would imply that individuals with
USH1 do not become aware of their symptoms until a relatively later stage compared to
USH2, then declines at a comparable rate between both groups. Thirdly, as the variable
for disease duration was derived from subjective data it is open to bias (some possible
reasons for this are discussed in the summary section of the last chapter) it is possible
that there was a difference in the subjective reporting of first visual symptoms between
the USH1 or USH2 groups, such that ether USH1 reported symptoms later or USH2
reported symptoms earlier.
VA - comparison between molecular groups
The comparison of molecular groups showed that the VA and age in those with a molec-
ular diagnosis of one of the four USH1 genes MYO7A, USH1C, CDH23 and PCDH15
was similar. Due in part to the small numbers in the above molecular groups, regres-
sion models were not statistically significant in interpreting the VA data controlling for
the effect of age. The lack of significant difference in this sub-group of USH1 genes is
informative. Due to the similar median ages of these four molecular groups, it suggests
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that the VA prognosis is similar amongst these molecular groups, at least over the age
ranges analysed. Due to the large number of private alleles and consequent allelic het-
erogeneity, no conclusions can be drawn regarding the VA within each of the molecular
groups MYO7A, USH1C, CDH23 and PCDH15 groups.
Due to the much larger numbers in the largest molecular group USH2A, an attempt
to reduce some of this allelic heterogeneity was made by performing sub-group analy-
sis between individuals who carried the common p.Glu767SerfsX2 mutation in USH2A.
As most of the p.Glu767SerfsX2 allele sub-group carried this allele with another disease
causing change (only 7 individuals from 6 families were homozygous for p.Glu767SerfsX2)
it does not negate the effect of allelic heterogeneity within the USH2A group, however it
does represent an attempt to control for it. Comparison between those that carried the
allele (n=61) and those that did not (n=56) suggesting that the VA phenotype in the
p.Glu767SerfsX2 subgroup was not distinguishable from the remainder of the USH2A
group, which represents an important finding.
VA - rate of decline in VA observed
The rate of deterioration in VA implied from observational data in this study was sim-
ilar for the entire cohort and remained statistically similar after interpreting the data
following subdivision on the basis of clinical subtype (USH1 vs USH2) and within the
largest molecular group, USH2A. This rate was equivalent to 0.01 logMAR units per
year, which equates to loosing a line of VA every decade.
Notably the USH2 group VA data showed that visual acuity remained well preserved
in most individuals through adult life, with logMAR=0.5 at age 60.5 years (from the
USH2 regression line). Using the USH2 regression line to comment on VA the within
the observed age ranges we can see that visual acuity is good at the age of 18.8 years
(logMAR VA=0) explaining the modest deterioration in VA for USH2 over adult life.
Although most of the USH1 VA data in this study was from younger individuals, a
significant difference in elevation of the USH1 regression line overall suggests that for
a given age, the VA was worse, however this increment could not be quantified (the
y-intercept for the USH1 regression line could not confidently be predicted).
LogMAR=0 is equivalent to a visual acuity of 20/20, and is generally accepted as rep-
resenting the lower limit of ‘normal’ visual acuity. USH2 regression line predicts a value
of 18.8 years when logMAR=0 (6/6 or 20/20 Snellen equivalent).
In the previous chapter, the median reported age of onset of visual symptoms in USH2
was 17 years of age, which equates to a VA level of -0.02 from the USH2 regression line.
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A useful statistic that can be delivered to patients with Usher syndrome is that from
the observational data in this study, half of those with USH1 (including its largest
constituent molecular group MYO7A) maintained driving vision until their mid thirties,
and this figure was much later for those with USH2 (including its largest constituent
molecular group USH2A) at the mid-fifties. If is important to note that ‘driving vision’
to satisfy the DVLA also requires that the minimum standards are met for visual field
size and sensitivity and not just based on VA.
8.5.2 Cystoid Macular Oedema
This prospective study found the prevalence of CMO to be 25% for the whole cohort
with 38% (n= 14/38) of USH1 and 22% (n=27/125) of USH2. This difference was
approaching statistical significance, dependent on the statistical test used with two-
tailed Chi Squared Test P=0.04 and with Fisher?s exact test P=0.07.
An important finding was that there appeared to be no relationship between age and
presence of CMO as a study group overall and also when comparing USH1 and USH2
groups separately. Moreover there was also there was no apparent relationship between
the presence of CMO on OCT scans and reduced visual acuity.
Earlier reports based on clinical examination alone found the prevalence of CMO in
Usher syndrome to be much lower 8% [177] and 9% [27]. The advent of OCT imaging
suggested that many cases of CMO in Usher syndrome were sub-clinical A recent ret-
rospective study did not assess visual acuity. but found a 25% incidence of CMO in 76
USH2 individuals which is comparable to the USH2 group incidence in this study. A
small but detailed study using OCT in molecularly diagnosed USH2 cases found CMO
in 1 of 3 GPR98 patients and 6 of 10 USH2A cases. Interestingly they also noted that
despite the presence of CMO, all cases maintained good visual acuity of 20/30 (0.18
logMAR) or better. Previous studies in to other forms of RP have identified that retinal
thickness does not always correlate with visual acuity [178] [179].
The pathogenesis of RP-related CMO remains unclear. Various theories exist to explain
the pathogenesis in RP. Increased vascular permeability from the outer and inner blood-
retinal barriers have been reported [180] [181] and studies have considered the role of
antiretinal antibodies [182].
Acetazolamide therapy has been studied and in some cases of RP and Usher syndrome
whilst it has been shown to decrease retinal thickness, this has not been strongly asso-
ciated with a commensurate increase in visual acuity [183][184][185][186].
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In eyes without retinal dystrophy it has been shown that the presence of cystic changes
at the fovea may develop in to partial of full thickness macular holes [187], and such
changes have been reported in Usher syndrome as well as noted in one individual in
this study and one rationale for treating CMO might be to reduce the risk of structural
damage to the macular.
But it is interesting to note that the CMO seen in Usher syndrome and other forms of RP
appears not to affect visual acuity as much as other causes of CMO such as diabetes and
secondary to ocular inflammation, which likely reflects differences in the pathogenesis of
this common pathological finding.
8.5.3 AF imaging
Lipofuscin is a naturally occurring fluorophore that is generated from the continual
lysosymal degredation of photoreceptor outer segments by the retinal pigment epithelium
(RPE). AF imaging provides a non-invasive method of visualisation of the distribution
of lipofuscin across the poster pole of the eye enabling an in vivo method of assessing
the functioning of the RPE/photoreceptor complex.
Previous studies have documented the presence of parafoveal rings of hyperfluoresent/high-
density in individuals with a variety of retinal dystrophies including RP [188][188][189–
191], X-linked retinoschisis, Lebers congenital amaurosis (LCA) [192], cone-rod dys-
trophies [193, 194] pigmented paravenous retinochoroidal atrophy (PPRCA)[195], and
Bests disease[196].
Work carried out alongside this study, including a subset of individuals with USH2 from
this study has documented a decrease in the size of hyperflorescent rings over time in
a subset of individuals with RP and USH2[190], which was associated with a decline in
visual fields and macular function as assessed by electroretinography. Interestingly sim-
ilar rings have been noted to possibly increase in area with time, in cone-rod dystrophy,
where the primary site of disease is at the macular area [191].
This study contributes the largest cohort of AF images in a cohort individuals with
Usher syndrome, most of which also have a molecular diagnosis.
Foveal hyperfluorescence
Foveal hyperfluorescence was a common finding amongst those with Usher syndrome
type 1 and 2. Its presence was associated with poorer visual acuity. CMO was a major
cause for foveal hyperfluorescence, however foveal hyperfluorescence was also identified
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in approximately half of the cases where CMO was absent. Qualitatively, the foveal
hyperfluoresence in the presence of CMO was generally of a softer less dense nature (e.g.
Figure 8.29 Panel B) but in those cases of advanced disease in the absence of CMO
the hyperfluoresence was generally of contiguous areas of high density hyperfluorescence
(e.g. Figure 8.29 Panel A).
Whilst foveal hyperfluorescent signals can be caused by CMO in some cases the source
of the hyperfluorescent signal in those eyes without CMO is unclear. One possibility
is that the high density signal may be due to the deposition of fluorescent material
such as lipofuscin. High resolution OCT scans taken appeared to reveal an optically
dense material in the inner retina corresponding to areas of high density AF signal seen.
Foveal autofluorescence is masked my the macular pigment in a normal eye, another
possibility to account for the hyerfluorescent signal might be loss of this masking effect.
One observation was that many of the individuals with advanced disease and foveal
hyperfluorescence had a history of CMO in the past.
Ring size
This study documents that amongst the cohort of Usher syndrome clinical subtypes.
The presence of AF rings was associated with younger age and better visual acuity.
Rings were seen in all three clinical subtypes and in all molecular groups identified,
representing a novel finding.
In all clinical subtypes AF rings were associated with better visual acuity and younger
age, suggesting that they are likely to occur earlier rather than later in the retinal
pathogenesis of Usher syndrome.
The relationship between decreasing ring size with advancing age was demonstrated
for the USH2 clinical or USH2A molecular groups, with linear regression, however no
such relationship could be made amongst the USH1 or MYO7A groups. Figure 8.34
demonstrates a slight preponderance of larger ring areas for USH1, but this difference
was not statistically significant nor could a significant correlation being achieved. With
longitudinal follow up of these USH1 individuals with large AF ring areas, it will be
interesting to see if their ring size increases or decreases with time.
Another intresting observation was that AF rings in the USH2 molecular subtypes
(USH2A and GPR98 ) were geographically located within the vascular arcades, how-
ever for the USH1 molecular subtypes the AF rings were generally much larger and
located anterior to the vascular arcades. Interestingly the AF rings seen in the family
with an atypical phenotype due to the USH1C gene had larger AF rings, extending in
to the retinal periphery.
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Parafoveal hypofluorescence
Previous studies on foveal pathology in Usher syndrome have noted the presence of
clinically atrophic foveal lesions or ‘bull’s eye’ macular lesions which were more prevalent
in USH2 compared to USH1 [177, 197]. This study has characterized the atrophic lesions
further with AF imaging. The areas of parafoveal atrophy highlighted by AF are likely
to represent areas of RPE +/- photoreceptor death and therefore visually significant.
The combination of central hyperfluorescene and perifoveal hypofluorescence could be
described as a ‘bull’s eye’ picture. Moreover these lesions were more commonly, but not
exclusively seen in the USH2A molecular group.
Serial AF images in one individual (Figure 8.41) document increase in the area of
parafoveal hypofluorescence over a period of 4 years. These features appear to be more
common later on in the retinal disease process.
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Figure 8.41: Serial AF images in the left eye of an individual with USH2 documenting
significant progression of the area of parafoveal hypofluorescence over a 4 year period
The findings on autofluorescence in this study have demonstrated AF rings in all molec-
ular subtypes, which is a common finding amongst RP and other forms of retinal dys-
trophy. The additional and frequent findings of foveal hyperfluorescence and parafoveal
areas of hypofluorescence are much less common and whilst not pathognomic of Usher
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syndrome appear to be more frequent in this disorder, which may suggest a common
pathological aetiology in this disorder.
Chapter 9
Results - Peripheral retinal
function
9.1 Visual field (VF) area
This chapter reports on the results of kinetic visual field testing using Goldmann visual
fields. Three sizes of identical luminance were used to map the visual field at different
levels of sensitivity. The largest target was V4e, the intermediate target was II4e and
the smallest target I4e.
9.1.1 Left vs Right VF area
There was a high degree of left/right correlation between the visual field area recorded
for each of the three isopters. The correlation coefficients for each of the three isopters
were high (r=0.947 (largest), r=0.854 (intermediate), r=0.842 (smallest)) and all highly
significant (p<0.0001) indicating a high degree of similarity between the visual fields in
both eyes.
For the remainder of this chapter visual field analysis was undertaken using the value in
the better eye (larger visual field area). This was similar to the analysis of visual acuity
which analysed the better seeing eye.
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9.2 VF area - regression analysis
When analysing the median visual field area in the better eye, there was no significant
difference between USH1 and USH2 groups for any of the isopters (Mann Whitney test,
P>0.3.
As visual field size is known to deteriorate with age this difference should be interpreted
with caution as the median ages of these two groups were significantly different.
Table 9.1: Summary of linear regression analysis for age and disease duration vs.
visual field data comparing USH1 and USH2 clinical groups. The gradient of the slopes
and elevations of USH1 and USH2 regression lines were compared statistically. Each
yes or no response is the answers to the question: “Is there a statistically significant
difference between the USH1 vs. USH2 groups?”
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To account for age, linear regression models were constructed for age vs. visual field
area (calculated in degrees squared) and then using the natural log of visual field area.
Due to the better fit of data for the logarithmic models, these results are presented.
A summary of the regression analysis is presented in Table 9.1.
When using linear regression models to predict visual field size as a function of disease
duration, there was no significant difference between USH1 and USH2 groups. Graph-
ically this can be seen by the similar gradient and elevations of the USH1 and USH2
regression lines.
When using linear regression to to predict visual field size as a function of age, only the
elevation of the USH1 and USH2 regression lines for the largest and intermediate isopter
sizes were statistically different, but for the smallest isopter the difference between the
two groups was not.
As the gradient for all regresion models was statistically similar this suggests that the
rate of observable decline was similar in USH1 and USH2 groups was also similar.
The following figures represent the regression plots against age and disease duration.
Each page represents the same isopter size.
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The regression equations are given below for USH1 and USH2 for the largest V4e isopter.
USH1: y= -0.097x + 10.021 (r2=0.478 , 41 d.f., P <0.0001)
95% confidence intervals for SLOPE (-0.129 to -0.065)
95% confidence intervals for Y-INTERCEPT (9.049 to 10.994)
USH2: y= -0.086x + 10.767 (r2=0.418 , 117 d.f., P <0.0001)
95% confidence intervals for SLOPE (-0.105 to -0.068)
95% confidence intervals for Y-INTERCEPT (9.989 to 11.545)
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Figure 9.1: Scattergraph of Age vs. natural log of VF size for the LARGEST isopter
(V4e) in the better eye for USH1 and USH2 groups. The linear regression models
provided a significant fit for the data and are shown for USH1 and USH2, with their
respective 95% confidence intervals shown by broken lines. The regression lines have
the same gradient. The dotted lines either side of the regression lines do not overlap
because the elevations of the lines are significantly different
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Figure 9.2: Scattergraph of DISEASE DURATION vs natural log of VF size for the
LARGEST isopter (V4e) in the better eye for USH1 and USH2 groups. The linear
regression models provided a significant fit for the data and are shown for USH1 and
USH2, with their respective 95% confidence intervals shown by dotted lines. The re-
gression lines have the same gradient and elevation resulting in significant overlap of
the broken lines for each regression line.
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Figure 9.3: Scattergraph of Age vs. natural log of VF size for the INTERMEDIATE
SIZE isopter (II4e) in the better eye for USH1 and USH2 groups. The linear r gression
models provided a significant fit for the data and are shown for USH1 and USH2, with
their respective 95% confidence intervals shown by broken lines. The regression lines
have the same gradient. The dotted lines either side of the regression lines do not
significantly ov rlap because t e elevations of the lines are significantly different
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Figure 9.4: Scattergraph of Disease duration vs. natural log of VF size for the
INTERMEDIATE SIZE isopter (II4e) in the better eye for USH1 and USH2 groups.
The linear regression models provided a significant fit for the data and are shown for
USH1 and U H2, with their respective 95% confidence intervals shown by broken lines.
The regression lines have the same gradient and elevation resulting in significant overlap
of the broken lines for each regression line.
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Figure 9.5: Scattergraph of Age vs. natural log of VF size for the SMALLEST
isopter (I4e) in the better eye for USH1 and USH2 groups. The linear regression
models provided a significant fit for the data and are shown for USH1 and USH2, with
their respective 95% confidence intervals shown by broken lines. The regression lines
have the same gradient and elevation resulting in significant overlap of the broken lines
for each regression line
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Figure 9.6: Scattergraph of Disease duration vs. natural log of VF size for the
SMALLEST isopter (I4e) in the better eye for USH1 and USH2 groups. The linear
regression models provided a significant fit for the data and are shown for USH1 and
USH2. The 95% confidence intervals are not shown as the regression lines run a visibly
similar course.
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9.2.1 Molecular subtypes
There was a highly significant difference between the elevation of the regression lines
(P<0.0001) but there was no statistically significant difference in their gradients.
Linear regression models were significant fit for the data and were effective at predicting
visual field from age.
The lines were a better fit for MYO7A (r2=0.78 , 18 d.f., P <0.001) than for USH2A
(r2=0.47 , 89 d.f., P <0.001).
If the overall elevations were identical, there is a less than 0.01% chance of randomly
choosing data points with elevations this different.
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Figure 9.7: Regression models for age vs. visual field area for the LARGEST V4e
isopter
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9.3 Survival analysis
To quantify the data in terms of a tangible area of visual field size, the area of 10
degrees squared was taken as an end point. Survival curves were plotted for USH1 and
USH2 groups as well as for their largest constituent molecular groups, MYO7A and
USH2A respectively. The median survival point represents the age at which 50% of each
population reduce the area of visual field to 10 degrees squared.
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Figure 9.8: Survival curve analysis for USH1 and USH2 clinical groups. The end
point used was a visual field size of 10 degrees squared or less. The three plots on
the left represent the survival curves using the variable AGE and the plots on the right
represent the variable DISEASE DURATION. The median survival points are indicated
with dotted lines. The vertical arrows represent the median survival points for the two
groups, but are only shown where the curves were statistically different from each other
(P <0.0001)
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Figure 9.9: Survival curve analysis for USH2A and MYO7A molecular groups. The
end point used was a visual field size of 10 degrees squared or less. The three plots
on the left represent the survival curves using the variable AGE and the plots on the
right represent the variable DISEASE DURATION. The median survival points are
indicated with dotted lines. The arrows represent the median survival points for the
two groups, but are only shown where the curves were statistically different from each
other (P <0.0001)
Chapter 9. Results - Peripheral retinal function 266
9.4 Visual fields summary
Table 9.2: Summary of median survival points (age in years) for the time taken for
USH1 and USH2 groups to drop their field size to 10 degrees squared
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Table 9.3: Summary of median survival points (age in years) for the time taken for
MYO7A and USH2A molecular groups to drop their field size to 10 degrees squared
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Previous studies comparing USH1 and USH2 clinical groups have documented that visual
fields are worse for a given age in USH1 compared to USH2 [198]. Two longitudinal
studies done on small numbers of molecularly subtyped individuals withUSH2A reported
that the rate of longitudinal visual field loss is similar in Usher syndrome to RP, and
that visual field loss in USH2 appeared to correlate better with disease duration than
with age [199][28].
Although this study is an observational cohort study and not longitudinal in design, the
linear regression data suggests that for a given age, USH2 have a larger visual field area
than USH1 for the larger targets, but for smaller targets this difference is less significant.
The survival curves support this data, also found a highly significant difference between
USH1 and USH2 groups. The time taken for half of each cohort to drop their visual
field size to 10 degrees squared occurred a decade earlier in USH1 (mid-forties) than
USH2 for the largest isopter. This remained the case when repeating the analysis for
the MYO7A and USH2A molecular groups. Statistically the difference between these
two molecular groups was highly significant for the largest and intermediate isopter, and
borderline significance (P=0.00502) for the smallest isopter.
The data from the survival curve analysis is of use when counselling patients with Usher
syndrome.
Chapter 10
Non Usher families
10.1 Syndromic families with non-USH
10.1.1 Family with sector RP and hearing loss due to mutations in
USH1C
This section reports Family 142, who were recruited in to the study. The index case had
received a diagnosis of USH2 previously. As additional tests were performed outside the
remit of the NCUS, the methodology relating to the relevant aspects of clinical analysis of
this family is described in this section rather than in the main body of clinical methods.
Electrodiagnostic and Fine Matrix Mapping methods
(Dr Anthony Robson, Dr Graham Holder, Mr V Luong) Pattern and full-field elec-
troretinograms (ERGs) were performed to incorporate existing International standards
[200, 201]. One of the siblings underwent photopic and scotopic fine matrix mapping
(FMM) performed according using previously described protocol [202–206]. The matrix
of retinal luminance sensitivity at each test location was used to generate a surface or
contour plot showing the size and location of luminance sensitivity gradients across the
grid (contour steps: 0.1 log unit). The numerical matrices and luminance sensitivity
contour plots were superimposed onto the AF images with custom image-analysis soft-
ware. Accurate superimposition was achieved by aligning anatomic landmarks, such as
the center of the optic disc and the fovea, with the corresponding perimetry landmarks,
such as the center of the blind spot and fixation. Scotopic FMM was performed over
identical retinal locations following pupil dilation (tropicamide 1%) and 40 min dark
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adaptation. Fixation was monitored continuously. Photopic and scotopic threshold val-
ues were compared with those obtained in a control group of 10 normal individuals
[189].
Audiovestibular phenotyping
(Dr Nell Rangesh and Prof Linda Luxon)
Audiological evaluation included pure tone audiometry, tympanometry, stapedial re-
flexes, transient evoked otoacoustic emissions recordings and auditory brain stem evoked
responses using standard protocol [207][208][209][210] [207–210]. Subjective pure tone
air and bone conduction thresholds were determined at 0.25, 0.5, 1, 2, 4, and 8 kHz
using a GSI 61 audiometer (Guymark, Cradley Heath, UK) TDH39 supra aural ear-
phones (Sennheiser U.K Ltd, High Wycombe, UK) and the British Society of Audiology
(BSA) recommended procedure. Audiometric descriptors of mild, moderate, severe and
profound hearing loss were calculated according to BSA descriptors (2004). Vestibular
function was evaluated with infra-red videonystagmography, a rotary chair system (Neu-
rokinetics, Pittsburgh USA) and vestibulo-ocular reflex responses (VOR) [209]. Binaural
bithermal caloric testing was undertaken using the BSA recommended protocol (1999)
and departmental normative data for peak slow component velocity were used to de-
termine normality. Canal paresis (>17%) and directional preponderance (>16%) were
calculated according to Jongkees formulae (Jongkees 1953) and vestibular hypofunction
was defined by total eye velocity less than 78 degrees/sec. All parameters were defined
by departmental normative data. Bilateral horizontal semicircular canal function was
assessed using sinusoidal (60 degrees peak velocity and 0.05 Hz) and step rotation testing
(acceleration 0-60 degrees/sec constant velocity in <1 sec.). A gain of less than 0.23 in
either test or a time constant of less than 8 seconds on impulsive rotation was considered
vestibular hypofunction.
Additional Molecular methods
Variants were annotated according to accession number GenBank:NM 153676.3. Anal-
ysis of putative splice site sequence changes was performed using the online splice site
prediction software.
Clinical history
Family 142 consisted of the index case (NCUS 497) aged 42yrs, her affected sibling
(NCUS 505) 40 yrs old and their parents, both of whom were of Caucasian European
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origin. Their parents were both in their seventies and although they were not clinically
examined they did not suffer from any visual problems. Molecular data were available
from all four family members.
Figure 10.1: Pedigree of sector RP family with hearing loss. Black symbols represent
affected siblings. The index case is indicated with a solid arrow. Mutations are indicated
with a star
Both siblings were diagnosed with severe hearing loss at four years of age and had worn
hearing aids since that time. Language acquisition and speech development were normal.
There was no history of delay in motor milestones, consistent with normal vestibular
function in infancy. When last examined, the affected siblings were 42 years and 40
years old and maintained good central visual acuity and color vision (Table 10.1).
Table 10.1: Table summarizing ophthalmic clinical findings of the two affected siblings
NCUS 497 and 505
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The elder sibling (NCUS 497) noticed visual field loss from age 22 years, but denied any
night blindness at age 42 years of age. Her younger brother (NCUS 505) experienced no
visual symptoms until the age of 39 years, when he became aware of night blindness and
difficulties adjusting to changed lighting conditions, which prompted ophthalmic review.
Unlike his elder sister, he was not aware of any visual field loss when last examined aged
40 years.
Despite their unusual sectorial retinal disease , the siblings had previously been diagnosed
with Usher syndrome type 2 and had initially been recruited to a comprehensive clinical
and molecular study of Usher syndrome.
Retinal phenotype
Both siblings demonstrated bilateral symmetrical areas of retinal and retinal pigment
epithelial change restricted to the inferior fundus. In the more severely affected index
case, the changes extended to the nasal retina (Figure 10.2). FAF imaging (Figure
10.2 middle row) revealed a thick curvilinear band of hyperfluoresence, which appeared
to separate preserved central fluorescence from the abnormal areas of hypofluoresence
corresponding to the abnormal areas of intraretinal pigment migration seen clinically
(Figure 10.2 top row).
Interestingly this prominent hyperfluorescent band did not correspond to any obvious
visible changes on fundoscopy. The inferior and nasal abnormal retinal areas corre-
sponded to the superior and temporal areas of visual field loss noted on kinetic perimetry
respectively. Bilateral vitreous separation and subclinical lens opacities were noted in
both siblings, which were not visually significant. The photopic and scotopic sensitivity
was tested psychophysically at specific retinal locations in the index case (Figure 10.5).
Retinal sensitivity was relatively preserved within the central area of preserved autoflu-
orescence. The thick band of hyperfluorescence was associated with a gradient of retinal
sensitivity change, with retinal sensitivity being abnormally elevated outside the band
(Figure 10.5 4c, 4d).
Photopic fine matrix mapping revealed normal thresholds over central (Figure 10.5) and
the innermost eccentric locations (Figure 10.5). Thresholds increased gradually with
eccentricity (within 2 SDs of the normal mean) and showed a steep gradient of sensitivity
loss across the arc of high density (Figure 10.5). Cone system sensitivity showed the
steepest gradient of loss over an area spatially associated with the hyperfluorescent
arc seen on FAF imaging. Significant loss in rod system sensitivity occurred at a less
eccentric location, internal to the arc (Figure 10.6 5d). Photopic thresholds peripheral
to the arc of high density were elevated by approximately 2.2-2.6 log units (5.0-5.9
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Figure 10.2: Composite of images from index case NCUS 497 (A) and NCUS 505 (B).
In each panel images from the right eye are shown in the left-hand column and images
from the left eye shown in the right-hand column. (top) Colour fundus photographs
show bilateral symmetrical areas of retinal and retinal pigment epithelial changes re-
stricted to the inferior and nasal areas of the fundus in both siblings. Retinal pigment
epithelial (RPE) atrophy results in increased visibility of the underlying choroidal vascu-
lature in affected areas, blood vessel attenuation and intraretinal ‘bone-spicule’ pigment
migration. Outside these areas the blood vessels appeared to be of normal caliber. The
fundus appearance is otherwise unremarkable (middle) Fundus autofluoresence imag-
ing reveals a thick curvilinear hyperfluorescent band that appears to separate normal
from abnormal retina. In both individuals the hyperfluorescent band runs outside the
inferior vascular arcades. The band In the more severely affected index case NCUS 497
(A), takes a course nasal to the optic disc running superiorly in to the nasal retina,
whereas in the less severely affected sibling NCUS 505 (B), the hyperfluorescent band
and abnormal area is restricted to the inferior retina. In both siblings the abnormal
areas are generally hypofluorescent with additional discrete areas of denser atrophy.
(bottom) Goldmann visual fields relate to isopters V4e (largest target) in black, II4e
isopter in green and I4e isopter (smallest target) in red. In the more severely affected
index case NCUS 497 (A) there is a tongue of field loss in the mid-periphery of the
superotemporal visual field, whilst in the less severely affected sibling NCUS 505 (B),
only relatively minor visual field loss is evident in the superotemporal part of the visual
field.
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Figure 10.3: Left eye of Index case with colour fundus photos (above) and AF imaging
(below)
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Figure 10.4: Right eye of affected sibling colour fundus photos (above) and AF imag-
ing (below)
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Figure 10.5: Contour plots (top row) and threshold plots (bottom row) obtained in
the index case under photopic (a and c) and scotopic (b and d) conditions. Testing
was performed at central (a and b) and eccentric (c and d) retinal locations. Labelling
(x) illustrates correspondence between the orientation of contour and threshold plots.
x-axis: retinal location (degrees); y-axis: threshold (log units).
SDs) above the normal mean, with milder elevation close to the optic disc. Thresholds
eccentric to this region were elevated by approximately 2.1-2.45 log units (3.0-3.4 SDs)
above the normal mean, with some sparing of sensitivity close to the optic disc.
Electrophysiological testing (Figure 10.6) demonstrated a normal PERG in both siblings
indicating normal macular function, consistent with the preservation of photopic sensi-
tivity demonstrated by the FMM. Full field ERGs suggested a relatively mild rod-cone
dystrophy: scotopic ERGs were subnormal, consistent with rod photoreceptor dysfunc-
tion, and there was mild abnormality of cone response amplitude. There was no sig-
nificant delay in rod or cone-mediated ERGs, in keeping with restricted disease. Both
siblings demonstrated normal retinal and foveal architecture on OCT scanning, but both
had areas of retinal thickening above the 95th centile compared to age matched controls,
most obvious in the nasal half of the retina (Figure 10.7).
Audiovestibular phenotype
The index case had a moderate sensorineural hearing loss, which was bilateral and
symmetrical (Figure ??) Tympanometry and stapedial reflexes were normal but TEOAE
responses were absent, characteristic of cochlear hearing loss. Auditory brain stem
evoked responses were absent in spite of the moderate hearing loss, suggesting retrograde
neural degenerative changes. Rotational tests showed vestibular hypofunction with a
gain of 0.16 on sinusoidal rotation (normal limits: 0.39 +/- 0.16) and a right directional
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Figure 10.6: Full-field ERGs and pattern ERGs (PERG) from one eye of the affected
sibling (row 1) and index case (row 2). Representative normal data appear in the bot-
tom row.. All responses showed minimal inter-ocular asymmetry. PERGs were within
normal limits for both siblings. Rod-mediated full field ERGs in affected sibling (row 1)
were mildly subnormal; cone-mediated 30Hz flicker ERGs were mildly subnormal and
of borderline timing, in keeping with a mild rod-cone dystrophy. In index case (row
2) Rod-mediated responses were mildly subnormal with b-waves of borderline timing;
30Hz flicker ERGs were mildly subnormal and of normal timing. Dark-adapted ERGs
are shown for flash intensities of 0.01 and 11.5 cd.s.m-2; light-adapted ERGs for a flash
intensity of 3.0 cd.s.m-2. ON-OFF ERGs used an orange stimulus (560 cd.m-2, du-
ration 200ms) superimposed on a green background (150 cd.m-2). S-wavelength flash
ERGs used a blue stimulus (445 nm, 80 cd/m2) on an orange background (620 nm, 560
cd/m2). Eye movement artefacts are replaced by broken lines.
preponderance of 22% (normal limits ≤ 20%) which was confirmed by caloric testing,
which showed a significant right directional preponderance of 33% (normal limit ≤ 16%).
Her younger sibling showed a similar symmetrical sensorineural hearing loss, but of severe
degree with a steeper loss across the low frequencies but similar recovery at 4 kHz (Figure
??) His transient evoked otoacoustic emissions and auditory brain stems responses were
also absent. His vestibular function was within normal limits for sinusoidal rotation (0.25
Normal range 0.39+/-0.16) but showed mild hypofunction on impulsive rotation with a
gain of 0.19 (normal range 0.39+/-0.16). He also had a mild directional preponderance
of 20% (departmental norm ≤17%) on caloric testing.
USH1C mutations
Two USH1C mutations were identified, the previously reported c.308G(p.R103H) [64],
and the novel c.2227-1Ginvariant splice site change. Both sibs were compound heterozy-
gous for these two variants, which were inherited from each parent (Figure 10.1). Neither
allele was found in 866 control chromosomes. Screening of MYO7A, CDH23, PCDH15,
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Figure 10.7: 6mm Optical Coherence Tomography (OCT3) scans centered at the
fovea of the right eye (OD) and left eye (OS) of the index case (A) and her affected
sibling (B). The upper images are representative cross sectional scans showing normal
retinal architecture. The schematic below these images represent the average thickness
(in microns) of each quadrant after subdivision by three concentric circles of 6mm,
3mm and 1mm compared against age matched normative data. This demonstrates the
thickness of nasal retina to be above the 95th centile in both affected individuals.
USH2A, GPR98, WHRN, USH3A (the other seven genes associated with Usher syn-
drome) failed to reveal any putative pathogenic changes such as frameshift, splice site
or rare missense changes.
Discussion
We report a sibship with sector RP with associated hearing loss due to mutations in the
USH1C gene. To our knowledge this is the first reported case of sector RP associated
with mutations in this gene. The finding of a discrete arcs or rings of hyperfluorescence
has been reported in other forms of retinal dystrophy, and whilst they have no obvi-
ous correlation to changes observed with fundus biomicroscopy, they appear to be of
functional significance [211–215].
The affected individuals reported here demonstrate an unusual pattern of FAF with
a thick curvilinear band of hyperfluorescence separating preserved central fluorescence
with abnormal areas of hyperfluorescence inferiorly and nasally. Previous reports of FAF
in sector RP have described areas of hypofluoresence [216] as well as hyperfluorescent
arcs bordering the area of dysfunction [195].
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Photopic and scotopic fine matrix mapping in the affected individuals reported here
revealed normal cone and rod system sensitivity over central macular locations. The
constriction of hyperfluorescent rings seen on FAF imaging have been reported in RP
due to mutations in one of the other genes associated with Usher syndrome (USH2A)
and it has been suggested that progressive visual field loss may mirror constriction of the
AF ring, led by encroaching rod dysfunction over more central and concentric macular
areas [189, 211].
Both USH1C alleles carried by the affected siblings were inherited independently, absent
in 866 control chromosomes and are likely to be pathogenic. The p.R103H allele has
been previously reported in a family with Usher syndrome (USH1 phenotype) and was
not found in another panel of 352 control chromosomes [64]. The novel c.2227-1G<T
allele reported here is predicted to abolish the invariant AG dinucleotide splice acceptor
site interfering with splicing at the intron 21/exon 22 junction. If exon 22 were to be
skipped as predicted, the mature transcript would result in an inframe loss of 18 amino
acids (743 to 760 inclusive). This is likely to have significant functional consequences,
however further functional studies would be required to confirm the pathogenicity of
this allele.
A full list of USH1C mutations can be found here at Usher group from Montpellier,
France [217]. Null alleles in USH1C result in profound hearing loss and RP; less severe
hypomorphic missense changes appear to spare retinal involvement but are still associ-
ated with profound hearing loss with normal [54], or unknown vestibular function [62].
The hearing loss in this sibship is less severe than previously reported in disease due
to USH1C, which is typically profound, preventing the attainment of language. Both
siblings used hearing aids since childhood but developed normal speech and language.
The sector retinitis pigmentosa in this sibship also represents a milder retinal phenotype
than other reported patients with mutation in USH1C, with regard to age of onset of
symptoms, ERG amplitude and visual field area [218]. It is tempting to suggest that the
milder retinal and audiovestibular phenotype reported in this sibship might represent
a form of USH1C hypofunction affecting the retina and inner ear less severely than in
cases of Usher syndrome due to mutations in USH1C.
Sector retinitis pigmentosa is a rare form of RP characterized by bilateral symmetri-
cal retinal degeneration restricted to one area of the ocular fundus, usually the inferior
nasal quadrant. Disease transmission is usually autosomal dominant although autoso-
mal recessive transmission and X-linked cases have been reported [219–222]. Although
clinical examination may suggest restricted disease, tests such as dark adaptation, fluo-
rescein angiography and electrophysiological testing can reveal generalized rather than
restricted retinal involvement ([220, 222–224]. In the literature, a case of sector RP with
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prelingual hearing loss has been reported in a male individual with a retinal vasopro-
liferative tumor [225], however there was only a brief description of phenotype and no
molecular diagnosis . The only molecular cause of sector RP reported to date has been
due to mutations in the Rhodopsin (RHO) gene (OMIM 80380) which encodes human
rhodopsin pigment of the retinal rods. Several missense mutations in RHO have been
associated with the sector RP phenotype [219, 226, 227]
The USH1C gene (OMIM 605242) encodes a PDZ-containing protein called Harmonin
or USH1C, which is expressed in alternatively spliced isoforms that make up three dif-
ferent sized subclasses [43, 44]. Mutations in this gene have been associated with Usher
syndrome (the combination of generalized RP and hearing loss) [44] [92] [93–97], as
well as with non-syndromic autosomal recessive hearing loss (DFNB18) [54, 62]. There
appears to be some genotype-phenotype correlation with hypomorphic alleles causing
hearing loss without RP, whilst more severe truncating mutations result in hearing loss
and RP [54, 62]. The audiovestibular phenotype associated with mutations in USH1C is
one of prelingual profound hearing loss with absent peripheral vestibular function when
associated with RP [43, 44, 97], and with normal vestibular function when associated
with non-syndromic hearing loss [54, 62]. The retinal phenotype is usually typical of RP
with widespread fundus changes and visual problems from childhood.
Despite both siblings being of similar age and sharing the same two alleles in USH1C, the
index case had a marginally worse retinal phenotype with mild vestibular hypofunction,
whilst her sibling who was only 2 years her junior, had worse hearing loss, normal
vestibular function, milder retinal phenotype and later age of onset of visual symptoms.
No other putative pathogenic changes were identified in the other seven genes associated
with Usher syndrome suggesting environmental or stochastic factors or genetic modifiers
may influence disease severity. With regard to the retinal phenotype, it may be relevant
that the index case had worked outdoors for most of her adult life, whilst her sibling with
a milder retinal phenotype, reported less cumulative sunlight exposure. Phototoxicity
as a modifier in accelerating retinal degeneration has been reported in sector RP due
to a missense mutation in RHO [219]. Abnormal genetically encoded sensitivity to
ultraviolet and blue light has also been proposed to explain inferior retinal changes [228].
Classically, RP is associated with generalized dysfunction, and therefore with peak-time
shift, particularly in the 30Hz flicker ERG [229]. The absence of a marked cone flicker
ERG delay in both affected siblings is consistent with restricted rather than generalized
dysfunction, the latter commonly causing peak-time delay. Whilst an early form of
slowly progressive generalized retinal dysfunction manifesting as sector RP cannot be
excluded, at this stage is not suggested by the ERG characteristics.
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In summary we report a sibship with sector retinitis pigmentosa, severe hearing loss
associated with mutation in USH1C. There was evidence of mild vestibular hypofunction
in one of the siblings and both siblings were able to develop speech. Both the retinal
and audiovestibular phenotypes are much milder than in previously reported cases of
USH1C -related nonsyndromic hearing loss or Usher syndrome type 1, representing a
new spectrum of phenotype associated with mutations in the USH1C gene.
10.1.2 Alstrom syndrome - Family 133
The index case (NCUS 448) from Family 133 was a 41 year old male who attended
for ophthalmic phenotyping for this study having received a diagnosis of Usher syn-
drome many years previously. At the time of examination, he had not been seen by an
Ophthalmologist for over 5 years.
He gave a history of poor vision noted by his mother since 2 years of age and a history
of nyctalopia from age 7 years. His primary visual problem during his school years was a
reduction of central vision, followed by progressive deterioration in his peripheral visual
field. On direct questioning he admitted to hemeralopia during his childhood. At age
12 he was moved from a mainstream school to a partially sighted school.
His hearing loss was noticed by teachers at school at age 18 and had been non-progressive
in nature. At the time of his initial diagnosis of hearing loss, due to additional symptoms
of weight gain, impotence and anxiety, a CT scan was arranged. At this time a diagnosis
was made, (presumably central hypogonadism) for which thrice weekly male hormone
replacement therapy was started and was ongoing.
He had three unaffected siblings and there was no family history of visual or au-
diovestibular dysfunction. In addition to the above, his medical history also included
hypertension and hypercholesterolaemia for which he was on treatment and non-insulin
dependant diabetes mellitus (diet controlled).
Examination revealed a blind left eye (no perception of light) and hand movements
vision in the right eye. Visual field testing was not possible due to significant visual
impairment.
Slit lamp biomicroscopy revealed dense nuclear scelerotic cataracts in both eyes prevent-
ing a useful fundal view. In the left eye there was irregular cortical opacification of the
nasal half of the lens. A large sentinel vessel was seen on the temporal aspect of the
iris and a pea-sized smooth dark swelling beneath the sclera was noted on the temporal
aspect of the globe. Intraocular pressures was high in the left eye (45 mmHg) and within
normal limits in the right (15 mmHg). Both anterior segments were quiet. Gonioscopy
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in the left eye revealed an open drainage angle for all but the temporal 3 clock hours
where the angle could not be visualised due to a hypermobile iris. No mass was seen on
gonioscopy. There was no history of ocular pain on direct questioning.
B-mode ultrasound scans revealed bilateral atrophic temporal retinal detachments (prob-
ably longstanding) and no evidence of an intraocular lesion. Recent Chest X ray and
liver funcion tests showed a mild rise in ALT levels. He was referred to a specialist ocular
oncology unit for assessment of the left choroidal mass. Ocular neoplasia was excluded
and a diagnosis of non-specific scleromalacia was made.
Clinically his symptoms were consstent with a diagnosis of Alstrom syndrome, a rare
multisystem disorder and he was referred to a specialist physician. Subsequent molecular
testing confirmed the diagnosis by identification of mutations in the ALMS1 gene.
10.1.3 Unknown syndromic cause
Figure 10.8: Pedigree for Family 160
Two siblings (NCUS 569 and 570) from Family 160 were recruited in the study having
previously received a diagnosis of Usher syndrome. The two siblings were 19 and 21
years old respectively. They were the product of a 1st cousin consanguineous union
and their grandparents were originally from Yemen (see Figure 10.8). There were five
additional unaffected siblings, the youngest of which was 5 years old. Other than the
sibling pair, there was no family history of cardiac, audiological or ophthalmic problems
with neither of the affected siblings being known to have a history of rheumatic fever
or infectious disease. There was difficulty in obtaining a clinical history as neither of
the affected siblings used sign language. The index case had a diagnosis of learning
difficulties. The affected older sibling was in college.
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Both brothers had been treated for congenital cardiac valvular abnormalities of an un-
specified nature. They were apparently under the care of a cardiologist and were not
on any active treatment or known to have any active cardiac problems, however more
detailed information was not available.
Both siblings had profound hearing loss, the younger index case apparently deriving
some benefit from hearing aids (which were used bilaterally). Subjectively the hearing
loss for both affected siblings was described as asymmetrical and non-progressive.
The index case had poor vision bilaterally (counting fingers vision OD, hand movements
vision OS). The poor vision in the left eye was due to a previous retinal detachment
which may have been post-traumatic in aetiology. Colour vision testing and visual field
testing was not possible due to poor cooperation.
Figure 10.9: (Above) Colour fundus photos from the left eye of the affected sibling
(NCUS 570). (Below left) Autofluorescence imaging from the left eye showing a hyper-
fluorescent ring just within the vascular arcades. (Below right) Goldmann visual fields
for V4e, II4e and I4e isopters
The affected sibling had best corrected logMAR VA of 0.5 OD and 0.42 OS. No defects
were noted on HRR colour vision testing. There was mild constriction of the V4e isopter
with marked constriction of smaller isopters (see Figure 10.9).
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On clinical examination, both siblings had normal anterior segments. The index case
had a lens implant from previous cataract surgery and signs consistent with previous
retinal detachment in the left eye. Both retina were flat.
Dilated fundoscopy in the right eye of the index case and both eyes in the affected
sibling showed a similar pattern of modest mid-peripheral pigment migration and RPE
changes in both fundi. The retinal periphery was notable by lack of peripheral retinal
vasculature.
No cystic changes were noted on examination or OCT scanning. Fundal autofluorescence
performed in the affected sibling revealed bilateral hyperfluorescent rings.
As part of a separate study genome wide linkage analysis was performed using the
Affymetrix 50K SNP Chip platform which revealed homozygosity in the affected siblings
for several regions outlined in table 3.2.
Table 10.2: Regions of homozygosity identified in the two affected siblings from Family
160
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10.1.4 Family 170
The index case NCUS 633 from Family 170 was unusual as her initial visual symptoms
were of central visual dysfunction aged 10. Her visual acuity was poor bilaterally at
logMAR 1.6 OD, 2.6 OS. Colour vision and visual field testing was not possible due to
severe visual dysfunction. She had two paternal half siblings and there was no family
history of visual or audiovestibular dysfunction.
On clinical examination she had nummular areas of retinal pigment migration across the
posterior pole along with puctate areas of retinal pigment epithelial atrophy. Autofluo-
rescence imaging revealed patchy areas of hyperfluoresnce acrro the posterior pole and
macular area with peripheral hypofluorescence.
No supporting audiovestibular data was available on this individual but severe to pro-
found hearing loss was suspected. Communication was by speech.
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Figure 10.10: Colour fundus photographs from index case 633 from Family 170 show-
ing the atypical nummular areas of retinal pigment migration across the posterior pole
Figure 10.11: AF imaging from index case 633 from Family 170 showing patchy areas
of hyper and hypofluorescence across the posterior pole
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Compared to the rest of the affected individuals in this study, retinal phenotype and
poor visual acuity at such a young age was atypical. No disease causing mutations were
found in any of the Usher genes.
10.1.5 Atypical audiovestibular phenotypes
Three families (Family 124, 140 and 29) had pedigrees consistent with hearing and visual
loss segregating as the same disorder. The index case from Family 124 had central
vestibular hypofunction and a history of progressive hearing loss. The index cases from
Family 140 and 29 both had atypical audiovestibular phenotypes in that both index
cases communicated via speech but with profound hearing loss. They were both found
to have audiograms highly atypical of Usher syndrome.
10.2 non-syndromic families with non-USH
10.2.1 Visual and hearing dysfunction segregating as separate disor-
ders
Family 37 represents an example of two separate disorders segregating in the same
family. Figure 10.12 shows the family pedigree which shows the segregation of autosomal
dominant adult onset hearing loss from the paternal and likley autosomal dominant RP
on the maternal side.
The index case (NCUS 501) from Family 144 had a retinal dystrophy which was atypical
for RP consisting of an atrophic fundus. Hearing loss did not occur until adult life and
although audiograms were reported as being consistent with an USH2 phenotype, they
were atypical.
10.2.2 Hearing loss with no retinal phenotype
The index case in Family 502 was an 11 years old with moderate congenital hearing
loss. Communication was by speech with the use of hearing aids. Referral to an oph-
thalmology service at around age 6 was prompted by his mother’s concern regarding
her child’s visual function. He was prescribed glasses for a moderate refractive error
and at some point during his work up had retinal electrodiagnostics. These showed
equivoval results. On examination acuity was logMAR 0.2 OD and 0.3 OS. Slit lamp
biomicroscopy was unremarkable and visual fields were full to all isopters tested. On
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Figure 10.12: Pedigree of Family 37. Half circles represent a diagnosis of RP in
childhood or early adulthood. Asterisks represent late onset deafness (40 years of age
or greater). The arrow indicates the index case
direct questioning, no symptoms of nyctalopia or visual field loss were identified. Repeat
retinal electrodiagnostics were performed and were entirely normal.
The index case of Family 167 was a 54 year old with a history of congenital or early
childhood onset hearing and visual impairment. It appears that a diagnosis of Usher
syndrome had been mentioned by a healthcare professional at some point, but never
formally confirmed. This individual did not complete clincial phenotyping or undergo
molecular analysis for this study as it came to light that their visual dysfunction was as
a result of congenital cataracts and secondary glaucoma.
10.2.3 Atypical or acquired hearing loss
The remainder of non-USH families were either found to have acquired hearing loss or
an atypical audiovestibular phenotype making a diagnosis of Usher syndrome unlikely,
supported by the lack of putative pathogenic alleles identified in this cohort.
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10.3 Summary of non-USH families
The importance of taking a detailed family history was illustrated by the segregation of
two separate disorders in Family 37. Aside from this family, the remainder of the non-
Usher families identified in this study were found to have retinal and/or audiovestibular
phenotypes that were atypical. Of the 11 non-Usher families identified, only one was
found to carry any putative pathogenic sequence variants in any of the known Usher
genes. This suggests that Usher syndrome due to mutations in the Usher genes screened
in this study produce phenotypes that are relatively similar. Specifically no cases of
severe childhood visual dysfunction were identified.
Only one affected individual under the age of 20 years old with USH1 or USH2 had a
visual acuity worse than logMAR=0.3 in their better seeing eye. This was a 4 year old
child with disease due to MYO7A (Family 80) who had VA of 0.56 in both eyes. This
suggests that if an affected person suspected of Usher syndrome has visual acuity worse
than logMAR=0.6, they would be unlikely to have disease due to any of the known
Usher genes.
However, the atypical phenotype identified in Family 142 with mutations in the USH1C
gene also highlights the variation in phenotype that mutation in these genes can produce.
Chapter 11
Discussion
11.1 Review of thesis aims and findings
This study represents the largest prospective clinical and molecular cohort study in
Usher syndrome to date.
Identify a cohort of genotyped individuals with Usher syndrome in the
UK
This study has achieved its initial goal in recruiting 187 families with a diagnosis of
Usher syndrome from the UK. 176 of these families were felt to have a clinical diagnosis
of Usher syndrome and a molecular diagnosis was achieved in 80% of the 175 families
who underwent molecular analysis.
The first and arguably the most important task to facilitate this study was the identifi-
cation and recruitment of UK families with a diagnosis of Usher syndrome. Recruitment
of families with a rare disease causing dual sensory impairment has its challenges and
was slow to start.
The use of email and publicising the study on the internet via the charity Sense’s website
were helpful in getting news of the study out in to the deafblind community, which proved
to be a critical factor in achieving our goals in terms of numbers of families recruited, as
a quarter of all families self referred in to the study. Email proved to be a valuable tool
and was the most frequently requested mode of contact for USH1 families and second
only to voicephone in USH2 families. Moorfields Eye Hospital, a tertiary centre for
ophthalmic care in the UK was a valuable resource in identifying families with Usher
syndrome and provided just over half of all families.
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Understand natural history of the disorder
One has to be careful in drawing conclusions from an observational cohort study such
as this. However the large dataset collected in this prospective study has provided some
insights in to the pathogenesis of Usher syndrome. 219 affected individuals from 187
families underwent ophthalmic phenotyping.
This study has shown that symptomatic onset of retinal disease occurs at a younger
age in USH1 (median age 9 years old) and USH2 (median age 17 years old). Whilst the
earlier onset of USH1 has been known for some time, the data from this study has shown
that the early onset in USH1 was seen in all the four USH1 genes (MYO7A, USH1C,
CDH23 and PCDH15 ) and the wider range for the age of onset of visual symptoms in
USH2 was reflected in both the USH2 molecular groups identified, USH2A and GPR98.
Only one affected individual under the age of 20 years old with USH1 or USH2 had a
visual acuity worse than logMAR=0.3 in their better seeing eye. This was a 4 year old
child with disease due to MYO7A (Family 80) who had VA of 0.56 in both eyes. From
the dataset collected in this study, this suggests that if an affected person under the age
of 20 years old suspected of Usher syndrome has visual acuity worse than logMAR=0.6,
they would be unlikely to have disease due to any of the known Usher genes sequenced
in this study, however as this study has not collected an exhaustive set of Usher patients
this is simply an interesting observation, rather than a statement.
Facilitate subsequent longitudinal studies
The large cohort of prospectively phenotyped individuals with a molecular diagnosis will
be a useful resource in the future for delineating genotype vs phenotype correlations by
generating longitudinal data on the same study recruits.
Help devise a strategy for subsequent molecular analysis in the UK
We embarked on the National Collaborative Usher Study in order to determine the
molecular epidemiology of Usher syndrome in the UK, and as a prerequisite to estab-
lishing a diagnostic service necessary for when trials and treatments become available.
Molecular diagnosis in Usher syndrome is hindered by significant genetic heterogeneity,
the large size of some of the Usher genes and the large number of missense changes in
genes such as MYO7A and USH2A. Demonstrating variants that are truly pathogenic,
rather than neutral, is often difficult. Although a number of molecular studies of Usher
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cohorts have been published to date, none have been designed in a way that would sys-
tematically detect digenic inheritance and whether or not this is a significant or recurring
phenomenon. Whilst a major undertaking in terms of time and expense, we decided to
sequence all the known Usher genes in all subjects, regardless of clinical subtype in or-
der to assess evidence for digenic inheritance and determine the extent of polymorphic
sequence variation within the genes.
MYO7A was the most prevalent gene resulting in an USH1 phenotye and 75% USH2
was due to the USH2A gene which is similar to previous studies [162, 174, 230]. It was
interesting to note that no mutations in the genes USH1G and WHRN were identified
whilst USH3A mutations were only identified in two families suggesting that these genes
are rare amongst the UK population.
It was anticipated that by looking at the spread of mutations and molecular groups, a
molecular analysis protocol could be devised to screen for mutations in the UK popula-
tion.
In the entire study, only a few common putative pathogenic alleles identified in three
genes, the rest of mutations being private to families. The common allele
USH2A:p.Glu767SerfsX21 accounted for over half of all families with USH2 and over a
quarter of all families in the study, regardless of phenotype. The high prevalence of this
allele has been widely reported in many different populations [161–163, 165, 166, 231,
232]. p.Cys419Phe in the same gene was identified in 6 families.
The third most prevalent allele among all families was the splice site change c.496+1G
>A which has been previously reported and identified as a founder mutation in the
French Canadian population [44, 94, 160]. Four sequence variants in the USH2A gene
were each identified in four different families, but the overwhelming majority of re-
maining families carried private alleles. This presents significant challenges in terms of
establishing a useful method of screening which is compounded by the large genomic
size of many of the USH genes.
Mutation detection rate
We detected at least one pathogenic/likely pathogenic mutant allele in 86% of probands
studied and found considerable genetic heterogeneity in the mutations involved. This
suggest that there are unlikely to be any other Usher genes of major impact in the
population, and that a significant proportion of mutations in the known genes remain
undetected by current conventional sequencing methods, as only a single mutation was
found in 30 families.
Chapter 10. Discussion 290
Although probands with a clinical classification of Usher syndrome type 1 were screened
for all USH genes, the causative mutations were only found in USH1 genes. Screening of
the USH2 genes in USH1 probands therefore can be expected to have a very low mutation
yield and the clinical classification of type 1 Usher, is generally very robust as it correlates
with a molecular diagnosis of type 1 Usher as well. Only only 1 out of 125 probands
clinically classified as USH2, had a single nonsense mutation in MYO7A, an USH1 gene,
and it is unclear as to whether this mutation is disease causing in this individual. In
another family who entered the study with a diagnosis of Usher syndrome type 2/3,
we identified two USH1C mutations and affected sibs were subsequently diagnosed as
having sector RP and hearing loss [233] . Therefore we can recommend that screening
all genes is unnecessary in most cases and molecular screening can be somewhat directed
by clinical diagnosis. Segregation analysis using haplotypes is also a valuable tool for
selecting candidate genes as shown by Roux et al. who detected putative disease-causing
mutations in more than 90% of 34 USH1 families from France [64, 234].
The use of genotyping microarrays using arrayed primer extension is an available and
cost effective tool to detect DNA sequence variants, however this technology is only
successful in identifying known mutations. Given the large number of private alleles
identified across all the Usher genes in our study, using genotyping microarrays is unlikely
to yield a high degree of sensitivity. The drawbacks of such techniques may also affect
specificity, for example if a deaf child was found to have one putative pathogenic allele
in an Usher gene, this result on its own would be equivocal. However on balance this
probably represents the most cost and time effective method of molecular diagnosis for
Usher syndrome at this time.
MYO7A has been detected in nasal epithelium [141] and a recent report has identified
mRNA expression of seven of the nine Usher genes in hair roots, representing a novel
method of mutation detection [235]. This may provide a useful diagnostic tool in the
future and is also the subject of further work carrying on from this study.
Relative involvement of Usher genes
In agreement with other studies [64, 110, 236], MYO7A was the most frequent cause
of USH1, implicated in 53.2% of USH1 families. Surprisingly however, USH1C was the
second most common USH1 gene, accounting for USH in 12.8% of USH1 cases. This is
different from USH1 studies of 34 French USH1 patients [64], 33 of USA/UK patients
[110] and 121 Spanish patients [237] populations, where USH1C was responsible for the
disease in 6%, 7% and 1.5% of cases, respectively. However, our USH1C frequency
is similar to the study of patients from Germany, Denmark and Switzerland where
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USH1C was responsible for 12.5% # of cases [94]. USH1C:c.496+1G>A was not only
the most frequent USH1C mutation (representing 75% of USH1C pathogenic alleles), it
was also the most frequent USH1 mutation overall accounting for USH in 10.6% of USH1
families. The patients who harboured the mutation had the same disease-associated
USH1C haplotype, but we cannot conclude that the mutation arose from a common
ancestor as the haplotype consisted of only three informative and highly polymorphic
SNPs. Proportions of CDH23 (11.1% of USH1 cases) and PCDH15 (6.7%) mutations
were lower than previously reported by Roux et al. who reports PCDH15 and CDH23
account for 19% of cases each (Roux et al., 2006).
Mutations in USH2A were the major cause of USH2 in our cohort of 125 patients with
at least one pathogenic/likely pathogenic variant found in 75.7% of USH2 families, a
finding similar to previous studies which report USH2A is involved in 25 out of 33 (75%)
USH2 cases[174], in 89 out of 118 (75.4%) USH patients [168] and 57-63 out of 100 (57%-
63%) USH2 patients [238]. Apart from the common USH2A:p.Glu767SerfsX21 mutation,
we identified a wide range of private mutations. Fifty (31.8%) pathogenic/UV4/UV3
USH2A alleles were not previously described. Data regarding the frequency of GPR98
mutations is scarce, but it appears to be a less common cause of USH2. In our USH2
cohort, 6.25% of families segregated GPR98 mutations, which is similar to the study in
the French population where GPR98 accounted for 5.6% of cases [239].
Investigate the possibility of digenic effects and unusual phenotypes
A strength of this study is the comprehensive nature of molecular testing. Sequencing all
nine known Usher genes in each proband could be criticised as being excessive however
it has enabled us to answer the important question as to whether pathogenic alleles in
more than one of the known Usher genes might cause disease. We were unable to find
any evidence of this in 186 families and this suggests that the likelihood of this is low.
However, we cannot exclude the possibility that this is the case or indeed that sequence
variants in other genes may play a disease modifying role in the pathogenesis of Usher
syndrome. Another interesting discovery to come about as a result of our approach to
molecular diagnosis was the identification of a family with the atypical phenotype of
sectorial retinal disease (sector RP) and hearing loss less severe than usually associated
with the USH1C gene. One explanation to the milder disease might be explained by the
pathogenic alleles in this family being hypomorphic compared to the other truncating
sequence variants that are usually associated with the USH1 phenotype. Prior to this
finding the only reported molecular cause of sector RP was due to mutations in the RHO
gene coding for the human rhodopsin pigment.
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Identify which DNA sequence changes are disease causing
The relatively high proportion of single alleles identified in families with disease due to
the most prevalent genes USH2A and MYO7A, suggest that sequencing methods alone
failed to identify the second allele. The reasons for this are unclear but might be due
to factors such as unidentified or missed heterozygous deletions, non-coding variants or
other potentially digenic effects with as yet unknown genes.
The large number of families with no molecular diagnosis (n=30) despite this compre-
hensive molecular analysis strategy, suggest that more disease-causing genes are yet to
be identified for this disorder. The challenges of determining the pathogenicity of the
large number of rare DNA sequence variants assayed in a control population have also
been demonstrated. Many of these sequence variants were missense changes that remain
of uncertain pathogenicity. In silico analysis was helpful in conforming our suspicions
for those missense changes felt to be likely to be disease causing (UV4) and those that
were less likely to be so (UV3 and UV2), but due to the nature of in silico bioinfor-
matics, we have still not been able to confidently determine whether many of the novel
sequence variants found are disease causing. This will be the topic of further work and
may involve other techniques. This brings to light an important factor to consider as
we enter the age of next generation sequencing, when the generation of vast amounts
of DNA sequence data is becoming exponentially more efficient and cheaper. The more
DNA sequence variants we identify, the more we will have to test to determine whether
they are disease causing or not. The increase in DNA sequencing power has not been
matched by a commensurate increase in novel technologies to perform “arrayed” in vitro
or in vivo studies and it is difficult to imaging how this problem will be resolved in the
near future.
The molecular algorithmic system devised and implemented to help the grading of pu-
tative pathogenic alleles for this study is simple and quite transferable to other genetic
studies of autosomal recessive disease. Using a benchmark minimum allele frequency
is helpful for an ethnically homogenous population, but as we found in this study, rare
ethnic population polymorphisms will be unrepresented in a homogenous control group.
One benefit projects such as the 1000 Genomes Project and other future studies utilising
next generation sequencing technologies will be to interrogate DNA variants in much
larger ethnically diverse populations to help with this problem.
The pathogenicity grade of missense changes in this study was determined by their pres-
ence or absence in control chromosomes, other Usher families, or other Usher genes, in
trans or in cis co-occurrence with a pathogenic mutation in the same gene and their
haplotype. As the majority of mutations identified were private, their presence in the
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control chromosomes with a frequency of less than 0.236% proved to be a good indi-
cator of non-pathogenicity. Thirty-five out of 218 (16.1%) missense changes showed
a frequency of over 0.236% in control chromosomes and were thus considered neutral.
Eighty-six out of 218 (33.4%) missense changes were not found in 876 control chromo-
somes and additional 25 (11.5%) had a frequency below the benchmark of 0.236%, but
were unlikely to be pathogenic as they did not segregate with disease or were found in
patients with other more certain pathogenic changes.
Those families from this study that had no putative pathogenic DNA variants identified
will undergo further molecular analysis including closer analysis of polymorphic markers
and Multiplex Ligation-dependent Probe Amplification to detect deletions which may
have been missed by direct sequencing.
Genetic counselling for individuals and families
Families involved in the study will have information regarding their molecular diagnosis
fed back to them and have the option of attending for genetic counselling and discussion
of results. As the results for this study were done as part of a research project and
not conducted in an NHS reference laboratory this information will carry a caveat and
would require confirmation in an accredited laboratory prior to any clinical decisions
being made in relation to their molecular diagnosis. In the short term, we plan to feed
back to each family the gene we believe their disease to be due to. We feel that giving
patients more detailed information on sequence variants ever we are unsure as to whether
they are pathogenic or not, may cause more confusion than is necessary.
Genotype vs. Phenotype: inform clinicians
An important finding to come out of this study was on retrospective questioning, onset
of visual symptoms occurred at a significantly younger age in USH1 (median age 9 years
old) compared to USH2 (median age 17 years old). In our data, no USH1 individuals
reported onset of visual symptoms later than 14 years of age, suggesting that if a child
with profound hearing loss does not develop any visual symptoms by their mid-teens
they would be unlikely to go on to develop RP (i.e have USH1). This generalisation does
not extend to individuals with mutations in USH1 genes that cause atypical phenotypes
(e.g. the family with sector RP and hearing loss due to USH1C who had onset of
symptoms much later in life), and so comes with a caveat. This information can be
taken in to consideration by ophthalmic clinicians, who now have evidence to exclude
a diagnosis of typical USH1 when assessing profoundly deaf adults who do not have
any visual symptoms. Conversely one cannot confidently exclude the possibility of an
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adult with moderate to severe hearing loss developing RP (i.e. USH2) on the basis of
age alone, as some individuals did not experience visual symptoms until their thirties or
forties. This also highlights the importance of specifically asking adults with RP for a
history of hearing loss, as moderate hearing loss with a well concealed hearing aid may
not be immediately apparent to the ophthalmic clinician on meeting a patient for the
first time.
This study found that overall USH2 had significantly better median visual acuity than
USH1 for any given age. A useful statistic that can be fed back to patients was that on
average, central visual acuity good enough to meet the criteria for driving was maintained
until mid-thirties for USH1 and mid-fifties for USH2. Restriction of visual fields similarly
occurred at a younger age for USH1, with half of individuals maintaining a visual field of
ten degrees squared (criteria for the legal definition of “blindness” or “severely visually
impaired”) by their mid-forties in USH1 and mid-fifties for USH2. These are useful
statistics that can be delivered to patients who enquire about prognosis for central
vision.
The clinical distinction between Usher syndrome clinical subtypes is made on the au-
diovestibular findings alone, however it appears that there are also similarities with
regard to visual function shared by these two groups and their constituent molecular
subsets. Similarity amongst the four USH1 genes and two USH2 genes with regard to
onset of disease, visual acuity and visual fields was noted in this study.
The p.Glu767SerfsX21 sequence variant in USH2A was the most prevalent allele iden-
tified in this UK study. When comparing those individuals with disease due to USH2A
and comparing those with this allele and those without, the only significantly different
finding was a slightly earlier age of reported onset of visual symptoms. Visual acuity,
visual fields, prevalence of cystoid macular oedema and AF features did not appear to
be distinct to those with this genotype.
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Table 11.1: Table documenting the clinical results from individuals with a molecular
diagnosis of USH2A who carry the p.Glu767SerfsX21 allele and those that do not. The
only statistical difference in any of the variables entered is the earlier age of onset of
visual symptoms in those with the common allele
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We have submitted our molecular findings to the online mutation USHbases database
(https://grenada.lumc.nl/LOVD2/Ushermontpellier/USHbases.html) to aid other re-
searchers in the same field and contribute to the wider body of knowledge regarding the
molecular genetics of Usher syndrome.
Many of the participants in this study expressed willingness to return in the future for
additional clinical investigations. This will afford the opportunity to collect longitudinal
clinical data on this UK cohort of genotyped individuals with Usher syndrome, which
will provide a clearer insight in the the clinical pathogenesis of this disorder.
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